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1 
ABSTRACT 
A realist evaluation of an 
integrated care pathway for 
inflammatory bowel disease in 
the North East of England 
William Horsley 
School of Medicine, Pharmacy & Health, Durham University 
April 2015 
A mixed-methods non-participant evaluation of an integrated care pathway for adult inflammatory 
bowel disease patients in a North East of England health economy was undertaken utilising a realist 
evaluation framework. The evaluation commenced at an early stage in the pathway’s life in October 
2009 and closed two and a half years later in March 2012. The evaluation identified internal and 
external enablers and inhibitors to the pathway, primarily in the design and implementation phases 
as opposed to the operational phase. Inferences were made to contemporaneous evaluations of 
integrated care projects which served to validate this evaluation and identify the additional value of 
the evaluation to the health services research field. Contextual enabling and inhibiting factors were 
identified along with their associated mechanisms and actual or potential outcomes. An additional 
pilot project identified the scope for, and potential nature of, a role for community pharmacy in the 
management of adult IBD patients. 
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Chapter 1: Introduction 
1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is not a single diagnosis and the term covers a number of 
different aetiologies. The most common single diagnoses are Crohn’s disease and ulcerative colitis 
typically accounting for over 90% of IBD diagnoses. The principal effects of the disease are 
inflammation and ulceration in the colon and rectum (ulcerative colitis) or anywhere in the 
gastrointestinal tract (Crohn’s disease). [1]  
1.1.1 Epidemiology 
Inflammatory bowel disease (IBD) is a chronic and, for most patients, lifelong condition estimated 
to affect nearly a quarter of a million people in the UK. [1] The prevalence of IBD within an English 
primary care population was estimated at 0.4%, with ulcerative colitis accounting for the majority 
of diagnoses (0.25%) than Crohn’s disease (0.15%). [2]  Annual incidence rates were estimated at 
0.014% for ulcerative colitis and 0.008% for Crohn’s disease. [2] These figures are broadly in-line 
with epidemiological reports from other localities. [3]  The prevalence of IBD is generally highest 
in areas of Caucasian populations, specifically Northern Europe including the UK, Ireland, 
Scandinavia, France and the low countries, and North America, Australia and New Zealand. The 
incidence and prevalence of IBD appears to be increasing over time in all localities with some, 
particularly in the developing world, experiencing rapid growth. [3] The ratio of ulcerative colitis 
to Crohn’s disease is generally slightly in favour of ulcerative colitis in UK populations [2, 4] 
although this is not true in all localities. [3] 
Age at diagnosis is bimodal, with a first peak presenting in the teenage years or the third decade 
of life and a second less pronounced peak in the 6th decade. [1]  The median age at diagnosis is 
29 years. [2] IBD affects males and females in similar proportions. [2]  Paediatric IBD, typically 
defined by patient age less than 18 or 16 years, is estimated to account for between 7% and 20% 
of all IBD cases. [3] 
1.1.2 Aetiology and causes 
The aetiology of IBD is not entirely clear. [5, 6] Both Crohn’s disease and ulcerative colitis appear 
to be triggered by an unknown, possibly environmental, factor affecting genetically susceptible 
individuals. [6] An immunological mechanism in the pathogenesis of the condition appears to be 
triggered in these individuals. [5] Evidence for a genetic component to the disease comes from a 
recognised greater incidence of IBD in first-degree relatives of IBD patients which may be slightly 
stronger for Crohn’s disease than ulcerative colitis. [5, 6]  
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1.1.3 Symptoms and natural course 
General symptoms common to Crohn’s disease and ulcerative colitis include feelings of bowel 
urgency, frequent and excessive defecation, diarrhoea, pain, anaemia and fatigue. Malnutrition 
and weight loss are common consequences associated with IBD. [1, 5-7] 
Symptoms which are more specific to the individual diagnoses of IBD can help in distinguishing 
between Crohn’s disease and ulcerative colitis. For example, bloody diarrhoea is more typical of 
ulcerative colitis than Crohn’s disease, and effects in the right lower quadrant such as the 
presence of an abdominal mass with or without constant pain are more typical of Crohn’s disease 
than ulcerative colitis. [5] However, a diagnosis can only be confirmed following colonoscopy, 
biopsy and histological tissue classification. [7] 
The frequency, severity and duration of symptoms and disease episodes show considerable inter-
patient variation, and intra-patient variation over time. [1] 
The course of the condition, in common with other conditions considered to have a significant 
autoimmune and inflammatory aspect, typically results in patients experiencing periods of 
‘remission’ during which symptoms are well controlled or even absent, possibly with the aid of 
medication and dietary modification. Periods of remission vary in frequency and duration but can 
be prolonged extending to several years or longer. However, and often with no discernible 
aggravating or precipitating factor, patients may experience an acute exacerbation of the 
condition known as a relapse or ‘flare-up’, particularly patients with ulcerative colitis. [3, 5-7] 
About 50% of ulcerative colitis patients have a relapse in any year [7] compared with less than 40% 
in Crohn’s disease. [8]  
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Not all patients experience a remitting-relapsing disease course with a significant proportion 
experiencing constant, persistent or progressive symptoms. Crohn’s disease in particular is more 
likely to follow a progressive pattern from the outset compared with ulcerative colitis. [3, 5-7] 
The symptoms and consequences associated with an IBD relapse may include profuse, painful, 
and bloody diarrhoea, sudden and drastic weight loss, and loss of appetite, dehydration, rectal 
bleeding and painful cramps. [5, 6] Such flare-ups will often require urgent specialist attention to 
manage the acute phase and regain symptom control. [7] 
Due to faecal blood loss, malabsorption, dietary restrictions and other reasons anaemia is a 
common longer-term consequence of the condition. [9] 
Fatigue, which can be severe, is also relatively common in IBD patients. It may occur either as a 
consequence of anaemia, malnutrition, or for other reasons. [7, 9] 
Osteoporosis is common in IBD patients and may be influenced by the effects of the condition on 
an individual’s nutritional status but also adverse effects from commonly used steroid drugs. 
Screening and, where appropriate, treatment is recommended. [7] 
Extra-intestinal symptoms are more commonly seen with Crohn’s disease than with ulcerative 
colitis. [7] The most prevalent extra-intestinal symptoms are arthritis, erythema nodosum, iritis, 
uveitis, aphthous stomatitis, ankylosing spondilitis and pyoderma gangreosum. [1, 7] 
A more serious feature of Crohn’s disease is the emergence of strictures, fistulae and 
abscesses. Often these can go unnoticed by the patient but once symptomatic will usually require 
surgery to resolve. [7] 
IBD is also associated with an increased risk of developing cancer, primarily in the colon. The risk 
of colorectal cancer in ulcerative colitis is increased with the extent and severity of the disease, 
the age of onset and duration of the disease. Evidence has demonstrated that colorectal cancer 
rates are slightly less in Crohn’s disease than in ulcerative colitis. [1] 
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1.1.4 Psychological impact 
IBD is associated with psychological effects such as depression and anxiety. Patients with IBD are 
estimated to have a greater than two-fold incidence of depressive illness compared with control 
populations.  In IBD patients the lifetime prevalence of depressive illness is estimated at about 27% 
and annual prevalence at 15%. Anxiety has also been found to be more common in IBD patients 
than matched control populations. [7] 
As is the nature of mental illnesses it is difficult to identify causality; mood disorders may not 
solely be a consequence of the disease but could also be related to treatment, for example 
steroid therapy and surgery. Knowledge of the associated health risks of IBD such as cancer, and 
the associated measures such as cancer surveillance, may also contribute to the increased risk of 
psychological disorders in IBD patients. [10] 
An interesting and repeated finding has been that psychological stress and even the way in which 
IBD patients cope with it can impact on their IBD-related health. For example, greater levels of 
stress can worsen the course of IBD, and ‘low-avoidance’ behaviour when employed as a coping 
strategy (i.e. keeping themselves to themselves) is associated with greater rates of sustained 
disease remission than other coping strategies such as high-avoidance (distraction) behaviour. [11] 
1.1.5 Quality of life in IBD 
Several studies have reported that patients with IBD have lower quality of life compared with age 
and sex matched controls without IBD. [12, 13]  
A survey of IBD patients in the North East of England found that lower quality of life was 
associated with female gender, lower socioeconomic status, Crohn’s disease, and being under 
specialist care which itself may act as a proxy for disease severity. [14] However, in a wider review 
of the literature, age was not consistently found to be associated with quality of life in IBD. [15] 
The factors which were found to be more clearly associated with lower quality of life in IBD 
patients were female gender, lower socioeconomic status, lower education levels and lower levels 
of IBD knowledge. [15] 
Disease severity and disease activity have themselves been found to be inversely correlated with 
quality of life in patients with IBD. [12, 13, 16]  
IBD affects other parts of a patient’s life in some obvious and some more subtle ways. For 
example, a number of reports have found that patients with IBD, particularly female patients, 
have concerns and issues regarding self-image, sexuality and the ability to engage in personal and 
sexual relationships. [15] 
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Another report, again using a North East of England patient population, found that people with 
IBD and low quality of life scores perceived their illness as embarrassing, taboo and 
misunderstood. Patients tended to make social comparisons with other IBD patients and non-
patients and appraised their situation relative to those. Patients would seek, fight for, or adapt to 
achieve normality based on what they perceived as normal through these comparisons, which 
were somewhat dynamic. [17] 
The evidence demonstrates that the effects of IBD on an individual patient will often extend well 
beyond the direct manifestations of the disease, impacting upon education, employment, 
personal relationships, social and family life. Social functioning and self-esteem can be adversely 
affected and patients adapt to and accept undesirable and unnecessary constraints in their 
everyday lives. [1] 
1.1.6 Treatment 
1.1.6.1 Management 
IBD patients may experience different models of care provision depending on disease activity, 
local facilities and personal preferences. [18] 
Specialists working in the acute sector, i.e. hospital-based consultant gastroenterologists, have a 
key role in the care of IBD patients. [19] 
However in the NHS, and many other healthcare systems, general practitioners act as a first point 
of access and gatekeepers to specialist care for most health problems including IBD. [20] This can 
create problems for example with delay in diagnosis stemming from inadequate assessment in 
primary care or prolonged waiting times for specialist consultation. [1, 21] Once under the care of 
a specialist patients may remain there for a prolonged period of time or indefinitely. Where 
patients are discharged back to their GP (general medical practitioner) care will often continue 
under guidance from the specialist and the patient may still see the specialist periodically for 
review even if well. [21] 
Increasingly specialist IBD nurses are being employed in hospitals for a range of roles in the care 
of IBD patients. [22] The role of specialist IBD nurses is supported by clinical evidence where a 
number of positive effects have been demonstrated, such as improved patient satisfaction and 
reduced costs of healthcare. [23] Consequently, the role of specialist IBD nurse is endorsed in 
guidelines [7] and practice standards. [1] 
1.1.6.2 Nutritional therapies 
Although specific and general malnutrition are relatively common features of IBD, the use of 
specific nutritional and dietary strategies to alleviate the symptoms of IBD is associated, at best, 
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with only limited efficacy. Short-term enteral nutritional feeding may be particularly useful in 
managing severe active Crohn’s disease. Enteral nutrition diets can be used as an alternative to 
steroid therapy to induce remission in Crohn’s disease. [7]  
Exclusion diets such as gluten-free and dairy-free diets can alleviate some symptoms but only 
where there is a specific intolerance. [7] Numerous other exclusion and special diets have been 
evaluated in IBD but have not been proven to be of clinical benefit. [24] 
Patients may require specific supplements or types of feeds such as liquid feeds and enteral 
nutritional therapy. For severely ill patients, long-term intravenous parenteral nutrition may be 
required. There is limited clinical evidence to support use of microbiological preparations, often 
called ‘probiotics’ in the maintenance [25] and induction [26] of remission in ulcerative colitis. The 
clinical evidence does not support the use of microbiological preparations to induce remission in 
Crohn’s disease. [27]  
1.1.6.3 Medical therapies 
The mainstay of long-term treatment in all forms of IBD is the use of aminosalicylate anti-
inflammatory drugs typified by mesalazine. These drugs liberate anti-inflammatory entities 
predominantly in the lower gastrointestinal tract and therefore exert a local anti-inflammatory 
action. [7] A number of drugs are available in a large range of formulations including for rectal 
administration. [28]  
One problem with long-term medical therapy in IBD is adherence to the prescribed medication 
regimen with typical non-adherence rates estimated at about 30 to 45%. [29] Psychological 
distress, patient’s beliefs about medicines, and discordance in the doctor-patient relationship 
have been consistently associated with non-adherence of IBD patients. [29, 30] 
Steroid therapy such as oral prednisolone is frequently used to manage acute exacerbations of 
IBD, i.e. relapses or flare-ups. At high-doses steroids are effective at gaining rapid symptomatic 
control but long-term use, even at lower doses, is avoided due to concerns about adverse effects. 
Other routes of administration of steroids include rectal preparations which may be used in the 
longer-term due to reduced systemic absorption, and parenteral formulations for very ill 
patients. [29] 
For longer-term steroid-sparing medical management immunosuppressive drugs such as 
azathioprine, mercaptopurine, ciclosporin and methotrexate are used. Although these drugs are 
not associated with some of the troublesome adverse effects seen with steroids they are 
associated with their own distinct adverse effect profiles and must be closely monitored. [7] 
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Biological therapies targeted against specific components of the immune system have become 
available for treating both Crohn’s disease and ulcerative colitis. These include infliximab (1999) 
and adalimumab (2006).  Some of these indications have been approved by the National Institute 
for Health and Clinical Excellence under specific criteria. [31, 32] Due to the positioning of 
biological therapies in treatment pathways and, in the case of infliximab the need for intravenous 
administration, these drugs remain in the specialist domain. [1, 7] The UK IBD biological therapy 
audit found that infliximab and adalimumab are usually prescribed according to the 
recommendations from NICE and that use in ulcerative colitis is low, especially relative to use of 
infliximab in Crohn’s disease. The audit also revealed that the expected efficacy based on clinical 
studies appeared to be borne out in practice and that few adverse events had been reported. [33]  
1.1.6.4 Surgery 
A large proportion of IBD patients, particularly those with Crohn’s disease, are still treated 
surgically at some point in the natural course of their condition. The historical lifetime probability 
for surgery may be as high as 70-80% for Crohn’s disease and 20-30% for ulcerative colitis, 
depending on disease severity and location. A number of different surgical techniques are used in 
IBD ranging from the relatively conservative to extensive and radical surgery. [7] 
Surgery in Crohn’s disease is not curative and is only used to achieve symptomatic relief where 
conservative treatment options have failed. [7] UK-based data has demonstrated that surgery is 
less commonly used now than in the past, potentially due to increased medical therapy. [34] The 
UK national IBD audit found that, of more than 3,000 in-patient admissions for Crohn’s disease in 
2010, 17% were elective admissions for surgery. [22] It is estimated that 70% of Crohn’s disease 
patients who do have surgery develop further disease within 15 years. [5] 
Depending on the extent of surgery, surgical treatment of ulcerative colitis can be curative 
although patients will be left with lasting consequences due to the total absence of their colon, 
for example reduced bowel transit time, reduced faecal storage capacity, and potentially the 
permanent use of stoma. [7] The UK national IBD audit found that, of more than 3,000 in-patient 
admissions for ulcerative colitis in 2010, 16% were elective admissions for surgery. In addition, the 
audit found that ulcerative colitis patients were more likely to receive surgery following an 
emergency admission compared with Crohn’s disease patients. [22] 
1.1.7 Healthcare utilisation 
Patients with IBD require a substantial level of healthcare, which increases with disease 
severity. [35] One UK study found that 1 in 7 of all patients known to a hospital IBD service were 
hospitalised in a six-month period. [36] Although in any given time period a minority of patients 
require hospital in-patient care, hospital care accounts for the majority of costs associated with 
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IBD. [36] The cost of IBD in the UK, based on 2006 data, has been estimated at £720 million per 
year. [35] Crohn’s disease appears to be consistently slightly more costly to healthcare providers 
and patients than ulcerative colitis due to greater use of surgical interventions and greater 
hospital in-patient stays. [36] 
Of all hospital admissions for IBD in 2010, nearly two-thirds were emergency admissions, and 1 in 
6 were elective admissions for surgery. The median length of stay for IBD patients was about one 
week (7 days) with more than one-fifth of patients staying for at least 14 days. [22] There may be 
a minority of patients with particularly high healthcare requirements, for example one-third of 
patients with ulcerative colitis admitted to hospital in 2010 had been admitted in the preceding  
two years. [22] 
Clinical care of IBD patients is fairly equally shared between gastroenterologists and GPs. In the 
first 12 months after diagnosis patients had a mean of 3.9 specialist consultations and 3.3 GP 
consultations specifically related to IBD. Patients with duration of diagnosis ≥ 2 years had a mean 
of 1.02 specialist and 1.04 GP consultations in the preceding 12 months. [2] It is estimated that 
about two-thirds of IBD patients visit their GP regarding IBD in any given year with nearly one-
third making at least three visits.[37]  
Prescription medication is widely used by IBD patients, identified at over 85% in a local IBD adult 
patient population. [38]  
1.2 The IMAGE project 
The Improving Management in Gastroenterology (IMAGE) project was a national quality 
improvement study funded by the Health Foundation in the UK. Thirty-nine general medical 
practices in England were involved. Quality criteria, derived from the views of patients and 
recommendations in evidence-based clinical practice guidelines, were incorporated into decision 
support software to guide primary care clinicians towards better management of four common 
gastrointestinal disorders including IBD. [39] The project commenced in 2007 and was completed 
in 2010. [40] One of the key outputs of the project was a comprehensive, evidence-based and 
‘road-tested’ template for conducting annual reviews with IBD patients. This template was 
developed in primary care but is equally suitable for review of any IBD patient with stable disease 
in remission, including, for example, patients who are reviewed in secondary care. 
1.3 The IBD Standards of Care 
The IBD Standards of Care were developed through a collaboration of six healthcare professional 
representative organisations and one leading patient charity. [1] They were published in 2009 as 
part of a wider strategy to improve services and care for patients with ulcerative colitis or Crohn’s 
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disease, the two most common inflammatory bowel diseases. The standards are broken down 
into six categories, each further sub-categorised in greater detail. The six categories related to 
clinical care, local delivery, patient-centred services, patient education and support, information 
technology and audit, and evidence-based practice & research. [1] 
The IMAGE project is referred to in the IBD standards as an important project which could 
potentially improve the management of IBD by using established approaches which have 
delivered improvements in the management of other chronic health conditions within the NHS. [1]  
1.4 Integrated care 
Integrated care is not consistently defined and multiple definitions exist in an extensive literature 
base. [41] The Royal College of General Practitioners has defined it as ‘care that places patients at 
the centre of its design and delivery, meeting their needs in a co-ordinated and individually 
tailored way’. This is further qualified as being ‘patient centred, primary care-led, shared working 
with multi-professional teams where each profession retains their autonomy but works across 
professional boundaries ideally with a shared electronic GP record’. [42] A report from the 
Nuffield Trust defined integrated care more loosely as ‘an approach that seeks to improve the 
quality of care for individual patients, service users and carers by ensuring that services are well 
co-ordinated around their needs’. [43]  
Irrespective of the definition of integrated care the provision of generalist and specialist 
healthcare (primary and secondary care, respectively) within the NHS is distinguished by 
boundaries or ‘interfaces’, both tangible and intangible.  
Integrated healthcare is often described as being vertically or horizontally integrated. [44] Vertical 
integration will typically involve disease-specific care plans or pathways which negotiate the 
boundaries across generalist (primary) and specialist (secondary) care. Horizontal integration 
involves broader collaborations often with non-health organisations such as local authorities or 
charities to improve overall health. [44] 
These healthcare boundaries, or interfaces, have been broadly differentiated into three non-
exclusive levels; patient and provider, organisational, and system-based. Some of the problems 
which arise from delivery of care across the primary-secondary care boundary, or interface, are 
described in box 1. [45]  
Better integration of care is often presented as a potential solution to some or even all of the 
problems arising from the primary-secondary care interface. This can be delivered in many ways 
including integrated care pathways. [46] 
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As with ‘integrated care’ there is also no single universally accepted definition of what an 
‘integrated care pathway’ is. A particular and thorough description is provided in box 2.  
Box 1. Problems observed with the boundaries between primary and secondary care [45] 
Patient and provider level boundaries 
Poor communication characterised by transfer of patient information via hard copy (i.e. 
paper), separate information management and technology systems, separate consultations 
and locations resulting in additional transport and temporal impositions for patients, 
separate personnel. 
Organisational level boundaries 
Absence of agreed pathways and associated standards of care and service leading to 
variation in patient experiences, different levels of access to or provision of non-treatment 
interventions, cumbersome referral pathways leading to temporal delays to appropriate 
care. 
System level boundaries 
Separate funding arrangements leading to a purchaser-provider relationship and potential 
power imbalance. 
Box 2. Integrated care pathways [47]  
Integrated care pathways are structured multidisciplinary care plans which detail essential 
steps in the care of patients with a specific clinical problem and describe the expected 
progress of the patient. 
They aim to facilitate the introduction into clinical practice of clinical guidelines and 
systematic on-going audit into clinical practice. They can provide a link between the 
establishment of clinical guidelines and their use. 
They help in communication with patients by giving them access to a clearly written 
summary of their expected care plan and progress over time. 
 
The functions of integrated care pathways have also been defined as: ‘An integrated care pathway 
determines locally agreed, multidisciplinary practice based on guidelines and evidence, where 
available, for a specific patient/client group. It forms all or part of the clinical record, documents 
the care given and facilitates the evaluation of outcomes for continuous quality  
improvement.’ [48] 
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1.4.1 The Darzi Review 
The NHS next stage review ‘High Quality Care For All’, more commonly known as the ‘Darzi review’ 
after the lead author, was published in June 2008. [49] This review supported the case for 
‘integrated care’ although it did not explicitly define what was meant by this term. The report 
built upon numerous earlier NHS and department of health reports and reviews, all of which 
supported the process of integrated care. [50, 51] For example, the practice guidance 
‘Implementing care closer to home: Convenient quality care for all patients’, published in 2006 by 
the Department of Health, emphasised patient-centred care and used examples of integrated care 
pathways to illustrate good practice. [51] 
1.4.2 Integrated Care Pilots 
As a direct consequence of the Darzi review the Department of Health for England launched a 
competitive initiative in autumn 2008 entitled the Integrated Care Pilots. [52] Applications were 
invited for integrated care projects within the English NHS to become one of a number of pilot 
sites within an integrated care pilots programme. For the successful projects, inclusion within the 
programme would result in automatic participation in an independent comprehensive evaluation 
programme commissioned by the Department of Health. [52]  The evaluation was designed to run 
for three years and would objectively and independently report on several aspects of the  
pilots. [53] 
1.5 The locality 
The locality of interest to the research project is a predominantly urban conurbation in the North 
East of England characterised by former industrial sites and urban sprawl, interspersed with rural 
areas. [52] Eighty-six per cent of the population is classified as living in ‘urban areas’ compared 
with the English average of 73%. [53] 
The population of the health district conurbation is between 100,000 and 250,000. The area 
demonstrates higher than average overall deprivation within England. [54] and contains a high 
concentration of areas which are amongst the most deprived in England. [55] The locality displays 
a number of measures indicative of greater social and community deprivation compared with 
national and regional averages. [54, 55] 
The health of people in the locality is worse than the national average for England as described by 
several public health criteria. Although the all-cause mortality rate has decreased over the 
preceding decade it remains slightly greater than the average for England. [54]  Life expectancy is 
slightly less than the average for England for males and females [53] although there is 
considerable variation in life expectancy across different areas within the locality. [54] 
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The locality was served by a single commissioning healthcare organisation, known at the time as a 
Primary Care Trust (PCT). This contained between 20 and 30 general medical practices governed 
by the PCT. The practices ranged in scale and size from a small single GP practice with about 1,000 
patients to a large multi-professional practice with several GP’s and over 20,000 patients. [56] The 
PCT and local authority boundaries were closely but not identically aligned. [57] 
The locality was served primarily by one hospital of the district general hospital model located in 
the main conurbation of the locality. The hospital principally served the local community. [58] 
Prior to the introduction of the integrated care pathway for IBD there was no defined pathway for 
patients with IBD in the locality. Instead care was based on a historical system of referral from GPs 
to hospital-based consultant-led care. The majority of specialist care of IBD patients residing 
within the locality was delivered by the gastroenterology department at the main hospital site 
located in the main conurbation. A minority of IBD patients within the locality received their care 
from neighbouring hospital trusts in other major conurbations. 
1.5.1 A local healthcare programme 
In 2007 two neighbouring PCTs, including the locality PCT, formed a partnership with the hospital 
trust which principally served their populations. One of the aims of the programme was to serve 
as a national exemplar for the provision of modern integrated healthcare. [59, 60] 
One of the key components of the programme was to deliver as much care as possible in primary 
and community settings. The strategic aim of the programme was described as: 
“ … the provision of a new acute hospital to replace the existing two along with a redesign of the 
health care system across primary, community and secondary care … ”. [61] 
The programme was described in its own literature as developing a vision for future healthcare: 
[59] 
A patient-centred and clinically driven local NHS that is responsive to the needs of local 
people, that can deliver the best quality health and social care available in an integrated 
and efficient way, provided in first rate facilities that are as close to home as possible by 
well trained professionals using state of the art equipment. 
The programme included clinicians, patients, staff, public, carers and other partners, and was 
expected to run between April 2007 and March 2014. [59, 60] There were six projects within the 
overall programme, one of which related to long term conditions. [60] 
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1.5.1.1 Long-term conditions 
The management of long term conditions was considered as a separate project within the 
programme. A report on the initial findings of the long term conditions project was published in 
2008.[60] This part of the project focused on ten long term conditions for which data was 
collected and presented. Although IBD was not listed among the ten long term conditions covered 
in the 2008 report the data collected and presented, and the corresponding conclusions, were 
described as being generalisable to the local management of all long term conditions. 
Regarding local service models for long term conditions, the report made several conclusions: [60] 
• There were some good examples of care for patients with long term conditions 
• Access routes to services was variable and caused confusion and delay 
• Delays were inherent in the current model 
• The focus was on management of chronic disease 
• There was lack and/or inconsistency of patient information 
• Links between services and service providers were not fully coordinated 
• The role of voluntary, charitable and independent organisations was not explicit 
• The current model of care was not patient-centred 
• There were more reactive care services than proactive care services 
The report concluded that the future management of long term conditions should be via a single 
point of access, be proactive via disease management programmes, feature integrated data 
systems, ensure workforce development, utilise multidisciplinary working to reduce variations in 
care, and include prospectively defined audit and review. [60] 
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1.6 Aims and objectives of this thesis 
In this thesis a combination of qualitative and quantitative research methods have been used to 
evaluate the design, implementation, operational processes and outcomes of an integrated care 
pathway for IBD. Qualitative and quantitative data have been combined to identify convergent 
findings in the context of a complex evaluation in the expectation that the combination of the two 
different types of data would be greater than the sum of the parts. [62] 
The over-arching evaluation utilises the technique of realist evaluation, first described in detail by 
Pawson & Tilley. [63] Embedded within this are more focused evaluation techniques applied to 
specific data components, for example, a framework analysis of interview transcripts and 
summary statistics relating to quantitative outputs and metrics. A fundamental aspect of realist 
evaluation is the elucidation of the contextual factors in which a programme operates to deliver 
observable outcomes via specific mechanisms. This evaluation used diverse data sources including 
minutes of meetings, official publications and reports, electronic mail correspondence, 
observational notes, and interview transcripts. [63]  Quantitative data was also obtained from a 
range of different sources including those integral to the pathway such as the collection of 
symptom scores, and also from sources which are routinely generated by the NHS such as 
prescribing and hospital episodes statistics data. Control or reference groups were utilised where 
these could be reliably identified. 
A complementary exploratory investigation of the potential role of community pharmacy in the 
care of patients with IBD was performed in tandem with the pathway evaluation. 
1.7 Structure of this thesis  
Chapter 2 of this thesis is a comprehensive literature review which examines the current evidence 
base for the use of realist evaluation in healthcare, disease-specific models of integrated 
healthcare, and examples of other pathways for IBD. Chapter 3 describes the methodologies used 
in the conduct of the research. Chapter 4 constitutes provides the results obtained to support the 
findings of the thesis, utilising extensive qualitative and quantitative sources. Chapter 5 brings 
together the various components of the thesis and considers them within the context of an in-
depth discussion and relationship to the wider evidence base. Chapter 6 draws conclusions based 
on the previous chapters and other relevant work. 
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1.8 Personal statement of interest 
My first degree is in pharmacy and I have worked for several years at the patient interface in 
different fields of pharmacy. However, I was drawn from the outset of my career towards more 
reflexive and enquiring aspects of healthcare, particularly in terms of optimising patient care and 
experience with fixed resources. Initially this focused on the application of evidence-based 
medicine with respect to specific drug treatments. For this purpose I undertook a diploma in 
statistics, which proved invaluable when interpreting and understanding often complex statistical 
data. In order to maintain my clinical knowledge I also undertook a diploma in medicines 
management. During this time I developed an interest in the more general field of health 
economics and I recognised that health economics was becoming increasingly important in 
healthcare systems throughout the world as well as the NHS. This led to my undertaking a 
Master’s degree in health economics.  
Of course, seldom is a treatment or intervention made in isolation of what are usually complex 
interactions between carers, patients, and organisations. These interactions, combined with the 
inherent properties of each, can influence the health outcomes of individual patients and by 
extension whole patient groups and communities. It was to develop a better understanding of 
how these interactions exist in a programme of healthcare development for a defined chronically 
ill patient group that I was drawn to undertake a doctoral research degree. My existing 
educational and research background, and extensive experience in the commissioning side of the 
NHS, provided a useful starting point to undertake a long term, observational, and objective 
evaluation of a new service in a specific locality. The specific condition for which the service had 
been developed, IBD, lay within the same therapeutic field of gastroenterology in which the host 
research department has particular expertise and recognition. In addition, compared with several 
other long term conditions, IBD has a limited profile both amongst the public and within the 
media. Indeed, it is somewhat neglected by healthcare organisations and governmental 
departments, as exemplified by the continued omission of IBD from the national quality outcomes 
framework programme. However, in the context of the external relevance of this thesis, I hope 
that the lessons learned and findings can be extended to other long term conditions specifically or 
generally. 
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Chapter 2: A review of the relevant literature 
This literature review considers the published literature on the key points relevant to this thesis.  
The first section reviews the published literature regarding the use of realist, or realistic, 
evaluation as an evaluation technique of healthcare interventions as well as considering the 
broader evidence base for change, and specifically pathway redesign, in the context of large 
healthcare organisations such as the NHS. 
The next section considers the use of specific integrated care pathways to achieve changes and 
the outcomes produced. First it is important to define what is integrated care, what is a care 
pathway, and is an integrated care pathway. Identifying the relevant evidence is confounded by a 
variations in the terminology used to describe integrated care pathways. Over time integrated 
care appears to have been increasingly associated with models of healthcare which are examples 
of horizontal integration across different healthcare providers at the same level of need. For 
example, traditional primary care healthcare providers integrating with social care providers to 
deliver community-based patient care. This is a shift from early intimations of integrated care 
which more often related to vertical healthcare integration across boundaries defined largely by 
the level of patient care required, for example integration between primary and secondary 
care. [64] The IBD integrated care pathway which is the focus of this evaluation is an example of 
vertically integrated care and this will be the focus of the evidence considered in this section. A 
vertically integrated care pathway is increasingly described as ‘disease management’, which does 
at least help to distinguish it from horizontal models of integrated care. In addition, disease 
management adds some detail to the descriptor as vertically integrated care pathways are usually 
focused on a single morbidity whereas horizontally integrated models of care are usually more 
holistic. A further distinction must be drawn between the morbidity (illness, disease, condition) 
which is the focus of the vertically integrated care pathway. The integrated care pathway in this 
evaluation related only to IBD, an example of a chronic morbidity. Pathways which deal with time-
limited morbidities such as an acute or one-off intervention (e.g. orthopaedic or surgical 
procedures), an acute medical emergency, terminal or palliative care, rehabilitation, or infections 
and wound care, are better and more often described as critical care pathways. The evidence 
reviewed in this section therefore relates specifically to vertically integrated care pathways for 
chronic conditions, such that the evidence may be relevant to the IBD integrated care pathway. 
Evidence specific to IBD will be identified and considered with relevance to the IBD pathway of 
this project. 
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2.1 Realist evaluation 
2.1.1 What is realist evaluation? 
Realist, or realistic, evaluation was formally described only in the 1990’s and yet, due to its 
flexible nature and applicability to multifaceted and complex programmes of change, it was 
rapidly adopted by researchers and others in healthcare and other fields. Fundamentally it is a 
pragmatic, naturalistic and comprehensive evaluation not just of the traditional causes 
(mechanisms) and effects (outcomes) of an intervention but one which also, crucially, includes 
identification of contextual factors. [63] 
Context is itself something of an abstract and often subtle concept which can exist in many forms, 
for example the policy background, the prevailing economic situation, geographical, socio-
economic, political, social, inter-personal, institutional or other. [63]  In realist evaluation it is the 
elucidation of unique combinations of contexts, mechanisms and outcomes (CMO) which is 
important and should be one of the key aims of the evaluation. [65] The following schematic is 
useful to conceptualise the process. 
Context + mechanism = outcome 
The same mechanism, if applied in a situation with different contextual attributes, may therefore 
lead to different outcomes. Observation of mechanisms alone can be misleading about the 
outcomes which might be expected and it is important to identify what these contextual 
attributes, both enablers and inhibitors, might be. The actual details about how each mechanism 
is evaluated is not explicitly defined within the realist evaluation framework but, because ‘context’ 
and the many forms it can take are relatively abstract concepts, qualitative techniques are a 
common feature of realist evaluations. However this does not preclude the use of quantitative 
evaluation techniques and these are often employed alongside qualitative techniques in realist 
evaluations. 
Realist evaluation has amongst its founding principles the theory of critical realism, first described 
formally by Bhaskar in 1975. [66] In critical realism actors have to operate in an environment of 
structural constraints and possibilities which they neither created nor are able to exert any 
obvious control upon. It is the role of realist evaluation to try and identify some of these unseen 
constraints and influences which may manifest as unintended consequences, tacit skills, 
unacknowledged conditions, unconscious motivations, and other subtleties of a social construct. 
More simply, the basic tenet of realist evaluation is that the observed outcomes in a real, social, 
world, are not the sole consequence of the mechanisms which have been, presumably, put in 
place or otherwise identified as causal. The critical realist will recognise that the same 
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mechanisms, when transferred to a new but almost certainly different social environment will be 
unlikely to yield the same outcomes. If considered prospectively, implementation in a real social 
environment of a specific mechanism from which there is an expectation of a set of specific 
outcomes is in fact likely to yield outcomes other than those intended or expected due to the very 
nature of the social environment in which the mechanisms existed. It is the details of the social 
environment which have a tangible effect on the mechanisms, which are collectively labelled as 
‘context’ by Pawson and Tilley, which a realist evaluation seeks to identify.  
Context can therefore take many forms across single, to few, to many attributes. Context in this 
respect can vary from the overt and objective to the subtle and abstract. It is the nature of realist 
evaluations that the source of contextual attributes are more often of the subtle, unseen, abstract 
and inherently subjective nature, elucidated after several iterations and refinements. It is for the 
realist evaluator to demonstrate their skill in elucidating these contextual abstracts and making a 
case accordingly. 
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2.1.2 The evolution of healthcare programme evaluation 
The evaluation of healthcare and related programmes has had an interesting and at times 
controversial modern history. [67-69]  Pawson and Tilley provided an thorough history of 
evaluation in the first chapter of their seminal text on realist evaluation. [63]  Initially healthcare 
programme evaluations, in common with programme evaluation in general, were founded in 
positivist objective traditions, often referred to as ‘goal-bound’. [69]  These evaluations tended to 
have a predominant emphasis on the quantitative outcomes or outputs of programmes and 
sought to identify causality within a programme through experimental design. Evaluations of this 
nature have included randomised controlled studies, [70, 71] cluster-randomised studies [72, 73] 
and other variations of randomised [74] and non-randomised comparative studies. [75]  Such 
evaluations are still performed and are useful to present neater and easier to understand 
conclusions of cause and effect. [76]  However, many healthcare programmes are complex 
interventions which exist in the real world. There are often ethical and practical limitations to 
conducting experimentally designed evaluations of such complex interventions. 
After a prolonged period where experimental positivism reigned unchallenged, qualitative 
techniques and less scientifically focused evaluation techniques emerged.   Various new 
terminologies and specialities emerged from the social sciences field, all with a common 
qualitative thread. [63, 77]  These were collectively known as constructivist [63, 76, 77] and 
included a now familiar and largely standardised range of qualitative research techniques. Taking 
this new qualitative approach was considered by its proponents to offer a different and more 
enlightened view of not just what happened and what were the causes, but also why certain 
outcomes occurred and explanations for those outcomes. Examples of qualitative evaluation of 
healthcare programmes include the use of grounded theory to identify social phenomena, [78] 
action research used to evaluate the impact of new working practices, [79] and an ethnographic 
study of professional relationships [80] to name but a few. Qualitative and quantitative evaluation 
techniques do not have to be mutually exclusive and there are numerous examples of healthcare 
programme evaluations which have used both approaches to deliver an array of reported 
outcomes. Developing this theme further, quantitative and qualitative research methods can be 
combined, and not just reported alongside each other, to yield an evaluation which is greater 
than the sum of its components. Such a combination of evaluation or research methods is more 
commonly referred to as a mixed methods study. Mixed methods research combines qualitative 
and quantitative data to produce convergent findings with data from each paradigm informing 
the other. Tensions between these different methods can generate new insights. The mixed 
methods descriptor may also refer to a mix of different qualitative techniques and outcomes and 
not only a combination of qualitative and quantitative techniques and outcomes.[62] 
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Contemporary to the emergence of qualitative techniques in programme evaluation was the 
emergence of theory-based evaluation. [81]  As with much of the evaluation and research 
literature the terminology is variable. Theory-based, -driven or -oriented evaluation was 
developed primarily as a response to problems of the generalisation of other, particularly 
positivist, evaluations to new situations or environments. It marked an important departure from 
previous debates in the field of evaluation research in which developments had been largely 
methodological of the quantitative (positivist) vs. qualitative (constructivist) nature. The seminal 
text in this field was the publication of Chen’s ‘Programme Evaluation’ in 1990. [81]  Programme 
theory deals with ‘the assumptions that guide the way specific programmes, treatments, or 
interventions are implemented and expected to bring about change’. [82]  Such theories are 
seldom explicit within healthcare programmes or interventions and often require careful and 
somewhat subjective identification by evaluators.  
Most of the key authorities in programme theory evaluation make a distinction between theories 
which explain how certain activities are expected to produce specific outcomes, and other 
theories which explain how certain mechanisms which are released or enabled by a programme 
are causally linked to specific outcomes (i.e. how, why and to what extent different individuals 
and stakeholder groups will respond to an intervention). In common with much of the programme 
theory field, these two distinct theoretical perspectives go by a number of different and 
sometimes similar descriptions but are described herein as implementation and programme 
theory respectively. The way in which the theories identified are then incorporated into the 
evaluation process will vary depending on the programme evaluation theory framework which is 
utilised by the evaluators. The programme theory evaluation field is dominated by two 
frameworks; ‘theories of change’ and ‘realist evaluation’. Table 1 highlights key methodological 
and functional differences between the two approaches. [83] 
The transformation in approach to the evaluation of healthcare programmes has emerged in 
official guidance. The Medical Research Council (MRC) has published guidance on developing and 
evaluating complex interventions [84] although there was still a preference for randomised study 
designs and a more conventional, or positivist, elicitation of cause and effect. This was only 
guidance and it explicitly stated that it was not intended to be prescriptive. The authors have 
stated that understanding processes [of complex interventions] is important but does not replace 
evaluation of outcomes. [85] Other commentators have expressed disappointment at this 
positivist stance. [86] In an editorial published in the same year, Freeman claimed that a study of 
a health promotion intervention, which was evaluated by means of a randomised controlled trial, 
may have been better served if it had been evaluated within a realist evaluation framework. [86] 
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Table 1. Summary of methodological and functional differences between two related evaluation 
frameworks 
Framework attribute Theories of change Realist evaluation 
Identification and 
nature of theories 
Much preferred at programme 
design or commencement. More 
suited to uncovering implementation 
theory. 
Preferred at programme design or 
commencement, but can be 
adequately incorporated within 
any stage of programme. Primarily 
concerned with uncovering the 
programme theory.  
Validation or approval 
of theories 
Each stakeholder must validate and 
agree the theories. Conflict between 
stakeholders must be resolved by 
the evaluation team. 
Validated and approved by 
evaluation team through 
observations, prior research and 
the relevant literature. 
Theories’ impact on 
evaluation 
 Used to identify mechanisms by 
which the theories are realised.  
Impact of contextual 
attributes 
Incorporated into the evaluation, 
often implicitly 
Explicitly identified and combined 
with mechanisms to yield ‘context 
+ mechanism = outcome’ 
combinations. 
Level of evaluator 
involvement and 
interaction with 
programme 
High, often intricate. Variable. Can operate as a passive 
observer with minimal influence 
but framework can incorporate 
various levels of evaluator 
involvement. 
Resource requirements Generally quite high due to intricate 
nature of involvement with 
programme. 
Generally lower than other 
evaluation frameworks, often 
relying on existing outputs and 
sources of data. 
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2.2 Evaluation of healthcare programmes 
Health and healthcare interventions such as new or redesigned services are by their nature 
complex, due not least to the number of different agents and agencies which are often 
involved. [87, 88]   As well as involving different groups or operating across different 
organisational levels, health service programmes must exist in a real world situation where 
numerous external variables are difficult, impractical or impossible to control. [89] 
2.2.1 Realist evaluation in healthcare 
Most research labelled as ‘realist’ or ‘realistic’ evaluation in the healthcare field has been 
published since the year 2000, with increasing numbers year on year. [90]  A review of realist 
evaluations in health systems research, published in 2012, identified eighteen published articles 
which met the strict inclusion criteria out of an initial cohort of over 1,000. [90] The main findings 
of the review were that there were few examples of self-styled realist evaluations which met the 
inclusion criteria, that those which did were the more recent, that realist evaluation had been 
applied in a variety of fields within health systems research, that there was considerable diversity 
in the application of the underpinning principles of realistic evaluation, and that all researchers 
encountered challenges in applying the principles in practice. The review identified seemingly 
indiscriminate use of related but distinct terms such as theory-driven evaluation, theories of 
change and realist evaluation which confounded the analysis. Other common issues identified 
were conflicts in distinguishing between mechanisms and context, and a lack of methodological 
guidance for conducting realist evaluations. [90] 
The specific issue of mechanism and context differentiation can present a significant 
interpretative and analytical hurdle. An example of the mechanism-context attribution conflict 
was given by Rycroft-Malone et al in considering whether a financial incentive which resulted in 
the consistent use of protocols for monitoring patient wellbeing was a mechanism which directly 
drove protocol use, or a contextual attribute which acted as motivation. [91]  Where this problem 
has been identified not all evaluators were able to present solutions. However a number of 
different approaches have emerged. For example, Byng et al resolved the issue by returning to 
the philosophical basis of realism and accepting that there may be multiple mechanisms in 
operation at the same time. [92]  Rycroft-Malone et al took a different conceptual approach by 
determining that some attributes can be both a mechanism and context at the same time 
depending on the organisational level under scrutiny. [91]  This approach required a clear and 
explicit identification of the level, or levels, at which a programme or components thereof were 
operating. Even Pawson, as co-author of a realist evaluation of a large-scale health improvement 
initiative, found that distinguishing between a context and a mechanism could prove to be a 
challenge. [93]  The solution in that case was found with an increasingly more abstract view of the 
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data so that two superficially distinct factors, exemplified by ‘replacement of examination rooms 
with self-management pods’ and ‘early discharge of patients so that rehabilitation shifts to their 
home’, each equally valid as a context or a mechanism, could subsequently be considered as 
being of the same mechanism described as ‘redesigning the physical environment for self-care’. 
As early as 2005, less than one decade after publication of the seminal text, [63] realist evaluation 
was specifically recommended for the evaluation of health care programmes in complex 
organisations or networks. [94] In order to successfully conduct a realist evaluation a detailed, 
multi-dimensional view of the experience of implementing the programme is required, and high-
quality data on a range of agreed and standardised process measures must be prospectively 
collected. [94]  
2.2.2 Innovation and change in healthcare organisations 
Evidence for the implementation of changes in healthcare organisations, especially across 
multiple organisations and at different levels, has been comprehensively and systematically 
reviewed by Greenhalgh et al. [94] This review identified multiple examples of changes and 
innovations in various healthcare systems, organisations, and looked at the evidence for the 
adoption and implementation of healthcare innovations or changes. In particular the review 
concluded that when an organisation moves into the implementation phase this occurs in a non-
linear process characterised by multiple shocks, setbacks and unanticipated events. The reviewers 
identified specific elements associated with successful implementation of an innovation or change 
in healthcare organisations and its subsequent routine adoption. [94] 
• Organisational structure: Adaptive, flexible, support for devolved decision-making (e.g. 
strategic decisions made by departments and operational decisions made by delivery 
teams). 
• Leadership and management: Support from senior managers and leaders, continued 
advocacy of the change and continued commitment. Alignment with prior goals of senior 
and very senior management levels with active involvement and consultation of leaders.  
• Human resources: Motivated and competent practitioners, adequate system capacity, 
involvement of staff from all levels, and early and wide staff engagement, formal 
facilitation initiatives.  
• Funding: Dedicated and on-going funding is associated with success compared to 
situations without such. 
• Intra-organisation communication: A coherent narrative for change and effective 
communications between parties, teams, departments, etc. 
• Extra-organisational networks: Of increasing significance with increasing complexity of the 
change or innovation. 
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• Feedback: accurate and timely information on impact of change increases chance of 
routine adoption. 
• Adaptation: Where innovations are adapted to the local context they are more likely to be 
successful. 
2.3 Integrated Care 
2.3.1 What is integrated care? 
Integrated care has a fluid and dynamic definition which varies depending on an individual’s or 
organisation’s perspective. [95, 96]. It has been defined by the World Health Organisation as:  
‘A concept bringing together inputs, delivery, management and organization of services related 
to diagnosis, treatment, care, rehabilitation and health promotion. Integration is a means to 
improve the services in relation to access, quality, user satisfaction and efficiency.’ [97] 
A systematic review of ‘integration in health systems’ identified more than 70 terms and phrases 
which in turn yielded about 175 definitions and concepts. The authors of the review specifically 
highlighted ‘integrated care’ as one of the more common but heterogeneous terms 
encountered. [96]  An international conference and discussion on integrated care in 2009 
concluded that ‘integrated care’ as it is now used is more akin to an umbrella term encompassing 
models which differ significantly in scope and point of view, although similarities exist with 
respect to the use of tools and the targeting of resembling problems. [98] 
A report from the Nuffield Trust sought to answer the question ‘What is integrated care?’ by 
providing an overview of integrated care in the NHS. [41]  The authors defined integrated care 
broadly as: 
‘… a term that reflects a concern to improve patient experience and achieve greater efficiency 
and value from health delivery systems. The aim is to address fragmentation in patient services, 
and enable better coordinated and more continuous care, frequently for an ageing population 
which has increasing incidence of chronic disease. [41]  
One perspective which has been taken when considering integrated care is to consider what care 
without integration would be like: 
Without integration at various levels, all aspects of health care performance suffer. Patients 
get lost, needed services fail to be delivered, or are delayed, quality and patient satisfaction 
decline, and the potential for cost-effectiveness diminishes. [99] 
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A common theme of integrated care, especially with respect to the UK and Department of Health 
documents, is ‘patient-centred care’. [49, 100] This has been more technically described as 
‘imposing the patient perspective as the organising principle of service delivery’. [101] Patient-
centred care and integrated care are often used interchangeably or are used in the same context. 
[49, 100, 102] 
2.3.2 Breadth of integration: Horizontal and vertical 
A useful distinction is often made between integration of care providers within a specific setting 
and integration which is specific to a defined patient group. Setting-specific integration is usually 
within primary and community care, and patient-specific integration is usually defined by a 
particular disease or condition across the hierarchy of medical care. These forms of integration 
are known as horizontal and vertical integration respectively. [44, 95] Both descriptors relate to 
the breadth of integration. Vertical and horizontal healthcare integration are not necessarily 
mutually exclusive, although in practice it is uncommon for the two to be present in the same 
system. [103]  
The World Health Organisation has defined vertical integration as ‘integration happening across 
organisational boundaries to align strategic approaches to care’, and horizontal integration as 
‘within organisations and across departments’. I.e. vertical integration is defined as linking 
different levels of care (e.g. primary, secondary, and tertiary) and horizontal integration is defined 
as linking similar levels of care across professional, departmental and organisational 
boundaries. [104]  
A comprehensive definition of the breadth of integration was provided by Thomas et al: [44] 
Vertical integration relates to the idea that diseases are treated at different (vertical) levels of 
specialisation. Horizontal integration relates to the idea that environments that more broadly 
support health require co-ordinated effort and collaborative planning at the (horizontal) level 
of whole people and communities. Whole system, or comprehensive, integration requires that 
vertical and horizontal integration develop in tune with each other. Vertical integration draws 
particularly on natural science, with an emphasis on laboratory (especially positivist) research 
and linear care pathways. Horizontal integration draws particularly on social science. [44] 
Vertical integration may be perceived as a more attainable short-term objective compared with 
horizontal integration which can only be achieved successfully in the longer term, if at all. [105]  
This difference may arise due to the narrower focus of vertical compared with horizontal 
integration and models of vertical integration more often build on existing labour and 
environmental resources. [105] 
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There has been much attention on integrated care in the English NHS between 2000 and 
2010. [43] However the focus appeared to have shifted towards horizontally integrated care as 
typified by Department of Health initiatives such as the Integrated Care Network [106] and the 
Community Health Partnerships [107]. There were no obvious equivalent central initiatives to 
promote and support vertically integrated care within the NHS. Despite the apparent bias towards 
horizontally integrated care models the sixteen pilot projects in the Department of Health 
Integrated Care Pilots programme did include a minority of projects described as demonstrating 
only vertical integration. [108]  
2.3.3 Evidence for benefits of integrated care 
A narrative review of systematic reviews of integrated care programmes for chronically ill patients 
was an important source of evidence for the effects and mode of integrated care. [109]   
Ouwens et al identified thirteen systematic reviews of integrated care programmes for chronically 
ill patients. The studies included in the reviews were similar in their aims which were to reduce 
fragmentation of service delivery and to improve continuity and co-ordination of care. However 
they varied considerably in the focus and content of each programme. The authors identified 
some of the more common components of integrated care programmes as patient education and 
support to self-manage, structured clinical follow-up, case management, multidisciplinary care 
teams, a multidisciplinary pathway, and healthcare professional targeted interventions consisting 
of feedback and education. In elucidating summary findings the authors came up against issues of 
inconsistent definitions and poorly described interventions. Despite this they identified generally 
positive effects on ‘quality of care’ loosely defined by a number of attributes such as process 
outcomes (e.g. use of guidelines), functional status, specific health outcomes, and mortality and 
hospitalisation rates. The authors stated that consistent definitions of integrated care 
programmes must be used, and the component interventions must be well described to enable 
better comparisons between programmes and to understand their effectiveness and cost 
impacts. [109] 
A Cochrane systematic review of shared care across the primary and secondary care interface, 
defined as ‘the joint participation of primary care physicians and specialty care physicians in the 
planned delivery of care, informed by an enhanced information exchange over and above routine 
discharge and referral notices’ included twenty studies, nineteen of which were randomised 
controlled trials. [110]  Most studies had at least one important methodological shortcoming. The 
definition of shared care used has clear similarities with definitions of integrated care, especially 
vertically integrated care. The review, which included meta-analyses, found mixed results with no 
consistent improvements in physical or mental health outcomes, psychosocial outcomes, 
measures of disability and functioning, hospital admission rates, default or participation rates, 
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recording of patient risk factors, and patient treatment satisfaction. One clear benefit was 
identified, in prescribing, although this was only evaluated in eleven of the studies. Evidence 
relating to cost impacts was only available from eleven studies and could not be collectively 
evaluated. 
A systematic review of randomised studies of integrated care including disease management 
programmes for long term conditions examined the evidence in the context of the UK health 
service. [111]  The review made a distinction between models of horizontal and vertical 
integration and identified 76 reports, the majority of which related to horizontal integration. With 
respect to vertically integrated models of healthcare for long term conditions the review 
concluded that there was a lack of evidence of effectiveness. A potential tension within vertically 
integrated structures such as care pathways was identified. Conflict may exist between the 
patient choice and empowerment agenda, a common theme in the management of long term 
conditions, and the use of a prescribed pathway. The review also concluded the main challenge 
for the care pathway process was development and documentation as opposed to 
implementation and maintenance. In particular, service user (‘patient’) involvement in the 
development of care pathways was found to be weak. The authors expressed surprise that NHS 
policy was leading to ever greater levels of both vertical and horizontal integration in the absence 
of evidence of effectiveness. They acknowledged the NHS integrated care pilots could add 
substantial new volume to the available evidence base on integrated models of healthcare. [111] 
A comprehensive updated review on the evidence specifically for models of vertically integrated 
healthcare was published in 2009. [112] However, the authors appear to have utilised an 
inflexible definition of integrated care which relied upon at least a degree of organisational 
merger. The report identified two main types of vertical integration; where agencies involved at 
different stages of the care pathway were part of a single organisation, and where payer and 
provider agencies were part of a single organisation. The inclusion of ‘single organisation’ in these 
examples may not reflect the depth of integrated healthcare which has been described as, or 
which describes that which is recognised as, vertical integration in other sources. The review 
identified a general lack of outcome data relating to models of vertically integrated healthcare 
compared with evidence for the processes of integration. [112]  With respect to integration of 
payment and provider functions (e.g. using pooled budgets, and organisational mergers and 
acquisitions) the evidence demonstrated there was at least a perception of improved partnership 
formation, some limited evidence for increased healthcare capacity, and an increased focus on 
case management and use of information technology. However there was mixed evidence for an 
effect on hospital admission rates, length of stay in hospital, and the overall impact on costs of 
healthcare. [112]  With respect to integration of healthcare providers, the evidence demonstrated 
a conflict between strengthened local partnerships and a lack of co-ordination at national policy 
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level. In addition, there were some reports of improved healthcare capacity, for example with 
freeing up labour, and an improved focus on governance and adherence to guidelines. There was, 
however, little evidence of an impact on health outcomes and limited evidence of an impact on 
costs. [112]  With respect to clinical integration by formation of networks the evidence 
demonstrated inconsistent effects on networking, specifically communication and personnel role 
changes, largely non-significant improvements in care provision, and potentially some 
improvements in costs and health outcomes. The authors expressed concerns about potential for 
reporting or publication bias. [112] 
Disease management programmes share a number of features with integrated healthcare 
interventions, particularly the narrow clinical focus. [113] A systematic review of disease 
management programmes, published in 2004, reviewed 102 reports of eleven chronic conditions. 
The review found that most disease management programmes improved patient satisfaction, 
patient medication adherence, and improved disease control. There was less clear evidence for 
the cost-effectiveness of, or reduction in expenditure associated with, disease management 
programmes. [114]  
Additional evidence for integrated care was reported by The Nuffield Trust using examples from 
the English NHS and other peer-reviewed sources. [115]  The conclusions were directed at the 
integrated care pilots which had been announced following the Department of Health ‘High 
Quality Care for All’ report (‘the Darzi review’). [49] Specifically, ten salient points were 
highlighted with relevant examples of good practice provided. The overall tone of the document 
was one of cautious optimism for the integrated care pilots and the evidence they could generate 
for future integrated care in the NHS. [115] 
Other reviews have focused on specific components of integrated care. [116] For example, a 
systematic review of disease management programmes, defined as ‘… patient-centred 
approaches of co-ordinated multiple healthcare interventions that structure chronic care to a 
specific patient group. … also referred to as e.g. integrated care, managed care, patient-centred 
care, and case management’ included 31 studies in the disease areas of diabetes, depression, 
heart failure and chronic-obstructive pulmonary disease. The focus of the review was the impact 
on healthcare expenditure. The evidence demonstrated substantial cost-savings for some 
programmes, although almost as many programmes demonstrated more modest cost increases. 
The balance was generally in favour of disease management programmes for reducing overall 
healthcare expenditure. [116] 
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2.4 Care Pathways 
2.4.1 What is a care pathway? 
It is important to consider first the definition of a ‘care pathway’. As with ‘integrated care’, the 
description is subject to a large degree of variation in terminologies used. Several definitions exist 
with as many complementary as there are distinct. The definition of an integrated care pathway 
and other types of care pathways have varied in the literature over time, geography, and 
healthcare setting. [117] 
Some of the more common terms in use which encompass the concept of a clinical pathway are 
care pathway, critical (care) pathway, integrated care pathway and care map. [118] 
A review on the use of these four terms (care pathway, critical pathway, integrated care pathway, 
and care map) in 263 published articles found they were collectively associated with 84 different 
definitions. [117]  Although a large degree of commonality and agreement between the various 
definitions was identified there still remained a considerable level of discordance. The authors 
generated a single definition of a clinical pathway presented as a starting point for further 
deliberation: [117] 
A clinical pathway is a method for the patient-care management of a well-defined group of 
patients during a well-defined period of time. A clinical pathway explicitly states the goals and 
key elements of care based on evidence based medicine guidelines, best practice and patient 
expectations by facilitating the communication, coordinating roles and sequencing the 
activities of the multidisciplinary care team, patients and their relatives; by documenting, 
monitoring and evaluating variances; and by providing the necessary resources and outcomes. 
The aim of a clinical pathway is to improve the quality of care, reduce risks, increase patient 
satisfaction and increase the efficiency in the use of resources. [117] 
The apparently now defunct National Pathways Association (UK) had defined a care pathway in 
1999 as: [118, 119] 
An integrated care pathway determines locally agreed, multidisciplinary practice based on 
guidelines and evidence where available, for a specific patient/client group. It forms all or part 
of the clinical record, documents the care given and facilities the evaluation of outcomes for 
continuous quality improvement. 
The European Pathway Association defined a care pathway as: [120] 
A complex intervention for the mutual decision making and organisation of care processes for a 
well-defined group of patients during a well-defined period.  
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Defining characteristics of care pathways include:  
• an explicit statement of the goals and key elements of care based on evidence, best 
practice, and patients’ expectations and their characteristics 
• the facilitation of the communication among the team members and with patients and 
families 
• the coordination of the care process by coordinating the roles and sequencing the 
activities of the multidisciplinary care team, patients and their relatives 
• the documentation, monitoring, and evaluation of variances and outcomes; and  
• the identification of the appropriate resources 
• The aim of a care pathway is to enhance the quality of care across the continuum by 
improving risk-adjusted patient outcomes, promoting patient safety, increasing patient 
satisfaction, and optimizing the use of resources. 
A Cochrane review on care pathways also came up against the issue of multiple definitions and 
varied terminologies for what a care pathway is. [121] The authors worked around the 
terminological issues by opting to use a broad definition of a care pathway as being any 
intervention or programme which was a ‘structured multidisciplinary plan of care’ and which met 
at least three of the four following criteria: 
1. It channelled the translation of guidelines or evidence into local structures. 
2. It detailed the steps in a course of treatment or care in a plan, pathway, algorithm, 
guideline, protocol or other ‘inventory of actions’. 
3. There were time-frames or criteria-based progression (i.e. steps were taken if designated 
criteria were met).  
4. The aim was to standardise care for a specific clinical problem, procedure or episode of 
care. 
Using these broad criteria the authors identified and screened over 3,200 article abstracts 
although only 28 met the inclusion criteria. [121] The definition used in the Cochrane review had 
been systematically elucidated using a targeted literature search. [122] However some respected 
commentators criticised the Cochrane definition as it did not stipulate that a pathway is a 
‘complex intervention’. This criticism was extended to the outcomes reported in the Cochrane 
review, in particular the distinction between simple pathways and pathways which were one 
component of a multifaceted intervention. The commentators argued that a pathway would 
always be part of a multifaceted intervention. [123] The same team of authors had previously 
asserted a view that care pathways were more than stand-alone documents or checklists but 
instead should be viewed as an encompassing and abstract intervention of a concept, model, 
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process and product. [124] In this same article the authors alluded to the term ‘integrated care 
pathway’ as being a UK-specific term used to describe a ‘clinical pathway’ and this is supported by 
the National Pathways Association’s definition of a care pathway reported in this same 
section. [124] 
2.4.2 Aims of care pathways 
The aims of care pathways are not always clear or explicit. There are many aims and uses for care 
pathways and these vary depending on the perspective. Care pathways have been used for 
multiple purposes: [119] 
• Implement guidelines and evidence-based practice; standardise care and reduce variation 
• Control and minimise costs 
• Improve the efficiency of the healthcare system 
• Improve patient documentation and providing patient education 
• Widen patient choice 
• Improve quality of care 
• Promote, improve or support clinical audit, benchmarking, accreditation and clinical 
governance 
• Promote, improve or support communication between different components of the 
pathway 
• Manage risk and litigation 
• Promote, improve or support the commissioning of services 
The evidence that care pathways achieve these aims was described in the Cochrane review 
referred to previously. [121] The review assessed the overall effects of clinical pathways on health 
professional practice, patient outcomes, length of (in-patient) stay, and hospital costs. In addition, 
the review sought to identify specific factors (setting, nature of intervention, specific types of 
intervention, and quality of intervention development and implementation) that might contribute 
to the effectiveness of a clinical pathway. The review concluded that clinical pathways were 
associated with reduced in-hospital complications and improved documentation without 
impacting negatively on the inpatient length-of-stay or hospital costs. [121]  
2.4.3 Other evidence for pathway redesign 
A report by the Government’s Audit Commission published in 2004 reviewed the redesign, 
planning and delivery of care pathways, particularly at the primary-secondary care interface, in 
English primary care trusts. [125] The redesign of pathways was found to improve the actual care 
delivered, reduce waiting times, and increase the range of healthcare options available to patients. 
However at it also found that only 7% of PCTs reported having sufficient staff available to drive 
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pathway redesign. Considerable challenges were identified in certain areas of pathway design and 
implementation, particularly with respect to communication and stakeholder engagement, 
notably with patients and hospital-based specialists (consultants). The generalisability of these 
conclusions was challenged as they were largely based on an assessment of 14 services focusing 
only on dermatology or orthopaedic care with a specialist practitioner working in primary care in 
each case. [125] 
One of the drivers for integrated care has been the identification of care provided in secondary 
care which could be provided adequately yet more conveniently for patients in primary care. 
Evidence which supports the transfer of acute inpatient and day-case services from hospitals into 
the community and the associated impact on care quality and healthcare costs was examined in a 
report published by The Health Foundation. [126]  The evidence demonstrated that community-
based services could, under certain conditions, provide care which was at least as good as that 
provided by hospitals and potentially at reduced cost. Evidence for patient-oriented outcomes has 
been limited, with some benefits from improved access to a range of services, easier travel to 
physically access services, and shorter waiting times. The conclusions of the report were 
necessarily cautious due in part to the quality and extent of the supporting evidence. For example, 
a potential for community-based services to reduce healthcare costs was highlighted although to 
achieve noticeable cost savings such a policy would need to operate with active decommissioning 
of hospital bed provision (i.e. ‘ward closures’). [126] 
A briefing paper from The Nuffield Trust described three successful examples of integration 
between primary and secondary care in the English NHS. [127] Each example employed a 
different strategy to achieve integration, with models consisting of community-based specialists, 
as was seen in the examples cited in the Audit Commission report of 2004; [125] or primary care 
reaching into hospitals with GPs accompanying specialists and provision of traditionally hospital-
based services in premises which are owned and staffed by primary care providers; and finally a 
model of partnership working in which strong relationships and organisational commitments were 
reinforced with some pooled budgets and the agreement of eight principles of contracting. A 
common feature of each of these examples was that they were developed locally with strong local 
leadership demonstrating initiative and commitment despite considerable challenges. Medical-
profession leadership is noted as being of crucial importance to the success of these examples of 
integrated care. The examples demonstrate that changes take considerable time and often 
involve a complex path of development. National policies have both promoted and inhibited 
clinical integration between primary and secondary care. [127] 
A review on the auditing of care pathways identified 15 care pathway audit tools although the 
majority of these had not been published in peer reviewed literature. Only one of the tools had 
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been piloted and externally validated. At the time of writing, the authors were not aware that any 
of the tools had been cited in a peer reviewed publication examining the effect of clinical 
pathways. Interestingly, the authors used a realistic evaluation framework to conduct their review 
of care pathway audit tools. [128] 
A report published as part of an NHS improvement programme identified examples of patient 
benefits associated with clinical pathway redesign specifically in the therapeutic areas of cancer, 
heart disease, lung disease, stroke care, and diagnostics. [129] The report described the benefits 
collectively as enabling patients to enjoy better health and well-being due to practical service 
improvements. Acknowledging the limited clinical range the report concluded that there was ‘no 
reason why these improvements could not be applied to other [therapeutic] areas’. [129] 
2.5 Integrated Care Pathways 
2.5.1 Definition of an integrated care pathway 
It is not clear whether an ‘integrated care pathway’ is distinct from other pathway definitions such 
as ‘care pathway’ and ‘clinical pathway’ etc. For example, the aforementioned care pathway 
definition from the National Pathways Association opened with ‘An integrated care 
pathway ….’. [118, 119]  An editorial accompanying a special edition of the International Journal 
of Integrated Care on integrated care pathways stated that the term ‘integrated care pathway’ 
should refer especially to pathways which were integrated across various health care settings, for 
example across hospitals and community health services. [130] Hence, multidisciplinary 
collaboration within a single ward, for example, was not in itself an example of an integrated care 
pathway. [130] This was at odds with a review of the terminologies of pathways which set out to 
define ‘care pathway’. This stated that the addition of ‘integrated’ was unnecessary as a care 
pathway must be, by default, integrated. [131] The authors proceeded to state that the term 
‘clinical pathway’ was reserved for use within a clinic or hospital department and a ‘care pathway’ 
would be differentiated by existing over a longer term and by including, for example, outpatient 
department activities, discharge from hospital and after-care. Further interrogation of the actual 
evidence considered in the review revealed a continued focus on acute or critical care, calling into 
question the validity of the authors’ terminological assertions. [131] As highlighted in the previous 
section, at least one team of respected pathway experts has asserted that ‘integrated care 
pathway’ was simply a UK-specific term which described a care / clinical pathway. [124] 
Nonetheless, an ‘integrated care pathway’ has been defined succinctly as: 
‘ … a structured multidisciplinary care plan which details essential steps in the care of patients 
with a specific clinical problem’ and which ‘ … describes the expected progress of the 
patient’. [47] 
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2.5.2 Evidence for integrated care pathways 
A state governmental report from Australia described five pilot projects as ‘integrated disease 
management projects’. [132] These involved models of integrated care for chronic disease, 
specifically diabetes (three), asthma, and hypertension. Each was funded for three years from 
2001. The design of the projects required that social care and services played an important role, 
i.e. there was a key element of horizontal integration. In addition, there appeared to be a less 
defined role for specialist care with the focus on primary medical care and social care support but 
with an expectation that demand for acute and specialist services would be subsequently reduced. 
Over 1,000 patients were treated within at least one of the individual projects. In each project 
patients were educated and empowered to take on a degree of responsibility for their own care. 
Some staff members, typically nursing staff, were given the task of delivering patient education. 
Patients were also able to attend events at which they could meet other patients with the same 
health problem. Patient opinions were reported as overwhelmingly positive although a reporting 
bias could not be ruled out. [132] 
A subsequent evaluation report of the programme sought to identify, amongst other things, the 
barriers and enablers to improving care for people with chronic conditions via the disease 
management programmes. [133] The enabling factors included: 
• Use of systems and protocols based on evidence of best practice 
• Building on existing resources and infrastructure 
• Promotion of a centrally coordinated care pathway with clear entry points for consumers 
(i.e. patients) 
• Resourced and stable workforce within agencies and programmes 
• Identification of key opinion leaders and change agents 
• Early and broad participation in planning, shared decision making and clear understanding 
of roles to foster ownership 
• Agency leadership and high level management commitment 
• Value added training and education of health care providers 
A number of barriers were also identified, all of which specifically related to primary care 
engagement. [133] 
• Competing initiatives 
• Lack of primary care medical professionals or large workloads 
• Reluctance to engage with untried and short-term initiatives 
• Misunderstanding the benefits of patient self-management and multidisciplinary care in 
chronic disease 
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Neither the official [132] nor the evaluation report [133] identified any specific outcome measures 
for any party (patients, professionals, or health economy/system). 
A mental health initiative from the south west of Scotland provided an example of horizontal and 
vertical integration within a single integrated health and social care pathway initiative. [134] The 
evaluation found a clear disconnect between what was expected and desired and what actually 
happened. In practice the pathway was seldom used and this was itself seen as a barrier to 
further integration. The focus of the evaluation shifted to identifying the barriers encountered 
when the pathway was implemented. These included those of an organisational nature 
(fragmentation, differing priorities, and distinct resources) and a general lack of resources for on-
going support, team development, and change management. 
A systematic review of integrated care pathways, using the European Pathways Association 
definition, [120] included only nine reports of seven randomised controlled trials from an initial 
sample of more than 4,000. [135] A narrative summary using a realist evaluation perspective was 
provided. Despite the small sample size, the review made a number of conclusions about when 
integrated care pathways were, and were not, effective. The review found that integrated care 
pathways were effective when care trajectories are predictable but the usefulness of care 
pathways in settings in which recovery is more variable was unclear. Integrated care pathways 
were most effective in achieving behavioural changes when there are known deficiencies and 
their value where inter-professional working is already well established was uncertain. None of 
the studies included an economic evaluation and therefore no conclusion could be made about 
the economic value of integrated care pathways and whether the benefits justified the 
implementation costs. [135] 
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2.6 Interventions specifically in IBD patient populations 
With respect to IBD specifically, little evidence of new or redesigned vertically integrated models 
of healthcare was identified. No evidence was identified of an evaluation of an integrated care 
pathway in IBD, irrespective of the evaluation approach or technique. A brief summary to the 
associated evidence specific to IBD is provided. 
2.6.1 Patient choice, shared care and shared decision-making 
A key feature of the IBD Standards [1] which would later be incorporated into the IBD pathway 
evaluated in this thesis was the notion of patient choice, also described as shared care and shared 
decision-making. Specifically this relates to macro-level choices about the location and provision 
of healthcare (e.g. primary vs. secondary, GP vs. specialist, hospital vs. home) and micro-level 
choices about particular treatments. [1] These particular standards (box 3) reflected the general 
healthcare and governmental policy background which supported patient choice.  [136] It was not 
clear whether this in turn reflected specific evidence for the benefits of increasing patient choice 
in decisions about different aspects of healthcare or whether it was politically motivated. 
A theory-driven systematic review of patient choice in healthcare examined the evidence for the 
demand and impact of two aspects of choice; provider and treatment. [137] In terms of demand 
for patient provider-choice, the data did not reveal any conclusive evidence of preferences for 
primary vs. secondary care treatment. However patients were interested in choosing between 
different secondary care providers so long as there was a tangible benefit to themselves such as 
reduced waiting times or better quality care. The data did reveal that certain types of patient 
based on demographic and socioeconomic factors were more or less likely to exercise a right to 
choose and therefore the ability to obtain benefit from the provider-choice agenda was 
potentially inequitable. In terms of patient treatment-choice, the review found that there was a 
greater volume of evidence supporting this aspect of patient choice. Patients reported a relatively 
high demand for treatment-choice which wasn’t always matched in practice even when the 
option to choose was available. The factors which influenced treatment-choice were highly 
complex and spanned social interactions and cultural beliefs as well as scientific interpretation. 
The authors concluded with an expression of caution regarding provider-choice but were more 
positive about treatment-choice, stating that patients ‘want to be more involved in individual 
decisions about their own treatment and generally participate much less in these decisions than 
they would wish’. [137] 
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Box 3. IBD Standards which related to patient choice and related themes [1] 
Standard B1. Arrangements for Shared Care 
The arrangements and scope for shared care and the circumstances in which the patients 
should be referred back to hospital care must be clearly defined between the hospital staff 
and the GP. They must be explained verbally to the patient and written information on this 
provided to the patient, ideally as a care plan. …. 
Arrangements should always be made in discussion with the patient. 
Standard C. Maintaining a patient-centred service 
Care for IBD patients that is patient-centred, responsive to individual needs and offers 
choice of clinical care and management where possible and appropriate. 
No single model [of healthcare provision] is appropriate for all patients all the time, and 
choice between three approaches is appropriate: hospital care, shared-care with primary 
care and supported self-managed care. 
Offering personalised and responsive healthcare means that any patient can migrate 
between models of care according to the activity and complexity of disease, local facilities 
and personal preference. They can also make different choices at different times in their 
illness. 
Standard C3. Supporting patients to exercise choice between treatments 
Where there are alternative treatment options then information and support should be 
offered to patients to enable them to participate in decisions about which treatment to 
select.  … 
Standard C4. Supporting patients to exercise choice between care strategies for outpatient 
management 
Patients may prefer continuing hospital management, shared care with their GP or 
supported self-management and they may wish to choose a different option at different 
stages in their illness.  … 
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Although no evidence was identified which specifically evaluated IBD patient choice, whether 
relating to the provider or treatment, a review of initiatives aimed at empowering IBD patients did 
include elements of patient choice as patients were educated to self-manage. [138] The self-
management involved self-determination of specialist consultation and self-medication with 
prescription only medicines. However in these scenarios patients were operating according to 
specific protocols and it did not appear they were in a position to choose whether to consult a 
specialist or a GP, or select from amongst a number of specialists, or whether they were involved 
in the selection of drug treatments. In these respects, although patients were clearly empowered, 
this occurred in the context of constrained choice. The review still concluded that ‘the effects of 
guided self-management on compliance have not been evaluated, but early, qualitative data 
suggest that when patients feel more responsible for symptom control they are more likely to 
adhere to the treatment regimen especially if they have been involved in the choice of 
regimen’. [138] 
One randomised controlled study incorporated elements of both provider and treatment choice 
within a patient empowerment programme, referred to as a self-guided management 
intervention [139] In this example the intervention involved discussion of treatment options with 
patients, presumably with a hospital-based specialist. A treatment regimen was then agreed 
which patients would use whenever symptoms of a relapse of ulcerative colitis occurred. In 
addition, if patients experienced symptoms of relapse they could consult their GP, or under 
specific circumstances consult specialist services, or commence self-medication with the agreed 
regimen. In the event, almost all intervention relapses were self-managed compared with just half 
of relapses in the control group. It was not clear what, if any, aspect of patient choice contributed 
to the positive outcomes in the intervention group as patient choice in this example was not 
isolated from patient and, to a lesser extent, primary-care physician empowerment. [139] 
An epidemiological study of IBD in a primary care population in North East England found that GPs 
made a significant contribution to meeting the healthcare needs of IBD patients. Published in 
2000, it reported that care was equally shared between GPs and gastroenterologists. The authors 
concluded that, given the large degree of care provided within primary health services, there was 
a need for GP training in the management of IBD and a redistribution of resources to  
primary care. [2] 
2.6.2 Routine vs. ‘when required’ specialist care 
One of the key reports available is of a UK-based project conducted in the mid-1990’s. Williams et 
al described a randomised controlled trial comparing ‘on-demand’ or open access with routine 
appointments for follow-up of patients with quiescent or mild, stable IBD. [140] Primary outcome 
measures utilised accepted quality of life indicators such as the SF36 and the disease-specific UK 
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quality-of-life IBD questionnaires as well as quantitative measures of healthcare utilisation. The 
study recruited 180 patients with similar numbers randomised to each type of care and high 
follow-up rates. The study ran for 12 months with patient-data collected for up to 24 months. The 
results demonstrated no significant differences in quality of life measurements. There was a clear 
patient preference for open access although a minority did express strong preferences for routine 
care. Open access patients used substantially and significantly fewer healthcare resources as 
measured by day visits and outpatient visits, with a corresponding reduction in the cost of total 
investigations. There were no significant differences in inpatient days or any specific individual 
investigation. However there were differences in use of drugs with open access patients 
demonstrating a greater level of use. No explanation for this observation was provided. The net 
effect on cost was small and not significant, with open access patients actually associated with 
slightly greater costs compared with those receiving routine care. Although total costs were 
similar the distribution did show clear differences with an apparent shift from secondary to 
primary care.[140] A separate report investigated the views of GPs (n = 69) whose patients were 
involved in the open access arm of the study. [141]  The results, which included both face-to-face 
interviews and postal survey responses, found that 13% experienced a problem with the 
management of at least one open access patient, only 8% were aware of the IBD shared care 
guideline, 42% had experience of using the specific patient paper record, and  81% were in favour 
of providing written patient guidelines for open access. Ultimately 68% preferred open access for 
IBD patients in general, and 65% supported the establishment of a gastrointestinal specialist 
nurse to support open access. There was some discordance between preferences expressed by 
patients and their GP, with agreement for care model in only 60% of 122 cases. [141]  
2.6.3 Routine vs. self-care in ulcerative colitis 
High-quality evidence from randomised-controlled trials has been published relating either to 
specific sub-diagnoses of IBD or aspects of treatment such as patient empowerment and 
education. Robinson et al described a randomised-controlled trial conducted in the North West of 
England. [139] Patients with ulcerative colitis were randomised to either open-access follow-up 
aided by a ‘personalised guided self-management regimen’ (n = 101) or usual practice which 
relied upon regularly scheduled follow-up and referrals for specialist care (n = 102). After a 
median follow-up of 14 months (minimum 11 months) the results were striking; relapses were 
treated earlier in patients in the open access group compared with those in the usual care group 
(mean 14.8 vs. 49.6 hours, p < 0.0001). In addition, 97% of open access patients commenced 
treatment for relapse within two days compared with 63% in the control group and a non-
significant trend towards a shorter duration of relapse was observed in patients who commenced 
treatment within 24 hours of the symptoms of a relapse (17.7 vs. 25.5 days, p = 0.16). Open 
access patients also demonstrated reduced healthcare utilisation as evidenced by a reduction in 
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the number of medical appointments (89 vs. 344) although this effect must be balanced against 
increased appointment duration in order to establish the patient management plan. Accordingly, 
there was a reduced impact for patients in terms of the time required to attend medical 
appointments and the direct costs of travelling to and from such appointments. The study 
identified strong and clear patient preferences for the self-management open access approach. 
The generalisability of this study was compromised because only patients with stable and 
uncomplicated ulcerative colitis were included, and it focused only on the management of 
relapses over a relatively short period of time.[139] 
2.6.4 Randomised study of patient-centred care 
Another randomised controlled trial conducted by the same researchers was published in 2003 
under the auspices of the NHS Health Technology Assessment programme. [142, 143]  This study 
was a cluster randomised trial of 19 secondary care centres within the English NHS. Selected 
patients had either ulcerative colitis or Crohn’s disease. Nine sites were randomly selected to 
deliver an intervention that consisted of; training consultants to provide a patient-centred 
approach to care, provision of an information guidebook to patients, development of a written 
self-management plan, and patient self-referral to specialist services. Ten control sites continued 
to deliver care in the usual way which generally manifested as a disease-centred approach to care 
with regular follow-up appointments and medical referral for specialist care. After one year, 
patients in the intervention group recorded fewer hospital visits (1.9 vs. 3.0, p < 0.001) and 
reported they felt more able to cope with their condition (p < 0.05). The intervention group also 
had fewer relapses (1.8 vs. 2.2, p < 0.01), and a strong patient preference was indicated for the 
intervention. The primary outcome measure was a patient-reported disease-specific quality of life 
score, which showed no significant difference between groups after one year. A number of 
quantitative patient-derived outcomes were measured and none demonstrated a significant 
difference although they were all consistently in favour of the intervention group. The 
intervention was found to be associated with reduced costs of about 14%, although it was also 
associated with a small decrease in quality adjusted life-years. [142, 144] The net effect meant the 
intervention was considered to be highly cost-effective to the NHS and the evidence supported 
greater use of patient-centred care in IBD.[142, 144] 
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The project also explored qualitative aspects from the point of view of both patients and 
secondary care medical consultants. [142] With respect to patients, several attributes were 
identified which correlated with a patient’s ability to manage and cope with self-care. With 
respect to medical consultants, they were generally supportive of greater self-management for 
their IBD patients although there were differences amongst them about which patients would be 
suitable for the intervention and concerns about the management and operation of the system 
[142]. 
2.6.5 Communicating clinical information to IBD patients 
Other disease-specific evidence identified was referred to in a publication from the Royal College 
of General Practitioners in their 2008 publication ‘Teams without walls’. This report described 
numerous examples of vertically integrated healthcare models within the UK. One project was 
described in which ‘patients with IBD were educated and empowered to manage their condition 
with hospital attendance if they were stable. The results of blood test monitoring and advice were 
sent by email or text.’ An evaluation of this project estimated that the freed outpatient slots alone 
saved an estimated £40,000 per annum and allowed rapid advice for patients suffering a relapse. 
More details were received from one of the lead clinicians involved in the project. Motivated by 
similar factors as the HTA study [142] it also appeared to focus on an apparent excess of routinely 
scheduled outpatient appointments. In particular, information was communicated to patients via 
novel methods concerning such details as the results of blood tests and other simple 
investigations which, if nothing untoward was identified and patients were otherwise stable, 
enabled a substantial reduction in outpatient appointments. The information was communicated 
via mobile telephone short message service, or ‘text messaging’, electronic mail, or both.[145] 
The service evaluation included 314 patients; 69% responded to the offer of the new service, 18% 
opted to remain with the existing service, 44% chose electronic mail, 31% chose text message, 
and 8% requested normal telephone communication. Thus, over half of all patients opted for at 
least one of the novel modes of communication offered. The proportion of out-patient 
appointments which were classified as ‘unproductive’ fell from 39% to 13% following 
implementation with estimated savings of about £30,000 per annum to payers. [146] 
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2.6.6 IBD-specific clinical information technology requirements 
One of the specific requirements of the IBD Standards [1] was for an integrated or shared 
information system (box 4). 
Box 4. IBD Standards which related to information sharing [1] 
Standard B1. Arrangements for Shared Care 
A system for sharing of information about test results or treatment changes should be in 
place through the use of IT, written communication between the GP and hospital or a 
patient-held record. 
Standard E1. Register of patients under the care of the IBD Service 
Every IBD Service should maintain a local Register of all diagnosed IBD patients in the 
catchment area (including those who have been diagnosed but are not currently being 
managed in secondary care) recorded on a searchable database and with adequate clerical 
support to maintain this. 
Standard E2. Developing an IBD database. 
IBD Services should develop towards keeping electronic records of patients’ disease histories 
and treatments. 
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A National Health Service information technology programme called ‘Do Once and Share’ 
featured IBD as one of its core therapeutic areas. [147] The aim of the programme was to obtain 
feedback from specialist groups for NHS Connecting for Health, part of the NHS National 
Programme for Information Technology, in order to assist in the specification of new NHS 
information technology systems. The IBD component was led by a team from an acute hospital 
trust based in the South West of England. Following a national consultation the team submitted a 
set of requirements that were considered essential and desirable for an integrated IBD care 
record. The requirements were extensive and covered several aspects of care ranging from 
patient requirements, clinical standards, medication, in-patient specific care, surveillance, tests 
and diagnostic procedures, communications and others. [147] This aspect of the national 
programme did not appear to have been realised and there was no common NHS IBD-specific 
electronic patient record in existence.  
  
53 
Chapter 3: Methodology 
3.1 Realist evaluation 
The direct observation period of the evaluation ran from October 2009 to December 2011; 27 
consecutive months. Some evidence was also gathered that pre-dated the direct observation 
period. Data relating to patient reviews, practice sign-up rates, and healthcare utilisation was 
collected up to 31
st
 March 2012.  
A diverse range of data sources was used within the realist evaluation of the IBD pathway. These 
were selected on the basis of their relevance to the project and evaluation, breadth of source 
type, availability and accessibility. 
Data sources included in the evaluation: 
• Official programme documents produced for, or otherwise supporting, the Department of 
Health integrated care pilots application including the IBD Standards (2009). 
• Video recording of a presentation made by a project board member as part of the IBD 
Standards launch strategy. 
• Official programme documents produced as outcomes of the pathway (e.g. patient 
information, clinician training aids). 
• Presentations made as part of the pathway (e.g. for training or communication purposes). 
• Official documents relating to project board meetings, such as agenda, minutes, action 
plans, and other associated documents. 
• Evaluator notes of project board meetings. 
• Evaluator notes of other associated meetings and events. 
• Electronic communications (e-mails) which the evaluator was party to. 
• Interviews with key actors and other relevant parties to the pathway. 
• Focus group with local IBD patients. 
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This data, which was largely qualitative in nature, was supported by quantitative data. 
• Descriptive measures of the IBD pathway relating to project management and 
implementation (e.g. number and frequency of project board meetings and other 
significant events, rate of sign-up from general medical practices). 
• Routinely collected data from the annual review component of the pathway, including 
descriptive measures (e.g. number of reviews, completion rate per component, quality-of-
life and symptom scores). 
• Routinely collected NHS data from prescribing analysis and cost (PACT) data sets and 
health episodes statistics (HES) data sets. 
3.1.1 Theories of change 
A crucial step in conducting a realist evaluation is to identify the theories of change, whether 
explicit or implicit, within the programme being evaluated. [63] Within the IBD pathway any such 
theories were not explicitly stated within any of the data sources. Therefore the theories of 
change were elicited from the empirical data and observations. 
3.1.2 Quantitative analysis 
3.1.2.1 Pathway descriptive outcomes 
A number of data sources were used to obtain descriptive outcomes relating to the pathway. Data 
was principally derived directly from the Primary Care Trust (PCT) project team and in particular 
the last update of the pathway audit template up to and including 31st March 2012. Data 
provided by the PCT project team was verified, where possible, against information provided 
during the course of the evaluation, for example during project board meetings and e-mail 
communications. Data has been presented in the most appropriate and easy to understand 
manner with particular reference to temporal parameters. 
3.1.2.2 Annual review audit data 
A comprehensive description of data relating to the delivery of primary care annual IBD patient 
reviews according to the IMAGE template (appendix 1) was planned. The source of data was the 
audit master sheets collated by the PCT commissioning team which collated separate audit data 
from individual practices using identical templates. 
Reviews of patients in secondary care were also planned and would be collated and reported to 
enable comparison between primary and specialist care managed patients. Both primary and 
secondary care clinicians planned to use identical templates for conducting reviews and the 
hospital IBD team was encouraged to record reviews using the same template used in primary 
care to facilitate comparison. 
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3.1.2.3 Other pathway quantitative outcomes, e.g. relating to healthcare utilisation 
A range of data sources was utilised to obtain quantitative data pertinent to the IBD pathway. 
Prescription data 
Data relating to prescription drug use was obtained from data collected by the NHS Business 
Services Authority – Prescription Pricing Division (PPD). This data is known as Prescribing and Cost 
Analysis (PACT) data [148] and has been widely used in studies of healthcare utilisation. Data was 
obtained for the whole of the target PCT and for the whole of the NHS North East Strategic Health 
Authority combined, consisting of 12 PCTs (‘the SHA’). This data was provided by a sub-contracted 
NHS organisation on the basis that individual patients, clinicians, or primary care medical practices 
could not be identified, and the organisation had received the necessary permissions from the 
data owners (the PCTs) for this use. Compliance with the Caldicott principles was assured. 
The PCT dataset was then subtracted from the SHA dataset which provided two datasets, one for 
the PCT and the other of the SHA-excluding the target PCT. The data was then analysed using a 
differences-in-differences approach, the same as that envisaged within certain quantitative 
aspects of the integrated care pilots programme evaluation. [149]  A differences-in-differences 
(DiD) approach would account for, either partially or wholly, the effect of contemporary changes 
to the pattern of prescribing regardless of whether these changes were associated with the IBD 
pathway or any other intervention. [150]  An implicit assumption within the DiD technique was 
that the only way in which the prescribing of the IBD drugs would differ between the target PCT 
and the rest of the SHA would be because the target PCT was subject to a specific integrated care 
pathway for IBD which might in turn have had an impact on prescribing of IBD drugs, i.e. it was 
assumed that the underlying trend in all data sets would be the same over time and other 
external factors were not included. 
PACT data is not linked to individual patients and therefore cannot be linked to specific 
therapeutic indications. The data is therefore relatively crude and limited in its applications. [151] 
However, some medicines are licensed and used only for IBD and related diagnoses, and other 
medicines are used predominantly for IBD and related diagnoses such that they can be considered 
essentially specific to IBD. A list of licensed medicinal products commonly used to manage IBD 
was derived objectively from searching the electronic medicines compendium [152] and the 
British National Formulary (BNF) [28]  to create a list of drugs known as the IBD basket and this 
formed the basis of prescription IBD-drug analysis. 
  
56 
Table 2. The IBD basket of drugs 
Therapeutic class Drug Presentations or route of administration 
Proprietary 
name or 
manufacturer 
Amino-salicylates 
Balsalazide All All 
Mesalazine All All 
Olsalazine All All 
Sulfasalazine 
Enema / suppositories / rectal All 
250 mg in 5 ml oral suspension Rosemont 
500 mg tablets  
(excluding enteric coated) 
All 
Steroid 
preparations 
Beclometasone 5 mg modified-release tablets All 
Budesonide 
Enema / rectal All 
3 mg modified-release capsules Entocort® 
9 mg modified-release capsules All 
Hydrocortisone Enema (foam) Colifoam® 
Prednisolone Enema / suppositories / rectal All 
The initial IBD basket of drugs was then refined by expert consensus through consultation with 
the academic adviser and consultant gastroenterologist members of the project board. Consensus 
was reached in entirety and only one change was made to the original list (table 2): Oral 
sulfasalazine was considered to lack sensitivity for IBD as it is used extensively in other 
inflammatory conditions, notably rheumatoid arthritis. [153]  All available aminosalicylate drugs 
with the exception of oral sulfasalazine were considered to be highly sensitive to IBD. 
Expert opinion was that sulfasalazine, even when differentiated by the nature of the tablet 
formulation, would not be sufficiently sensitive to IBD. PACT data was then extracted relating to 
the refined list of medicines and provided in Microsoft™ Excel™ format. The prescription data 
which was requested and provided covered 36 consecutive months from April 2009 to March 
2012. This permitted concatenation of data into twelve fiscal quarters (three-month tranches) or 
three fiscal years (each April to March) as required. 
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Given that the prescription data spanned two distinct classes of drugs commonly used in the 
management of IBD, and included two administration routes (oral and rectal), a combined data 
analysis by volume alone was not appropriate. Therefore a single and consistent measure of use 
was required to enable a combined analysis of the whole data set. Such measures are included 
within PACT data sets, specifically the Average Daily Quantity (ADQ) [154] where such a value 
exists, or otherwise the ‘defined daily dose’ (DDD). [155] Both ADQ [156] and DDD values are 
specific to a drug plus route combination. Not all drug-route combinations have an ADQ [156] or 
DDD [155] value determined and this was true for only one of the drugs in the IBD basket. In this 
particular case a typical daily dose was identified with reference to the relevant summary of 
product characteristics (SPC) [157] and the BNF [28]  and was substituted in place of an ADQ or 
DDD. 
As can be seen in table 3, all but one of the drug-route combinations in the IBD basket of drugs 
had an ADQ defined and in four out of 10 cases this matched the corresponding DDD value. In 
only two cases, both of which were mesalazine-route combinations, did the DDD value vary 
compared with the ADQ and in both cases the variation was small (1.5 g vs. 1.6 g, respectively). 
ADQ and DDD values are periodically reassessed and may therefore change over time. However, 
over the period for which the data was obtained no changes to the relevant ADQ or DDD values 
were identified. 
The total quantity of each drug-route combination was calculated from each data set per unit of 
time (month, quarter, year) and then divided by the daily dose values in table 3 to yield a figure 
for each drug which described the total number of daily doses prescribed in the respective time 
frame. The number of daily doses was then summed across all drugs to yield a single figure per 
unit of time and this was the primary figure used in analyses. 
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Table 3. Measures of daily dose consumption for the IBD basket of drugs 
Drug Route of administration Daily dose Source 
Balsalazide Oral 6.75 g ADQ* 
Mesalazine 
Oral 1.6 g ADQ 
Rectal 1.6 g ADQ 
Olsalazine Oral 1 g ADQ* 
Sulfasalazine Rectal 2 g ADQ* 
Beclometasone Oral 5 mg SPC/BNF 
Budesonide 
Rectal 2 mg ADQ 
Oral 9 mg ADQ* 
Hydrocortisone Rectal 250 mg ADQ 
Prednisolone Rectal 20 mg ADQ 
* : Same as DDD 
Hospital and specialist healthcare utilisation metrics 
Data relating to healthcare utilisation in hospital and specialist settings is routinely collected by 
the English NHS in the Health Episodes Statistics (HES) data set. [158] HES data is a valuable and 
rich source of data relating to diagnostic and procedural activities within the English NHS. Activity 
can even be tracked by individual patients and contains individual demographic details. [159]  
However, access to the full data set is restricted and can be costly to secure. For the purposes of 
this exploratory work, only the freely available HES data was utilised. This data consisted of 
current and historical data sets which could be aggregated at several administrative provider and 
purchaser levels. This analysis focused on the target PCT as a purchaser and the target NHS 
hospital trust as a provider. It was not possible to refine the provider by individual hospital site 
within the same trust, so that data relating to the actual hospital site in the target locality could 
not be distinguished from a secondary hospital site at the same trust in a neighbouring town not 
subject to the IBD pathway. 
HES data consists of a series of codes relating to diagnoses and procedures. The diagnosis codes 
used in HES were those defined by the International Classification of Diseases (tenth revision), 
known as ICD-10.[160]  The relevant diagnostic codes for IBD are listed in appendix 2.  
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The procedure codes used within the HES data set were the Office of Population, Censuses and 
Surveys: Classification of Interventions and Procedures (fourth revision), known as OPCS-4. 
At the greatest level of detail, the OPCS-4 contains 341 separate codes in the ‘lower digestive 
tract’ chapter. The description of each code was screened to eliminate those which were clearly 
unrelated or lacked sensitivity to IBD. The screening process reduced the procedure code list to 
158 codes. These codes were then subjected to independent expert consideration by the project 
academic adviser and consultant gastroenterologist, and a gastroenterological surgeon based at a 
local hospital trust. All three specialists were of the opinion that few of the codes were specific to 
IBD with the exception of those which related to the creation of a colonic pouch, total colectomy 
and panproctocolectomy. 
The final screening process resulted in the identification of only ten IBD-specific procedure codes, 
the descriptions for which are listed: 
• Panproctocolectomy and ileostomy 
• Panproctocolectomy and anastomosis of ileum to anus and creation of pouch (however 
further qualified) 
• Panproctocolectomy and anastomosis of ileum to anus (not elsewhere classified) 
• Total colectomy and anastomosis of ileum to rectum 
• Total colectomy and ileostomy and creation of rectal fistula (however further qualified) 
• Total colectomy and ileostomy (not elsewhere classified) 
• Subtotal excision of colon and rectum and creation of colonic pouch and anastomosis of 
colon to anus 
• Subtotal excision of colon and rectum and creation of colonic pouch (not elsewhere 
classified) 
• Subtotal excision of colon and creation of colonic pouch and anastomosis of colon to 
rectum 
• Subtotal excision of colon and creation of colonic pouch (not elsewhere classified) 
These codes formed the ‘IBD procedure basket’ used in analyses. Analysis was preferentially 
performed on a purchaser basis, i.e. using the target PCT as the defining data source commonality. 
A DiD analysis was performed with comparison against the SHA excepting the target PCT in a 
similar fashion to that performed with the prescribing data. Other analyses were performed as 
were considered suitable and appropriate due to any data or access constraints.  
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3.1.3 Ethical considerations – IBD pathway 
Ethical approval for the evaluation of the pathway was first approved by the Durham University 
Research Ethics Committee in April 2011 after which a submission was made to an NHS research 
ethics committee via the proportionate review process, a constrained ethical approval process for 
non-interventional studies. The NHS ethics application was made via the electronic web-based 
Integrated Research Application System (IRAS) and the study was approved by the NHS National 
Research Ethics Service committee ‘East Midlands – Derby 2’ in May 2011. Final approval to 
actually conduct the study was provided by the relevant PCTs research and governance unit in 
August 2011. 
During the ethical approval process specific concerns were highlighted regarding participant, 
especially patient, confidentiality both during the collection of data and in any publication thereof, 
retention and storage of data, and possible harm to patients. Advice was received from other 
researchers who had conducted patient-focused research with IBD patients. The participant 
information sheet used in this study (appendix 3) was based on one from an earlier study 
conducted by the same academic department. Concerns were raised in the event that a 
participant was not fully aware of the implications of a diagnosis of IBD, for example an increased 
risk of cancer. Therefore if any information was revealed which would cause alarm, distress, 
anxiety or any other emotional change a process would be needed to respond. The solution 
adopted was to ensure that any patients so affected would be encouraged to discuss concerns 
with the researchers present who could direct them to an appropriate service including 
consultation with an experienced medically trained and registered doctor. 
In addition to consultation with other researchers guidance was also sought from a local NHS 
research governance adviser. These discussions did not identify any further issues from those 
identified by the University ethics committee or departmental colleagues. 
An issue did arise concerning my dual role as both a researcher collecting data from the NHS and 
its staff, agents, and patients, and my concurrent NHS employment. Advice from the University 
ethics committee was that the NHS employee role, which could potentially facilitate a more 
flexible ethics approval approach due to the research being treated as an ‘internal (i.e. within NHS) 
process’ was irrelevant in the context of the research project being conducted. Consequently a 
full ethics committee submission as would be expected for research of the nature proposed was 
still required. 
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3.2 Pharmacy exploratory study 
An exploratory study relating to the potential role of community pharmacy and pharmacists in the 
management of adult IBD patients was embedded within the over-arching pathway evaluation. 
This exploratory study was conducted in two parts to reflect two distinct types of data collection 
in which the first would partially inform the second. The first part consisted of a postal survey of 
adult IBD patients and the second consisted of a series of semi-structured focus groups with adult 
IBD patients drawn from the same survey population. 
3.2.1 Survey 
A postal survey was sent to all adult members of a local branch of Crohn’s and Colitis UK, formerly 
the National Association for Colitis and Crohn’s disease. The survey was designed according to 
standard recommendations regarding the design of postal surveys and questionnaires. For 
example, questions relating to baseline demographic details such as age, gender, area of 
residence etc. were positioned at the end of the survey. Questions were designed to be as 
unambiguous as possible. For that purpose, published examples of community pharmacy-
orientated surveys were obtained and suitable questions were extracted or modified for 
inclusion. 
The survey was designed so that the majority of the questions could be answered with a simple 
‘tick-box’ response. There were two questions which could require a written response, although 
the survey was designed to keep any text to a minimum. Some single questions consisted of 
multiple separate assessments; some question responses were binary and mutually exclusive (i.e. 
‘yes’ or ‘no’ type responses) whereas other questions permitted single or multiple responses. 
Other questions essentially served as a filter to a subsequent question which may not have been 
appropriate to answer depending on the response to the preceding filter question. Survey 
questions were designed to flow in a logical fashion from one to the next with occasional step 
changes in specific topics. An experienced pharmacy practice researcher from a neighbouring 
university assisted in the overall design of the survey, and the composition and modification of 
some questions. 
The survey was composed in three distinct parts: The first was a series of eight questions designed 
to elicit baseline data relating to the opportunities that may exist for community pharmacy 
involvement in the management of IBD. The second section consisted of two questions, each 
itself consisting of multiple statements assessed on Likert scales. The second of these was a series 
of questions adapted from published examples. The third and final section consisted of five 
questions designed to elicit baseline demographic and disease characteristics. The final survey 
consisted of 15 questions (appendix 4). 
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The first of the multi-component Likert-scale questions in part 2 (question 9) was a modified 
version of a tested and validated patient satisfaction tool for community pharmacy services. [161] 
This consisted of 20 short statements about the provision of pharmaceutical care from a 
community pharmacy. The pharmaceutical tool was reviewed with an experienced pharmacy 
practice academic from a neighbouring university and it was determined that it would be suitable 
for a UK-based audience despite having been developed in the USA. The tool consisted of 20 
items, or statements, each assessed on a Likert scale ranging from 1 (low score, negative 
responses) to 5 (high score, positive responses). One relatively small but important amendment 
was made with the addition of a ‘no opinion’ option alongside the five standard responses. This 
was added because it was felt that respondents might not have experienced the level of 
pharmaceutical care which some of the items referred to. The ‘no opinion’ option would count as 
‘zero’ and would be recorded distinctly from an absent response. The 20 items were themselves 
split into two dimensions of pharmaceutical care; friendly explanation (FE) with 11 items and 
managing therapy (MT) with nine items. The items for each dimension did not appear to be in any 
specific order although most of the FE items were in the first ten items listed and correspondingly 
most of the MT items were in the final ten: FE items were in survey positions 1-7, 12-14 and 16. 
The order of the published survey was retained in the postal survey used in this study (appendix 
4). Overall FE and MT scores for each individual were calculated as the mean responses of each 
item within each dimension. 
The second of the multi-component Likert-scale questions in part 2 (question 10) consisted of 12 
statements assessed on a scale ranging from ‘strongly disagree’ to ‘strongly agree’. The 
statements were constructed to succinctly and objectively demonstrate the feelings of 
respondents about their experiences of community pharmacy, the involvement of community 
pharmacy and pharmacists in the management of IBD, and about IBD medication. Some 
statements were deliberately designed to contradict others in order to provide a measure of 
intra-responder reliability, to validate responses provided, and to identify non-complementary or 
conflicting responses within the same survey. All statements were derived from published 
examples. The questions were not designed for scoring of responses. 
The survey was first piloted amongst a small number of members of Crohn’s and Colitis UK from 
the national membership list. Several responses were received which resulted in some relatively 
minor amendments to create the final version of the survey. [162] 
The survey was presented as an eight-page A5 size booklet (appendix 4). Survey packs included an 
introductory letter on a single A4 sheet (appendix 5), a stamped addressed envelope for return of 
the survey, a small yellow card for patients to provide their contact details for further information 
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about participating in a patient focus group (appendix 6) and a separate small yellow stamped and 
addressed envelope for its return. 
Survey packs were packaged and stamped at the University. The survey packs were delivered to 
the chair of the branch of Crohn’s and Colitis UK to which the survey was to be distributed. 
Crohn’s and Colitis UK head office had provided stick-on address labels with the addresses of all 
adult branch members. The branch chair then applied one address label to each pack and posted 
397 packs. No one from the University had sight of or access to branch member names or 
addresses. 
3.2.2 Focus groups 
Three focus groups were planned and were prospectively stratified to consist of one group of 
patients with ulcerative colitis, one group with Crohn’s disease, and one group of younger 
patients with any IBD aetiology, defined as aged 50 years or less. This stratification was based on 
expert opinion of the potentially differing views and experiences of community pharmacy of the 
different groups. 
3.2.2.1 Recruitment 
Participants were recruited by volunteer subscription from the same population which received 
the IBD postal survey. Included in each survey pack was a request for further information 
concerning participation in a focus group. Interested parties were required to complete a small 
yellow reply card with their preferred contact details to enable details concerning the focus 
groups to be sent to them (appendix 6). A stamped-addressed envelope was also provided for the 
cards to be returned in. Those who expressed an interest in participating in a focus group were 
sent a separate pack of information, either via post or e-mail as requested.  
The follow-up focus group information consisted of an introductory letter (appendix 7), a 
participant information sheet (appendix 3), consent forms (appendix 8) and, for those sent via 
post, a postage-paid envelope for return. 
3.2.2.2 Conduct 
Each focus group was scheduled to continue for up to two hours. All focus groups were conducted 
in a large seminar room on the ground floor of the Wolfson Research Institute in Stockton-on-
Tees. Light refreshments were provided including the availability of lactose-free milk and gluten-
free biscuits. I served as the focus group facilitator for all focus groups. An experienced pharmacy 
practice researcher from a neighbouring institution was present and assisted on several aspects 
including observational note taking and sound recording. 
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Consent forms were available for participants at each focus group in case some had not provided 
them previously, for example those who had corresponded via e-mail. 
Both the facilitator and assistant were registered and practising pharmacists, although neither 
was working substantially within the community pharmacy field at the time. This information was 
declared to participants before the recording of each focus group commenced. 
The room was arranged so that the facilitator was seated at the head of the tables with 
participants down either side in a ‘boardroom’ style. A single unobtrusive microphone in the 
centre of the tables was connected to a laptop to make a digital sound recording of each focus 
group. 
3.2.2.3 Content 
The first part of each focus group involved a number of non-specific questions regarding the 
manner in which patients currently interacted with their community pharmacies and pharmacists, 
and their general impressions of those interactions and of the professionalism and clinical 
knowledge of pharmacists. More specific questions included topics such as the use of non-
prescription medicines and similar such as herbal, vitamin, and health-food products.  
The second part of each focus group was more structured and introduced six different types of 
service or intervention which could, in theory, be delivered by a community pharmacist or within 
a community pharmacy (see proceeding section and appendix 9). Five of the six scenarios were 
based on components of the IBD Standards [1] and the other was developed de novo using prior 
knowledge of community pharmacy practice and some common problems with medication use in 
long term conditions such as IBD. Each scenario itself consisted of between three and five steps 
with each subsequent step often representing a greater level of management or involvement 
from the community pharmacy or pharmacist. Each step within a scenario was presented in this 
order with subsequent steps only presented if the group was generally positive about the 
preceding step. The scenario schedule was adapted by the facilitator (myself) depending on the 
nature and content of preceding dialogue. 
The focus groups were semi-structured in nature although the structured element, a series of 
headings and topics which had been derived from survey responses was not proscriptive nor 
strictly adhered to. 
Development of scenarios for focus groups 
Several hypothetical scenarios relating to clinical services which could be provided by community 
pharmacies were developed for presentation to each focus group (appendix 9). The scenarios 
were developed primarily relative to the IBD Standards [1] but also with reference to knowledge 
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of existing community pharmacy best and experimental practice, both in the UK and in other 
healthcare systems, and the general profile of IBD management. 
A. Medication adherence 
This scenario was identified as being a common problem in the management of long term 
conditions [163] and specifically within IBD. [37, 164] It was developed using knowledge of 
interventions and developments in community pharmacy relating to other long-term conditions. 
It is the only scenario which did not relate directly to the IBD standards. [1] 
B. Medication monitoring 
This scenario suggested that community pharmacists could be involved in monitoring of oral 
immunosuppressant drugs. Different degrees of involvement were postulated with each step 
ranging from simple reminders given to patients that they were due, for example, a blood or liver 
function test, to extraction of a sample on the pharmacy premises with the pharmacist then 
receiving the results and making dose adjustments as required. This scenario related to IBD 
standard A6: Arrangements for use of immunosuppressive and biological therapies. [1] 
C. Supplemental and enteral feeds 
This scenario related to non-medicinal products sometimes used to manage poor nutritional 
status and were reflected in the IBD Standards (A5: Access to nutritional support and therapy). [1] 
Community pharmacies regularly dispense such items, potentially for IBD patients. The scenario 
consisted of five steps ranging from, at the most basic level, providing information about the 
available products through more targeted advice, on-site sampling, at-home sampling and 
assuming responsibility for ordering of products. 
D. Choice of medication 
This scenario suggested that community pharmacists could be involved in helping patients select a 
particular treatment modality, starting with choosing between medical or dietary control, on 
selecting between the most suitable type of medication, or selecting on a type of medication 
formulation or route of administration. It was made clear to participants that the decision to 
prescribe would remain with a medical prescriber in all steps within the scenario. This scenario 
linked to the IBD standards (C3: Supporting patients to exercise choice between treatments). [1] 
E. Managing a relapse 
This scenario suggested that pharmacists could be involved in helping patients to manage an IBD 
relapse if one occurred. At its most simple it consisted of providing information or counselling 
about how to prevent, cope with, and manage a relapse. At a greater level of involvement it 
suggested the provision of medication either with or without prior medical approval. This scenario 
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did not relate to a specific standard within the IBD Standards, however the standards did refer to 
‘rapid access to specialist care’ including that within the context of a relapse of disease. [1] 
F. Associated healthcare needs 
This scenario described the provision of other healthcare services where a specific need had been 
identified in IBD. It was derived jointly from the IBD Standards (A11: Outpatient care) [1] and 
components of the IMAGE project which related to IBD. [40] The elements derived from the 
IMAGE project specifically related to depressive illness, weight or body mass monitoring, and 
smoking cessation. 
3.2.3 Focus group analysis 
Digital sound recordings of each focus group were copied onto compact disc media and 
transcribed into electronic Microsoft™ Word™ documents by an external transcription service. 
Each transcript was checked for accuracy against the relevant sound recording and all transcripts 
were deemed accurate with no changes or editing following the first transcription. Analysis then 
commenced through reading and re-reading of each transcript to familiarise with the text. 
Transcripts were then formally analysed according to a framework analysis. A framework analysis 
permits certain prior assumptions and provided a starting point for the analysis of the focus 
groups. In view of the extensive survey results from the same participant group, and extensive 
background knowledge of pharmacy practice research, a framework analytical approach was 
considered to be an efficient and appropriate technique. It provided a more efficient analytical 
process compared with alternative analytical techniques, permited the incorporation or prior 
knowledge of quantitative findings, and facilitated external scrutiny of the analysis. [165, 166]  
The framework analysis was expected to yield of specific themes. Key words which were unusual, 
unexpected, or recurrent would be sought to guide the text analysis. 
3.2.4 Ethical considerations – Pharmacy component 
The pharmacy pilot project, both the survey and the subsequent focus groups, presented a 
number of ethical points which had to be considered. The survey was approved by the Durham 
University Research Ethics Committee (School of Medicine & Health) in December 2010 after 
initial submission in October 2010. The local NHS Research Ethics Committee confirmed in 
October 2010 that an NHS ethics approval was not required for this particular project. 
With respect to the surveys, although these would be distributed by a third party thus 
maintaining participant confidentiality, recipients were provided with an opportunity to engage 
with researchers. It was therefore important that any such engagement was kept separate from 
the patient’s survey responses. An additional consideration of the survey was to ensure that it did 
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not request information which could directly or indirectly compromise patient confidentiality. This 
was best reflected in the final section of the survey where patient demographic details were 
requested. The upper age category, for example, was left open-ended as it was felt that few 
participants would fall into that age group (older than 89 years). Another example was with the 
final question which requested the participant’s post code, but which only requested the first half 
of each post code as the full post code would likely be unique to individual participants. The 
survey was also piloted amongst a small number of known members of the same patient charity 
to which the survey would be distributed. Part of this pilot testing was also to identify any 
potential ethical issues which the survey might present, although in the event none were 
identified during the pilot testing process. A specific concern of the ethics committee was 
maintaining survey participant confidentiality with respect to participants requesting further 
information regarding focus groups. The initial plan had been for any such requests to be returned 
in the same envelope as completed surveys. However by separating the two, although at 
increased cost, participant confidentiality could be ensured as well as providing an opportunity for 
participants to opt out of the survey whilst still requesting information about the focus groups. 
Prior to conducting and during planning for the focus groups specific training in the conduct and 
interpretation of focus groups was undertaken by me and potential issues were discussed with 
other researchers who had conducted focus groups with IBD patients. These consultations elicited 
useful information which was reflected in the ethics committee submission and patient-related 
material. The patient information sheet used in this project (appendix 10) was based on one 
which had been used in another research project in the same department which utilised focus 
groups with adult IBD patients. 
Other changes which were made to the project through consideration of ethical aspects, and 
following feedback from the University ethics committee, included:  
• Providing information about possible non-selection for focus group participation 
• Requesting participants to respect the confidentiality of other focus group participants 
• Actions which would be taken by researchers in the event of participant withdrawal 
• Providing participants with information that transcripts would be produced by an external 
service, and that there was an appropriate confidentiality agreement with the provider 
• Providing consent forms for information in advance of each focus group in addition to 
obtaining signed copies at each focus group 
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Chapter 4: Results 
4.1 IBD integrated care pathway 
The pathway underwent three distinct phases with only limited temporal overlap between them. 
The three phases occurred, out of necessity, in the order of design, leading to implementation 
leading to operation. Due to limitations relating to temporal parameters the evaluation observed 
predominantly the design and implementation phases with only a short part of the evaluation 
coinciding with the operational phase. 
4.1.1 Theories of change 
The first step to identifying the theories of change is to identify the change or changes which were 
sought, desired or aimed for. However the aims of the IBD pathway were not explicitly stated 
either within any official documentation or during any project board meetings or any other source 
made available. Implicitly, the aim of the pathway was identified singularly through direct 
associations with other initiatives, such as the IBD Standards [1] and project documents as 
‘increasing the quality of care of IBD patients’.  
The aims and objectives of the IBD pathway when set within the context of the integrated care 
pilots were stated in documents dating from November 2008: 
‘… This proposal is based on the recommendations of the national IBD Standards Working 
Group, prepared for NHS Managers and Commissioning Organisations in order to improve 
services for patients (2006). …’ 
The crucial element herein is that of ‘quality’, a subjective and potentially abstract concept, which 
itself may consist of multiple dimensions. However, for the purpose of this evaluation and due to 
the clear link between the pathway and the IBD Standards, quality of care for IBD patients is 
considered in the context of, and defined by the criteria laid out in, the IBD Standards.[1] 
4.1.1.1 The IBD Standards as the aims of the pathway 
The IBD Standards were intrinsically linked to the genesis of the IBD pathway project. The aim of 
the IBD standards was singularly described as: [1] 
‘… to ensure that IBD patients receive consistent, high-quality care and that IBD Services 
throughout the UK are knowledge-based, engaged in local and national networking, based 
on modern IT and that they meet specific minimum standards.’ 
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4.1.1.2 Pathway mechanisms to deliver change 
After much deliberation and discussion, particularly during project board meetings but also 
through other mediums such as electronic mail, a final iteration of the pathway was arrived at. It 
was clear that several methods, or mechanisms, in the pathway redesign would be employed to 
deliver the aims through multiple changes to the existing model of care. The mechanisms 
identified were: 
1. Patient education, delivered with support from a leading IBD patient charity 
2. A subtle but important element of patient choice for a limited, clinically appropriate and 
objectively identifiable cohort of patients 
3. Improved quality and consistency of primary care management through clinician (GP and 
nurse) education, itself incentivised through financial payments 
4. Greater consistency of care within primary care, and between primary and secondary 
care, for non-acute patients in remission through use of a standardised and tested annual 
review template 
5. Identification of IBD patients through accurate and comprehensive coding of IBD 
diagnoses on primary care medical practice records 
6. Bilateral sharing of information across the primary and secondary care interface 
7. Expanded and increased patient access and communication with the hospital IBD team 
8. Identification and consistent application of evidence-based strategies for managing IBD 
patients within primary care 
In addition, the pathway would provide opportunities for primary and secondary care clinicians, 
both doctors and nurses, to meet and converse, i.e. ‘networking’ opportunities would be 
generated. 
The mechanisms as described, some of which would operate through the same processes, were 
driven by two theories of change which I had identified: 
1. Patient empowerment 
2. Clinician empowerment 
I identified these through a reflexive and iterative process and discussed them with my lead 
supervisor. I had sought to identify firstly how any change was to be delivered by the pathway. 
Following identification of several specific mechanisms which were either explicitly or implicitly 
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identified as a direct outcome of the pathway, these were refined and categorised at less granular 
and more abstract levels. The pathway would not be utilising any new hardware, structural 
facilities or labour resources but would instead be utilising existing care providers supported with 
new information flows and the consistent application of credible patient processes. To support 
this, the principal agents, i.e. the healthcare providers and patients, would be informed, educated 
and trained generally regarding IBD and specifically regarding agreed local processes. This led to 
the realisation that all change which the pathway sought to deliver would be achieved through 
the actions of either patients or clinicians and to enable each party to achieve this they were to be 
empowered both intellectually (through education and training) and through new ‘rights’. This led 
to the identification of two theories of change within the pathway, as distinct from the pathway 
development process, being patient and clinician empowerment. Each is considered separately. 
4.1.1.3 Patient empowerment 
The theory of patient empowerment has two main themes. The first, direct, and most obvious is 
that patients become empowered and enabled through various mechanisms to better manage 
their own health both preventatively and reactively. [167] The second theme to the theory of 
patient empowerment is that patients become better informed and more demanding health 
consumers with an attendant impact on the quality of healthcare with which they are provided. 
[168] Within the pathway both aspects of patient empowerment were present although that 
relating to patient self-management was more obvious. 
4.1.1.4 Clinician empowerment 
The term clinician- or clinical empowerment is not new, having featured in Department of Health 
publications, [169] however its association with an underlying theory of change does appear to be 
novel. No specific references to the theoretical concept or related terminologies have been 
identified in the relevant literature. 
In the context of the IBD pathway design which was eventually arrived at, and in project 
processes, there were several themes to the theory of clinician empowerment: 
• Ownership of, and meaningful involvement in, pathway design and project oversight. 
• Empowerment, principally through externally validated education, targeted at primary 
care clinicians to assist in the management of a condition which previously was seen 
largely as needing specialist care. Not only would this directly empower the clinicians who 
undertook the training, but it would give confidence to specialists to discharge patients 
into the care of primary care clinicians. Specialists were further empowered through a 
substantive role in delivering and validating the education provided for primary care 
clinicians. 
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• Sign-posting of clinicians to a single evidence-based, accessible, credible and in many 
cases familiar source of information regarding disease management. 
• Ensuring that quality of care with respect to providing an annual review was of the same 
evidence-based standard as that provided within secondary care. 
• Enabling primary and secondary care clinicians to meet and converse directly and 
establish on-going methods of communication. 
• Shared-informational structures and increased volume of bilateral data sharing between 
primary and secondary care. 
4.1.1.5 Project management to deliver the pathway 
Although two theories, patient and clinician empowerment, were identified as the driving 
mechanisms to deliver change from the implementation and operation of the pathway which was 
eventually designed, the overarching project processes themselves existed within their own 
context and mechanism paradigm to realise those changes, and thus were also linked to a theory, 
or theories, of change. There was explicit evidence that this complex process would be delivered 
by project management. Therefore a third theory of change was evident within the pathway 
project, that of project management. The theory of project management was identified as the 
theory underlying the process being utilised to design, implement and operate the IBD pathway 
project. 
The original project application for the Department of Health integrated care pilot scheme was 
the most explicit and specific of all project documents with respect to project management theory 
by identifying a specific methodology. 
Even though the project was not ultimately included within the Department of Health pilots 
scheme, correspondence between key actors and the sponsoring PCT confirmed that the project 
would still continue and that the PCT would ‘absorb’ the project management arrangements. The 
actual method of project management to be employed under the new ex-pilots arrangement was 
not stated. Under the care pilots scheme the project was to be managed according to the 
PRINCE2 methodology but this would not necessarily mean it should be assumed that the same 
methodology would also be utilised in the ex-pilots project where there would not be a dedicated 
project manager.  
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Box 5. Evidence of project management theory 
Excerpt from integrated care pilots stage one application form (November 2008) 
Describe the project management and governance arrangements for the pilot programme. 
… 
The utilisation of PRINCE2 methodology in the management and control of this project will 
provide structure, planned implementation and appropriate monitoring and evaluation. 
… 
A project manager will be appointed who has the authority to run the project on a day to 
day basis on behalf of the Project Board. 
The Roles and Responsibilities for the Project Board, Project Steering Group and Project 
Team will be clearly outlined within the Project Initiation Document. 
… 
Excerpt from subsequent information in ‘further questions regarding the integrated care pilots 
application’ (February 2009) 
… outline in detail your programme management processes and governance structures and 
explain why you are confident these are robust (including your approach to supporting 
clinical leadership of the programme). … 
The Programme Board will be jointly accountable to the joint PCT and Foundation Trust 
Momentum Board. The programme will have a dedicated project manager who will manage 
the pilot using PRINCE 2 methodology.  … 
 
A rational assumption was that the PCT would continue to manage the project according to 
PRINCE2 methodology as this methodology was described as ‘the UK's de facto standard for 
project management’. [170]  In addition, the individual initially given responsibility for managing 
the project by the PCT was already trained to PRINCE2 practitioner level. 
Therefore it was the project management organisations’ (i.e. the PCT) desire to manage the 
project in a structured way and the PCT appointed an experienced NHS project manager trained in 
PRINCE2 to manage the project. However it would appear that the culture within the organisation 
was not conducive to enabling and ensuring that PRINCE2 methodology was applied in practice. 
73 
The 1
st
 project manager (actor ‘H’, p84-5) reported in e-mail correspondence that the adoption of 
PRINCE2 methodology was somewhat tokenistic and did not reflect the realities of actually being 
a project manager within the NHS. 
In addition, the first project manager (H) was involved with other projects at the same time, 
claimed to be eight, including projects of a larger scale and much greater local interest and impact 
H: ‘… I don’t think I needed any more support from any of the board members. I mean, like 
any project, you can always argue that the project should have had more dedicated time 
but I think that would have been very difficult to justify when I had all manner of other, you 
know, bigger, larger scale, you know, higher profile projects to work on at the same time. 
You know, I was working on the closure of A&E in [locality]. You know, at the time ….’ 
Interviewer: ‘At the same time you were doing … ?’ 
H: ‘Oh, I was doing all manner of projects, I had, you know, something like eight 
Momentum work scheme projects on the go at the same time so it was just … this was a 
really small part of my day-to-day job.’ 
This mode of working within the PCT, whereby a project manager was assigned to several projects 
at potentially different stages simultaneously, was also true for the replacement project 
management team. The recruitment of all members of the project team appeared to have been 
undertaken on a convenience basis and did not appear to have been done purposefully by 
selecting members with particular skills, experience, or networks, as the following excerpt from 
project team member ‘L’ (p84-5) demonstrates: 
L: ‘ … the rest of my team were going so I was kind of the only person in the office at the 
time when they were saying, you know, “we need somebody to be the contact”.’ 
L: ‘ … . So then it was more formal that I would keep working on it but with [I] because [I]’s 
more senior than me, so he would be the lead for it. … ’ 
Both actors I and L (see p84-5) also reported being involved with numerous other projects at the 
same time, as H had reported. Members of the new project team (I and L), with no apparent prior 
involvement with the project, expressed concern about the longer-term viability or success-
likelihood of the project from the outset, as described succinctly by L in the following interview 
excerpts: 
L: ‘Because there are so many bits of work, I’m sure you know what the NHS is like, it’s the 
pathway changes and things like that, that just don’t happen for one reason or another and, 
you know, the genuine reasons they don’t happen. … ’ 
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L: ‘ … . But there’s always that nagging doubt that “Will it actually …”. Because it’s obviously 
not just me that’s going to make the project work, there was a number of key people that 
will make it work. Specifically, the practices as well. And I know how difficult it is getting 
practices signed up to something that’s different where they think they might need to do, 
maybe, a bit more work or change their processes for certain things.’ 
The extent and nature of senior management involvement with the project from within the 
project management organisation (the PCT) did not appear to be structured with absent 
automatic feedback or update mechanisms and only incidental and informal checks. 
Interviewer: ‘ … . Would either [of your managers], would they ask you about [the IBD 
pathway]? Would they say “What’s going on with the IBD pathway?” ’ 
I: ‘[line manager] probably would more because she’s the … she will ask me outside of the 
one-to-ones, I don’t actually have a one-to-one [with line manager], because she’s more 
closely linked to [the IBD pathway] really so ….’ [trails off] 
An explicit statement of project aims and objectives is part of the key stage of ‘project start-up’ 
within PRINCE2 project management and reflected in documents such as the project initiation 
document and mandate. The existence of an explicit mandate or project initiation document was 
not demonstrated within the IBD pathway project. In the first stage application for the integrated 
care pilots the aims and objectives were described as ‘based on the recommendations of the 
national IBD Standards Working Group’. This provided an explicit link between the project and the 
IBD Standards. Neither of the senior clinical representatives on the project board (actors B and G, 
p84-5) or any members of the project team made this link when interviewed about the aims and 
objectives of the project. In fact only two individuals did refer to the IBD Standards in this respect 
during interviews and they were both members of the Standards working group. However the 
project aims and objectives which were stated by interviewees were generally concordant and 
complementary to at least significant components of the IBD Standards. 
An aim or objective which was mentioned by both the first and second project managers (actors H 
and I, respectively, p84-5) was the effect of the pathway on the primary care health budget. For 
example both stated that the overall cost or budget impact of the pathway were important aims 
of the project or a crucial argument for ensuring continuing funding of the project:  
Interviewer: ‘Were you aware of any explicit aims and objectives of the project, of the 
pathway?’  
H: ‘Yeah, I mean there were very some generic ones about improving the care of patients 
with IBD but there were some, at the time we were all about value for money and we’d 
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moved into, now we call that QIPP - you know, invest-to-save, so there were some clear 
aims and objectives around saving admissions. I like to think of that as, if you improve the 
quality then they’re going to go into hospital less, so that’s the way I like to look at it. So 
they’re one and the same aim, really. 
Interviewer: ‘So a potential cost saving aspect was quite important?’ 
H: ‘Yeah, definitely.’ 
Interviewer: ‘To you or to your organisation?’ 
H: ‘To the organisation. I think basically if we didn’t have that invest-to-save value-for-
money element we wouldn’t have got any funding.’ 
And, 
I: ‘ [The pathway] has to be able to show that it’s either offering the same value for money 
and with increased quality or potentially has some cost savings attached to it and, yeah, I 
certainly think that was something, as well as the quality aspects and being able to manage 
patients with the GP, nurse, that they’re familiar with and within their own, closer setting 
to their own home. I do certainly think that the cost elements were taken into 
consideration, were quite important for the [practice-based commissioning] board.’ 
The motivations of the PCT were not entirely hidden from the consultant gastroenterologist 
member of the project board (B). He expressed scepticism about the motivation of the PCT and 
felt that it was too concerned with reducing costs: 
B: ‘ … it’s fairly clear from meetings that primary care really wants to take all of these 
patients back into primary care. So that’s, I guess, been a slight concern from my point of 
view that we don’t move away from this being patient-centred, that obviously there are 
financial drivers and political drivers to move patients back into primary care, and that’s 
good provided the patient wants that.’ 
The primary care medical lead (G) also had a concurrent although not obvious cost-saving agenda: 
G: ‘ … . The one thing that I eternally think is a waste of money are follow-up [outpatient] 
appointments. Eternally! … ’ 
Later during the same interview this point was reinforced: 
G: ‘ … . Well part of the success for me would be less patients coming into secondary care 
one way or another.’ 
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And, 
G: ‘I think if you genuinely say, you know “We would like to shift more of the management 
of IBD into primary care and therefore have less of it in secondary care” I actually think that 
secondary care would immediately step back a little bit … ’ 
Another aspect of the aims and objectives of the project was the apparent disconnect between 
the strategic aims of the pathway, as illustrated by the local ‘Momentum’ initiative, and the 
project team. This was apparent in the behaviour of the project team who appeared to view the 
project as a day-to-day functional task with occasional milestones and significant events to 
arrange, such as training events and project board meetings. Individually and collectively they did 
not appear to assent to the longer-term and strategic aims of the project or the Momentum 
initiative. The reasons for this were not further explored and this observation is presented as a 
untested theory. If true this would serve as a negative attribute with the main link between the 
project management organisation (the PCT, one of the key project partners) and the project 
board unaligned. 
4.1.2 Context: Healthcare policy 
Underpinning the pathway was a realisation from all parties involved in the provision, 
procurement and consumption of healthcare for IBD that demand would outstrip current 
provision and the gap between demand and provision would likely increase without intervention. 
[49] Ultimately this translated to a desire to constrain the relative costs of current and future 
healthcare. [171] The realisation that there was an increasing burden on healthcare through a 
longer-living, more chronically morbid and growing population has translated to several NHS 
policies over the past decade. None better encapsulates this than the 2006 White Paper ‘Our 
health, our care, our say’. [50] One of the four main goals of the White Paper was stated as 
providing ‘more support for people with long-term conditions’. Although not specifically identified 
as a long-term condition within the paper, IBD and its sub-diagnoses are recognised as long-term 
conditions. [1]  The IBD standards, [1] the implementation of which has been interpreted as the 
aim of the IBD pathway, did not refer to the 2006 White Paper, instead referring to the 2008 NHS 
Next Stage Review, ‘High Quality Care For All’. [172]  The next stage review also identified long-
term conditions as an important focus for the NHS however it only recommended the use of 
‘personal care plans’ with no underlying rationale for their use other than as a goal already set out 
in the 2006 White Paper.[50]  
Specifically, the 2006 White Paper stated: [50] 
‘… , everyone who requires and wants one has a personal health and social care plan as part 
of an integrated health and social care record. Initially we will focus on offering integrated 
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care plans to those individuals who have complex health and social care needs. By 2008 we 
would expect everyone with both long-term health and social care needs to have an 
integrated care plan if they want one. By 2010 we would expect everyone with a long-term 
condition to be offered a care plan.’ 
The IBD standards made only limited reference to use of personal care plans with a greater 
emphasis on community-based care in preference to specialist care in general. [1] 
The general policy of the Department of Health and many other healthcare systems towards long-
term conditions over the preceding 10 years has been a shift from specialist to non-specialist care 
such as primary and community-based care. [43] This directly influenced the policy landscape 
surrounding the IBD pathway project. 
Firstly, the patient charity which had been heavily involved in the design and implementation of 
the pathway was the same charity which published the IBD Standards. [1] Thus, they were 
explicitly aligned to promoting community-based management of IBD in preference to specialist-
led care for specific types of IBD patient, consistent with general healthcare policy. 
Secondly, healthcare providers and commissioners, and the academic advisor working within the 
project board were likely to have had at least a working knowledge, if not greater, of the general 
policy direction from the Department of Health with respect to long-term conditions. [173] This 
may have manifested itself overtly or more subtly. For example, the rationale or evidence for the 
following aspects of the pathway were not questioned within the project board and may have 
represented a fatalist approach to, or inevitability about, centrally driven policies of the nature 
described: 
• Permitting patients to choose between secondary and primary care for annual review 
• Patient education elements of the pathway such as provision of specific educational 
material and provision of time-limited free membership of a leading IBD patient charity 
• Provision of patients with a copy of their annual review and the ultimately abandoned 
idea for patients to own a personal written care plan and record 
Transferring care of patients with long-term conditions from specialist to community settings is 
not entirely motivated by a desire to reduce healthcare costs. Other advantages which might be 
expected, or which are at least alluded to, with a transfer of care from specialist to community 
include improved health and wellbeing for patients and greater patient satisfaction. The evidence 
for these benefits, including cost reductions, is limited at best. [130]  
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4.1.3 Design phase 
4.1.3.1 The origins of the integrated care pathway for IBD 
The IBD integrated care pathway emerged in the local health economy due primarily to historical 
professional relationships between leading protagonists; the locality did not appear to have been 
otherwise purposively selected. The IBD integrated care pathway project was initially submitted 
for inclusion within a Department of Health project but despite the significant setback of not 
being accepted into that project there was sufficient local interest and desire to ensure the IBD 
pathway project was still progressed locally. This may have been facilitated by the local context in 
which the project was complementary to a large cross-sector healthcare project. [59] 
4.1.3.2 Aims and objectives 
One of the first and crucial outcomes required was a pathway design that could realistically 
achieve the relevant aims and objectives of the project and which would be acceptable to all 
parties. The first problem encountered in this respect was that the project aims and objectives 
had not been explicitly stated or agreed. Without such it would prove difficult to gain consensus 
amongst the project board. 
Interviews with members of the project board (p84-5) revealed little consideration and a 
somewhat confused picture regarding the aims and objectives of the pathway. 
H: ‘… there were some very generic [aims] about improving the care of patients with IBD 
but there were some … at the time we were all about value for money, and we’d moved 
into – now we call that QIPP - you know, that’s to save. So there were some clear aims and 
objectives around saving commissions. …’ 
G: ‘… what were the aims and objectives? If the aims and objectives are to deliver the IBD 
standards of care I still think the jury is out whether it will deliver that. I think if the aims 
and objectives are to deliver us to a point where there is a disease register for IBD and 
practices are doing something a little bit more structured and organised to proactively 
manage IBD, I think that we’ve got a better chance of delivering that. The other one for me 
is, have we raised the profile of IBD as a long term condition among local GPs? … ’ 
B: ‘ … I guess over a course of a number of meetings the aims were made fairly clear.’ 
Although others, particularly the two individuals who had also been members of the IBD 
Standards Group (A and D), had a clearer and better formed idea about what the pathway was 
trying to achieve: 
(Following a lengthy explanation from ‘D of the aims and objectives of the IBD Standards [1]) 
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Interviewer: ‘So if I was to suggest that [the project aim] was, in a nutshell, to 
operationalize the IBD standards, would you agree with that?’ 
D: ‘Yes. Yeah, exactly, and it’s to pilot the fact that you could do it.’ 
And from a separate interview: 
A: ‘At the outset [the aims] were to see if you could implement the IBD standards through a 
kind of more integrated approach from primary and secondary care. I think that there’s a 
subsidiary aim in that; which is the role of [the patient charity] and whether they can have a 
more structured input into service delivery. … ’ 
Regardless of the aims and objectives which members of the de facto project board believed they 
were working to, the specific aims and objectives laid out in the original care pilots application 
were seldom referred to at any point during the design or any other phase and the generic aim of 
implementing the IBD Standards was only occasionally referred to whether in one-to-one 
interviews or within project communications and during project board meetings. 
A notable omission from the design of the IBD integrated care pathway was an attempt to map 
the existing provision of IBD services and referral pathways. This task was not formally 
undertaken although a presentation delivered by the project manager (H) at the 6
th
 project board 
meeting in September 2010 did include a brief outline of the current and proposed ‘model of 
care’ (box 6). 
Despite the existing provision of IBD care not being mapped out previously there was general 
agreement within the project board that current care was almost exclusively delivered by 
specialists, that primary care clinicians tended to refer IBD patients for most if not all IBD-related 
issues, and that primary care clinicians had little confidence to manage IBD patients. [174] 
For an extended period during the evaluation, between its commencement in October 2009 and 
leading up to the pathway ‘launch’ in November 2010, discussion about the integrated pathway 
lacked any significant specific detail. [174] 
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Box 6. Content from a presentation at the Project board meeting of 6
th
 September 2010 
Model of Care: 
Maintain current outpatient arrangements including IBD nurse helpline and perhaps telephone 
clinic. 
Any IBD patient who has attended the hospital previously can contact the IBD Nurse direct who 
will decide if the patient needs to be seen in clinic. 
Depending on situation (e.g. how long since patient last seen/complexity of problem) nurse books 
patient as a ‘new’ or a ‘follow-up’ without needing a new GP referral 
Annual reviews: 
If active disease/associated on-going problems patient will be being seen in clinic. 
If not, patients can discuss & agree with the IBD Team what follow-up system they should be on: 
• Attend hospital for annual review 
• IBD Nurse telephone review 
• GP Annual Review 
• Each will use same structured annual review 
 
From about July 2010 shared efforts from two project board members (A and B, p84-5) were 
made to develop an ‘Integrated care model’.  
At the project board meeting on the 6
th
 September 2010 the board was introduced to two 
previously unknown individuals employed by the PCT in senior project management roles, 
identified as actors ‘J‘ and ‘K‘ (p84-5). They were brought into the project as part of the project 
management team under the then project manager’s (H) direction. At the September 2010 
project board meeting they focused on identifying the existing tasks that needed to be performed 
and both individuals discussed creating a ‘project plan’ and ‘communication plan’ for the project. 
This was the first time planning of this nature had been explicitly discussed despite such plans 
being key components of PRINCE2 project management methodology. [175]  Following the 
meeting an attempt was made to diagrammatically represent the proposed integrated care 
pathway for IBD using a flow-chart design. Despite some uncertainties regarding the process for 
GP registration or ‘sign-up’ to the pathway, the ‘process map for the model of care for IBD’ was e-
mailed to the project board on 20
th
 September 2010. This was commented on by two members of 
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the project board, the academic adviser (A) and the consultant gastroenterologist (B) with neither 
in agreement with the model of care presented. Consequently the pathway model was further 
refined, primarily by the academic adviser, until the final version (figure 1) was arrived at. 
In October 2010, a pathway design was presented by the academic adviser and this was accepted 
by the project board as an acceptable pathway for implementation. This two-part pathway 
distinguished between newly diagnosed and established IBD patients. The pathway continued to 
undergo several small but cumulatively substantive refinements after this point and some 
additional details were added to certain aspects. The final version agreed by the project board is 
reproduced in figure 1. The pathway design did not undergo any further changes after September 
2011. 
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Figure 1. Final version of the integrated care pathway for IBD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key:  MoM – Map of Medicine™; NACC – National Association for Colitis and Crohn’s Disease. 
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4.1.3.3 Project board 
One of the first steps in structured project management protocols is to establish a project 
board. [175] This task was not formally conducted within the IBD pathway project although a 
leadership group did emerge early on which performed this role throughout. The de facto project 
board also required a chair-person and again no formal appointment was evident. However an 
earlier iteration of a diagram included within the care pilots application outlined the ‘project 
management and governance framework’ for the project which included an ‘IBD Programme 
Board’, later referred to as the ‘IBD Steering Group’. These documents identified the primary care 
medical lead (G) as chairman and the consultant gastroenterologist (B) as vice-chairman.  
However neither individual formally took on such roles at any project board meeting during the 
evaluation although the primary care medical lead frequently conducted himself in a manner 
which could be interpreted as the chairman of the meeting. This behaviour received the tacit and, 
on at least one occasion, the explicit approval of other group members. Regardless of the name of 
the group, the role assumed and functions performed by it were most similar to that of a project 
board. 
Four agencies were represented on the project board by multiple individuals: 
1. Primary care, represented from a clinical (medical) perspective and a 
budgetary/commissioning perspective. 
2. Secondary care, represented from a dual clinical perspective (medical and nursing) and 
from an operational or managerial perspective. 
3. Users or patients, represented principally through non-patient representatives but also 
indirectly through a local patient panel. 
4. Academia, represented by a single academic adviser. 
Some individuals brought more than one perspective to the table. For example, the primary care 
medical representative (G) for the majority of the evaluation period was also the practice-based 
commissioning (PBC) lead employed on a part-time basis by the PCT. Therefore he also brought a 
commissioning perspective as well as a clinical perspective to the board. Another example was 
the academic adviser (A), a practicing GP within the locality who therefore brought primary care 
medical experience as well as an academic perspective to the project board. 
For the majority of the time over which the evaluation operated the project board consisted of 
eight core individuals or representative roles. Figure 2 shows the make-up of the core project 
board and its links to an external ‘patient panel’. 
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Figure 2. Constitution of core project board and relationship to patient panel 
 
       Project Board Patient Panel 
• Academic adviser  
• Consultant gastroenterologist  
• IBD specialist nurse Convener and attendee 
• Patient representative (1)  
• Patient representative (2) ‘Chair’ 
• Patient representative (3) Attendee & facilitator 
• Primary care medical lead  
• Project manager  
From the commencement of the evaluation in October 2009 to the end of the evaluation in 
December 2011 the project board met on eleven occasions. A review of project documents also 
revealed two earlier project board meetings therefore for the purpose of the evaluation there 
were 13 project board meetings and these are, henceforth, identified numerically in chronological 
order. The total number of different individuals who attended or otherwise participated in each 
meeting, excluding myself as an independent observer, was fifteen.  
Individuals who attended project board meetings at various stages of the evaluation are listed, 
with core project board members listed first, but otherwise in no particular order: 
A. Academic adviser, Professor of primary care, formerly a part-time GP within the locality, 
and a member of the IBD Standards Working Group. 
B. Consultant gastroenterologist based at the main hospital site within the project locality 
and later honorary lecturer at the same institution as the academic adviser. 
C. IBD specialist nurse based at the main hospital site within the project locality. 
D. Patient representative 1 was the chief executive of a leading IBD patient charity and a 
member of the IBD Standards Working Group. 
E. Patient representative 2 was a national patient involvement advisor employed on a 
contractual basis by the same leading IBD patient charity. 
F. Patient representative 3 was the chair of the local branch of the same IBD patient charity 
and which included the project locality. 
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G. Primary care medical lead, also a practising GP and partner in a general medical practice 
in the project locality employed on a sessional basis by the locality PCT as its Lead for 
practice-based commissioning (PBC lead) until about December 2010.  
H. Project manager-1 ( March 2009 until about December 2010) was the ‘Commissioning 
manager for health systems development’ at the locality PCT and also PCT project 
manager for the Digestion & Bowel (planned) component of the local joint pathways 
project. 
I. Project manager-2 (from about January 2011 until the evaluation close) was the 
‘Commissioning manager’ for the PCT cluster with specific responsibility for the project 
locality. 
J. Project management team member 1 was a project support officer at the locality PCT 
until about January 2011. 
K. Project management team member 2 was a project support officer at the locality PCT 
until about December 2010. 
L. Project management team member 3 was a Commissioning support officer at the locality 
PCT. 
M. Clinical champion, also a local GP and partner at a medical practice within the project 
locality. 
N. In attendance at one board meeting was the ‘Assistant director for commissioning and 
systems development’ at the locality PCT cluster. 
O. In attendance at three later project board meetings was the ‘Strategic development 
manager’ at the main hospital trust within the locality. 
Table 4 shows the dates, locations and participation metrics of the 13 project board meetings 
which fell within the scope of the evaluation. Note that these project board meetings span the 
phases of design, implementation and operation. 
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Table 4. Dates and attendees of the IBD pathway project board meetings up to December 2011. 
 Attendee initials N A H G D B C E F J K I L O M Total meeting attendance 
1 18/05/2009** 1 1 1 1 1* 
          
5 
2 01/09/2009** 
 
1 
             
Unclear 
3 16/11/2009 
 
1 1 1 1* 1 
         
5 
4 15/03/2010 
 
1 1 1 1 1 
 
1 
       
6 
5 08/06/2010 
 
1 1 
 
1 1 1 1 1 
      
7 
6 06/09/2010 
  
1 1 1 1 
 
1 
 
1 1 
    
7 
7 26/10/2010 
  
1 
 
1 
  
1 1 1 
     
5 
8 09/11/2010 
 
1 1 1 
   
1 1 
      
5 
9 09/02/2011 
 
1 
 
1 
 
1 
  
1 
  
1 
   
5 
10 12/05/2011 
     
1 
 
1 1 
  
1 1 
  
5 
11 18/07/2011 
   
1 1 
 
1 1 1 
  
1 
 
1 
 
7 
12 15/09/2011 
 
1* 
 
1 
    
1 
  
1 
 
1 
 
5 
13 08/12/2011 
 
1 
 
1 
 
1 
      
1 1 1 6 
Total meetings attended 1 9 7 9 7 7 2 7 7 2 1 4 2 3 1 
 
* : Participation via teleconferencing facilities. ** : Only partial meeting information available as both meetings preceded the commencement of the evaluation.  
Attendance was usually for the entire duration of a meeting although on several occasions an attendee was present for only part of a meeting. Greyed-out  
segments indicate that individual had departed the organisation or project by these meetings, or was not involved with the project during these meetings. 
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4.1.3.4 Board members, roles and meetings 
Some members of the project board were not always clear about their role: 
E: ‘ … I feel I’m representing [the charity] who have invested money into the project. So it’s 
about making, you know, my role is to try and ensure that the project works because [the 
charity] want value for money. … , when you’re at a meeting, you try and look at things 
from the patient perspective rather than from a professional perspective and try and think 
“Well, what, how will that work for a patient, what will it be like for a patient?” ’ 
F: ‘ … . I’m chairman of the local [charity] group. I just thought it would be interesting to 
come along and see what was happening but I’ve always felt I’d be more of an observer 
even if I had put my penny’s worth in occasionally.’ 
Others had a much clearer idea of their role on the project board even if these did not meet the 
necessary roles for project members to fulfil: 
B: ‘ … And within this project I’m the secondary care lead so I’m, the idea of that is I, again, 
provide some sort of coordination from a secondary care point of view to give the voice of 
the [hospital] trust and the other consultants when we meet, and to convey any sort of 
information from our [project board] meetings back to the secondary care service. 
A theme that emerged from several members of the project board was that they were part of the 
project team in a more passive and observational role as opposed to taking a more involved or 
even a leading role. This perhaps reflected a general failing in the project management process 
with a lack of leadership both at project board meetings and strategically. Despite earlier project 
documents which were produced for the integrated care pilots application identifying the primary 
care medical lead as chair and the consultant gastroenterologist as vice-chair of the ‘steering 
group’ the role of chair at board meetings was often assumed and shared in a rather ad hoc 
fashion between the primary care medical lead and the project manager at the time. At later 
meetings the project manager, when present, did enquire about who would chair the meeting 
with the implied options being either the project manager or the primary care medical lead (e.g. 
meetings 11 and 12). 
A possible choice for project leadership and possibly also to serve as chair of project board 
meetings would have been the clinical champion. However no one was recruited to this role until 
about November 2011 and the first meeting the clinical champion was able to attend was the 
December 2011 meeting which was also the last meeting covered by the evaluation. 
Meetings tended to be arranged from one to the next with relatively short notice. The short 
notice for meetings presented particular problems for the secondary care clinical representatives 
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(project board members ‘B’ and ‘C’), both of whom were key individuals to the project and both 
of whom were the only full-time practicing clinicians on the board. For example, on many 
occasions notice of a project board meeting was given at less than six weeks which was the 
minimum notice required to provide patients to change or cancel clinical appointments. Both 
secondary care clinicians in particular reported problems in attending project board meetings for 
this reason as their record from meeting number 7 onwards demonstrates (table 4). Table 5 
highlights details concerning the organisation and administration of project board meetings.  
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Table 5. Administration of project board meetings 
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Other documents during meeting 
 
Other documents post-
meeting 
Key: 
DU: 
Durham 
University  
H: Hospital 
NK: Not 
known 
PCT: PCT 
head office 
Shading: 
Change in 
project 
manager 
1 18/05/2009  NK NK NK  Yes NK NK NK 
2 01/09/2009 106 NK NK Yes NK NK NK NK NK 
3 16/11/2009 76 DU NK No No No No No No 
4 15/03/2010 119 H 6 No No No  Actions, also provided post-meeting 
5 08/06/2010 85 PCT 4½ No No Yes No No No 
6 06/09/2010 90 PCT 9 No No   Presentation hand-out  
7 26/10/2010 50 PCT 6 No No No Project plan, also handed-out during meeting 
Actions in e-mail text 8 09/11/2010 14 PCT 8 No No In e-mail   
9 09/02/2011 92 PCT 2 No No No    
10 12/05/2011 92 PCT 2 No No    Actions 
11 18/07/2011 67 PCT > 2 Yes 5 days 5 days 3  Actions & document review 
12 15/09/2011 59 PCT 3 Yes 1 day 1 day 3  Actions 
13 08/12/2011 84 PCT 15 Yes 1 day No No  Actions 
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4.1.4 Implementation phase 
A pivotal event in the IBD pathway project was the ‘launch’ of the pathway in November 2010. 
Other events described as belonging clearly within the implementation phase of the project 
would be the education and training meetings. All of these events served as examples of clinician 
empowerment operating within the pathway, as well as, to a lesser degree, patient 
empowerment. 
Launch of the pathway 
The audience for the launch event itself consisted of general practitioners and practice managers, 
being the locality ‘GP commissioning forum’. Membership of the forum consisted of one GP from 
each of the 26 registered medical practices within the locality, although not all practices had a 
nominated representative and not all practices will have been represented at all forum 
meetings. [176] The actual attendance list was not available. 
The individual who took the lead at the launch event was the project primary care medical lead 
(G), who was also a local GP. He was supported by patient representatives 2 (E) and 3 (F) as well 
as other members of the project board although a complete list was not available. Although I was 
not present at this event information was obtained from subsequent meeting minutes, email 
correspondence and direct conversations.  
The primary care medical lead’s precise role in the local health economy appears to have been 
somewhat fluid during the IBD project but he did appear to have been a well-known and at times 
controversial individual within the local health system. He was also naturally gregarious and 
animated and was well suited to, and comfortable with, undertaking the lead role at an important 
project event such as the launch. However, he was conscious that his involvement could be 
viewed negatively by the audience, who may have been somewhat ambivalent towards another 
clinical initiative being promoted by the same individual: 
G: ‘ … [the pathway] was on an agenda with multiple other things. Many of which I was 
involved in, so this was another weakness of having somebody that’s doing ten different 
things.’ 
Education and training 
Following the pathway launch in November 2010 the first clinician educational event was 
delivered in March 2011. The reason for the delay between launch and first training event was 
not clear but it would at least have enabled practices to decide whether to partake in the pathway 
project and undertake preparatory work. A second educational event was delivered in November 
2011. The educational events also provide further examples of clinician empowerment operating 
within the pathway as well as providing networking opportunities for the locality clinical 
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community, both intra-primary care (i.e. practice to practice) and inter-professional (i.e. nursing 
and medical professionals) and inter-sectoral (i.e. hospital and primary care). 
The pathway design required primary care clinicians, both GPs and practice nurses, to undertake 
specific training and this was mandated in the practice agreement (appendix 11). At least one GP 
and one nurse from each participating practice were required to undertake verifiable education 
or training in relation to IBD and the mechanisms of the IBD pathway. Requirements differed for 
GPs and nurses; GPs had to undertake an online training package already provided by a third-
party (BMJ Learning™). This relied upon an assumption that any GP who wished to undertake the 
training would be a member of an organisation for medical professionals which would permit free 
access to the package. An equivalent online training package was not identified for non-medical 
(i.e. nurse) clinicians. Additionally, it was assumed that the majority of the annual reviews which 
would be performed in primary care would actually be performed by practice nurses. Therefore 
the project board felt that practice nurses would benefit from a more practical educational 
package which could also focus on the technicalities of conducting a patient review. Nurses were 
therefore required to attend a bespoke training event organised and delivered by members of the 
project board. 
Box 7. The pathway education and training meetings 
A personal experience and interpretation of the IBD Pathway education and training meetings 
The project, within the timespan of the evaluation, delivered two training meetings, each 
scheduled to last two hours on a Thursday afternoon at the head office of the PCT near the town 
centre. Thursday afternoons had been identified by the project board as convenient for all those 
required to deliver the sessions, especially those members of the Hospital IBD Team (the 
consultant gastroenterologist and the IBD specialist nurse).  The first meeting was held in a large 
space on the top floor of the office block where there was ample room and light. The second 
meeting was held in a small meeting room on the ground floor which was too small for the 
number present and which created a cramped and dark atmosphere. The format and agenda for 
each meeting was similar, consisting of five separate sessions linked in an intuitive progression 
from one to the next. In the second meeting the fourth and fifth sessions were delivered in 
reverse order (i.e. session 5 preceded the final session, number 4).  
Session 1 was delivered by the primary care medical lead and consisted of a relatively brief 
introduction and was less than 10 minutes in duration at both meetings. The presenter essentially 
chaired both meetings, introduced each session, and fielded, and often answered, any questions. 
Despite having a relatively short session at the start of each meeting the presenter had a 
dominant role at each meeting. 
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Session 2 was delivered by the consultant gastroenterologist and was about 30 minutes in 
duration. The session covered the disease, therapeutic and other treatment options for IBD 
patients. The session was delivered without the use of any presentation materials in a relaxed and 
informal manner. It also included audience participation with a number of questions presented to 
the audience and suitable pauses made for them to consider a response and reflect on the 
information. However, the audience was not entirely receptive and active in this aspect of the 
presentation. It was not clear what level of preparation was made for the session; overall it had 
the impression of being somewhat ad lib. However due to the presenter’s style, confidence and 
knowledge this was not detrimental and indeed could be viewed as a positive attribute. 
Session 3 was delivered by the academic adviser. This session was the first to introduce the use of 
presentation materials at each meeting, specifically a Microsoft PowerPoint™ presentation and, at 
the first meeting only, a paper hand-out. The session was about 30 minutes in duration at the first 
meeting and about 15 minutes at the second meeting. At the first meeting the initial part of this 
session focused primarily on the background to the project and the wider theory and evidence 
base, such as the IMAGE project and the IBD Standards. This was largely omitted from this session 
at the second meeting and explains the discrepancy in duration between both meetings. The 
omission of the background material from the second meeting did not appear to be detrimental 
to the session and indeed the background material in the first session seemed out of place 
amongst the other material. The presenter’s style and delivery was confident and relaxed, and he 
did not get flustered. 
Session 4 was delivered by the project board patient representative 2 (E). He also used a 
PowerPoint™ presentation and described the activities of the patient organisation both locally 
and nationally. The presentation consisted of 25 slides although many were not displayed for any 
significant amount of time, in particular at the second meeting. The presentation appeared to lack 
confidence in delivery with a hesitant and hurried style. Patient panels were described 
confidently, a topic the presenter was most familiar with. Overall, the session appeared to 
generate limited interest with each audience. At the first meeting the session was of about 20 
minutes duration and less than 10 minutes at the second meeting. 
Session 5 was delivered by the IBD specialist nurse. The description of the session had changed 
from ‘The interface between primary and secondary care’ to ‘Annual reviews’ in the meeting 
agenda from the 1
st
 to the 2
nd
 meeting, although the content differed little. During the second 
meeting a significant part of the session was taken over by the academic adviser and the primary 
care medical lead, and to a lesser extent the consultant gastroenterologist, who interjected and 
fielded multiple questions from the audience. The presenter appeared content with this as these 
questions related principally to some of the finer details of conducting annual reviews in primary 
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care, including some technical questions relating to coding systems. Despite, or perhaps because 
of, these interjections the presenter appeared more comfortable at the second meeting than at 
the first. The presenter also used a PowerPoint™ presentation with just ten slides. The presenter 
made an explicit appeal to fellow nursing colleagues and displayed empathy with them, with a 
slide providing contact details. The overall impression of this session was positive and it appeared 
to be well received by the audience. Many of the audience were observed to note down the 
contact details provided. The session was about 30 minutes duration at each meeting with a 
slightly longer duration at the second meeting largely due to questions from the audience. 
The overall delivery of the second meeting was noticeably better in style and content than the 
first meeting despite the facilities being worse. The presenters appeared more confident in 
delivering their presentations. Most presenters had subtly refined their presentations following 
the first meeting. The exception to this generalisation is with the final presentation at the second 
meeting from the patient representative. As the second meeting had overrun and the facilities 
were dark, cramped and becoming ‘stuffy’, the presentation was delivered in a hurried and 
disorganised style and it appeared to generate minimal interest from the audience. 
A particularly embarrassing incident occurred at the end of the first meeting when it became 
apparent that none of the presenters had actually shown a diagram of the ‘new’ pathway model. 
There was an implicit expectation that this might have been included within the final session 
delivered by the IBD specialist nurse. A frantic search for a digital copy of the pathway diagram 
ensued and one was found on a memory stick and duly presented by the academic adviser. The 
academic adviser stepped in to lead this closing part of the first meeting and duly made good of 
what was becoming a deteriorating scenario. No such mistake was made at the second meeting 
and the diagram was included in the academic adviser’s presentation. 
This experience suggests that a trial run of the education and training meeting would have been 
useful and might have negated some of the clumsiness which was evident at the first meeting. 
However, this would also have required additional commitment from the presenters which may 
not have been easy or considered an effective use of resources for all parties. The project 
management team could also have provided a better brief for each of the presenters. It appeared 
that, in preparing for the first session, each presenter was provided with only a brief title for their 
session and only a short period of time, about two weeks, to prepare for the first meeting. As well 
as the first meeting serving as a trial run for the second, presenters were provided with a more 
detailed presentation brief for the second meeting. 
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As well as providing the necessary educational content the training events served as networking 
opportunities for practice nurses to form a peer-support network. At the close of the evaluation 
the clinical champion and project support officer from the PCT indicated their intention to arrange 
some specific networking meetings for practice nurses, and at least one edition of a newsletter 
aimed primarily at practice nurses had been produced with a second edition planned. Both these 
separate aspects of clinician education could be expected to lead to some degree of clinician 
empowerment, both in the specific therapeutic field of IBD and more generally. A number of GPs 
also attended the training events which were organised primarily for practice nurses. 
Table 6. Details of the two IBD pathway project training meetings 
 1
st
 training meeting 2
nd
 training meeting 
Day, date and time 
Thursday, 31
st
 March  
2011, 2 to 4 pm 
Thursday, 17
th
 November 
2011, 2 to 4 pm 
Number of nurses in 
attendance 
Seven; all female Seven; all female 
Number of GPs in attendance Six; one female Two; one female 
Total number in attendance Thirteen* Nine* 
Number of different practices 
represented 
Eight Six 
Also present if not primary 
care clinician or presenting 
Patient representative 3 
(project board member ‘F’) 
Strategic development 
manager at the main 
hospital trust within the 
locality (project board 
member ‘O’) 
* : Included one member of the project board; primary care medical lead and clinical champion, 
respectively.  
4.1.4.1 Clinical Champion 
From the outset a ‘clinical champion’ was to be incorporated as a key element of the project for 
all phases including the pathway design. For example, the appointment of an individual to the role 
of clinical champion and discussion as to whether the primary care medical lead would take on 
that role was discussed in the preamble at the March 2010 board meeting. The scope of this 
discussion indicated that some relatively detailed discussions had preceded this point. 
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The clinical champion role was first formally defined in a document described as a draft job 
description. This was presented to the project board on the 17
th
 September 2010 by electronic 
mail by the newly appointed project management team. Up until that point discussions had 
remained at a relatively abstract level with the role being frequently referred to but not properly 
defined. The draft job description appeared to lack detail and was based on a generic template. 
The ‘Job purpose’ was described as: 
To work with PCT, GP Community and Specialist Care teams to assist the successful 
implementation of the new Inflammatory Bowel Disease integrated pathway in [the 
locality]. 
The ‘Key result areas’ were listed as: 
• Work with PCT, GP Community and Specialist Services colleagues in developing and 
implementing the new IBD integrated pathway 
• Commissioning/developing, with the IBD multi-disciplinary team, appropriate 
programmes of professional development regarding the care of patients with IBD 
• Promote the new pathway and accompanying audit via launch events and via other 
marketing opportunities. 
• Engage and influence others individually and collectively to achieve successful 
implementation, particularly within the GP community, to help to build the capacity 
structure, culture and framework that delivers effectively the new pathway. 
• Provide leadership regarding the IBD Integrated pathway in the GP Community. 
Both the draft ‘job purpose’ and ‘key result areas’ were unchanged in the final version of the 
clinical champion job description. 
A project plan distributed by electronic mail on the 25
th
 October 2010 defined the appointment of 
a clinical champion as a separate task with several components such as confirmation of funding, 
completion of the job description, identification of potential candidates, advertisement, 
interviews and candidate selection. The plan at this point was to advertise the post to local 
primary care medical practices between the 15
th
 and 29
th
 November, with interviews and 
candidate selection to be conducted between the 6
th
 and 13
th
 December 2010. This was a change 
in position from that stated at the previous project board meeting where an explicit desire had 
been made to have the clinical champion appointed in time to participate in the launch event 
scheduled for the 17
th
 November 2010. This position was reflected in the first iteration of the 
project plan, which was never circulated outside of the project team. In that version of the plan 
the post was to be advertised between the 27
th
 September and the 18
th
 October 2010, with 
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interviews and selection to be conducted between the 25
th
 October and 1
st
 November 2010 thus 
ensuring that the clinical champion role would be filled in time for the launch event. 
At the project board meeting in November 2010 the first point raised by the project manager was 
that the appointment of a clinical champion was delayed. The reason for this was given as issues 
existing within the PCT finance department on the mechanisms and ethics of accepting and 
handling funds from a commercial party which sells healthcare products to the NHS (i.e. a 
pharmaceutical company). The project manager and the primary care medical lead were open 
about expressing their frustrations with this apparent bureaucratic hurdle and this view appeared 
to be shared by the project board as a whole. At the same meeting the project manager informed 
the board that the primary care medical lead would fulfil the role of ‘clinical champion’ for the 
purposes of the launch event. 
The next (9
th
) project board meeting was in February 2011 by which time a new project manager 
was in place. At this meeting the primary care medical lead assumed the role of chair. One of the 
key reasons for the meeting having been arranged was given as a discussion of ‘finding a GP lead’ 
(i.e. recruiting a clinical champion). At the end of discussion of the clinical champion the project 
manager was directed by the primary care medical lead to advertise for the role. 
At the following project board meeting (10
th
) in May 2011 the project manager reported that the 
clinical champion job had been advertised twice but no applications had been received. The risk 
of not receiving any applications for the clinical champion job had been highlighted in the draft 
project plan of October 2010. The contingency for this risk was: ‘[primary care medical lead] picks 
up the role’. It was not clear how long this contingency plan was intended to remain in place. 
Despite much prior discussion of active recruitment strategies such as enlisting the hospital IBD 
team to identify primary care medical professionals with an interest in IBD, and reports from the 
primary care medical lead about actively canvassing colleagues concerning the role, the 
advertisement and recruitment strategy employed by the new project team appears to have been 
relatively passive. The strategy was reported as consisting of notices in routine paper and 
electronic communications which were distributed to primary care medical practices in the 
locality. It was not clear whether these communications were sent to the practices generally or 
directly to medical practitioners. 
The clinical champion job was discussed again at the next (11
th
) project board meeting in July 
2011. A potential candidate was discussed who later did not go on to fill the role. The key point 
that arose during this meeting was that the post had to be filled by the 30
th
 September 2011 to 
fulfil the conditions attached to the funding. It was not clear whether this condition was imposed 
by the funder (the pharmaceutical company) or whether it was stipulated by the PCT or NHS. 
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At the 12
th
 project board meeting in September 2011 the project manager and primary care 
medical lead reported a high level of optimism concerning recruitment of a named individual. This 
was the individual who was eventually recruited to the clinical champion role and it is assumed 
that the individual was officially appointed at about this time (late September 2011). 
Role of the clinical champion in the IBD pathway 
The roles that the clinical champion would fulfil had been alluded to or explicitly stated during 
several project board meetings. These included: 
• To lead, or chair, project board meetings 
• To promote the pathway to medical practices and practitioners, ensuring that practices 
sign-up to the pathway and fulfil the obligations that accompany it 
• To lead education and training events, including delivery of specific aspects or 
components 
• To act as a focal point for practice enquiries concerning audit completion 
• To provide clinical support for medical practitioners and nurses in primary care 
It was not possible to evaluate whether these or any other roles were realised as the clinical 
champion was recruited at the end of the evaluation period and there was no opportunity to 
assess whether the clinical champion fulfilled these roles. 
Recruitment of clinical champion 
The individual appointed as clinical champion learnt about the post by word of mouth from a 
practice colleague, who in turn had been informed about it by the primary care medical lead (G). 
The clinical champion (M) then followed this up with enquiries to the primary care medical lead 
and later conversed directly with the project team. The clinical champion indicated a particular 
interest in gastroenterology as a therapeutic speciality which led to her initial interest in the post. 
The following excerpts from a research interview highlight the recruitment process and 
motivation: 
M: ‘ … when I was a medical SHO I did a gastro job, gastroenterology job, over at [local 
hospital] and really enjoyed it and I think if I hadn’t gone down the GP line I’d have become 
a gastro consultant.’ 
Another appealing feature of the job may have been that it would help distinguish her amongst 
her peers and signal potential leadership qualities: 
Interviewer: ‘And what appealed about the job, what in particular? What interested you?’ 
M (joking expression): ‘The job title of course’ 
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Interviewer: ‘Is it clinical champion?’ 
M: ‘Clinical champion!  You’re on to a winner really if you’ve got that sort of title under 
your belt. …. ’ 
Although this was by no means the only motivation: 
M: ‘ …. But also, I think I’m interested in that sort of thing. I see, I’ve recently seen a lot of 
patients with new diagnoses of inflammatory bowel disease and I think just the variety of 
patients there have led me to have a bit of an interest in the condition and I just felt it 
would be a good bit of a challenge really.’ 
Interestingly, there appears to have been no direct financial motivation although the individual 
would not have been able to take up the post without financial recompense to her practice.  
At the point the individual took up the post she reported having been a general medical 
practitioner for five years and a partner in her practice for most of that time (4½ years). She also 
reported not having had a similar role in the past and appeared to be somewhat naïve with 
respect to the primary care commissioning landscape, processes and potential motivations: 
M: ‘ …. The PCT is somewhat an unknown force to me. I don’t know, and I couldn’t even 
start to guess, whether it’s something to do with, I don’t know, patient care and, you know, 
qualities and standards and all that sort of business. But I don’t know particularly what [the 
PCT] do gain from it. … ’ 
This relative inexperience, in terms of working with commissioning organisations and involvement 
in service redesign initiatives, did cause some concern: 
M: ‘Why aren’t more people interested in this? Why hasn’t somebody picked it up 
beforehand, you know, that sort of thing. But then again, though, thinking about it, where 
do GPs hear about this sort of thing coming up? And it is typically word of mouth.’ 
Especially when goaded by more senior peers: 
M: ‘ … at the first meeting I did get asked by two other doctors there “So, why have you 
signed up to this then?”.’ 
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4.1.5 Operational phase 
Results obtained relating to the operational phase of the pathway were substantially curtailed 
against expectations, due primarily to delays in the design phase which provided a reduced period 
for the evaluation to observe the operation phase. 
4.1.5.1 Pathway descriptive outcomes 
The first outcome of primary importance was the proportion of general medical practices within 
the locality which participated with the pathway. There were 26 general medical practices within 
the PCT with a registered primary care population of about 190,000 as of 2011. [20]  However one 
of these practices, with less than 1,000 registered patients, was essentially a drug addiction 
treatment centre and due to the nature of the patients it served was considered unlikely to 
participate with, or benefit from, an initiative such as the IBD pathway. The remaining 25 
practices therefore constituted the target general medical practice population. However one of 
these practices, and the smallest in terms of patient numbers with just over 1,000 registered 
patients, indicated that it was going to close on the imminent retirement of its only GP. For this 
purpose the project team ceased to actively pursue participation from that practice after October 
2011. Therefore for the purpose of the evaluation the effective target practice population 
consisted of 24 practices with a combined registered population of just fewer than 190,000, 
ranging in size from just over 1,000 patients to nearly 21,000 patients. 
The sources of data for practice outcomes were the records maintained by the PCT project team 
and provided in February and May 2012. Additional information was extracted separately from  
e-mail correspondence with missing values imputed to the end of the calendar month in question. 
By 31
st
 March 2012, 21 practices had agreed to participate with the pathway yielding an effective 
participation rate of 88%. These practices also accounted for 88% of the available registered 
patient population. The three practices which had not participated consisted of about 1,400; 
4,000 and nearly 17,000 patients each. All three non-participant practices were reported by the 
project team as having shown interest in the project and one, the smallest, had ‘agreed to take 
part’ in October 2011 although the necessary steps for participation had not been fulfilled by the 
evaluation close. Further information revealed that specific self-reported practice issues for non-
participation related to not having sufficient nursing staff available to enable participation and not 
having anyone available to participate in a scheduled training meeting. One practice which was 
not indicated as participating on the February project team record was subsequently stated to be 
participating by March 31
st
 2012. Therefore the participant date for this practice has been 
imputed as the 31
st
 March 2012 although the actual date will have been between 27
th
 February 
and 31
st
 March 2012. Figure 3 demonstrates the temporal pattern of practice participation 
following the launch of the pathway on the 17
th
 November 2010. 
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Figure 3. Cumulative practice recruitment to the IBD pathway (days) 
 
As can be seen in figure 3, the recruitment of practices appears to have occurred in three distinct 
phases. The first cohort consisted of nine practices which all commenced participation with the 
pathway within the first four months and before the end of the first fiscal year in which the 
pathway was launched (i.e. by 31
st
 March 2011). There was an interval of nearly five months 
between commencement of the ninth and tenth participating practice. Subsequently, between 
August and November 2011, which coincided with renewed activity from the project team, a 
further six practices commenced participation. A less distinct third phase is also evident which 
consisted of the final six practices to participate and this occurred in February and March 2012. 
The final phase coincided with a concerted effort from the project team which had by now been 
bolstered with a clinical champion who specifically undertook practice-recruitment tasks. This 
pattern of innovation diffusion, led by ‘early adopters’ and tailed by ‘laggards’, is a recognised 
feature of healthcare and non-healthcare innovations. [177]  It has been extensively analysed and 
described by others and could have been predicted. [178]  
Data relating to completion of the educational package for GPs is available for 12 out of the 21 
practices; 7 out of 9 in the early adopters cohort; 5 out of 6 in the medial cohort; and none of the 
laggard cohort. The educational package was completed at a mean of 82 days from the date of 
practice sign-up (range -3 to 273 days). The mean number of days between commencement of 
participation and training completion was 124 days in the early adopter cohort and 23 days in the 
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medial cohort. Training completion by practices was, naturally, constrained by the availability of 
the training events organised by the project team. 
All nine early-adopter practices had at least one clinician staff member present at the first training 
event on the 31
st
 March 2011, with between one and three staff present per practice. Smaller 
practices tended to be represented by only one attendee. A small discrepancy existed between 
the official attendance record provided by the project team, my notes, and a later attendance 
record provided by the PCT to track payments. Further scrutiny indicated that the official record 
was more likely to have been a list of those who had indicated they would attend as opposed to a 
list of those who actually attended. The majority of attendees were female (about 8 out of 12) 
and nurses; the majority of GP attendees were male (table 6).  
All six medial cohort practices had at least one clinician staff member present at the second 
training event on the 17
th
 November 2011. The meeting was attended by nine individuals; eight 
female, seven of whom were practice nurses, and one male GP. The other attendee was a female 
GP (table 6). 
No staff members from the laggard cohort had attended a training event as this group was 
defined from a sign-up date of February 2012 and the last training event was in November 2011. 
Data relating to the ‘number of patients to review’ was also available. The submission by a 
practice of a ‘number of patients to review’ indicated that a practice had performed one of the 
first steps in the audit process and identified the number of patients with IBD registered at the 
practice. This data was available for 18 practices with the three missing data all from the final 
cohort of practices to have signed-up. The number of patients to review ranged from 5 to 135 per 
practice and correlated closely with the number of registered patients, i.e. the practice size. The 
mean crude prevalence of adult IBD as a proportion of the practice population was 0.58% (range 
0.21% to 0.95%) which was similar to that obtained by Rubin et al in an epidemiological report on 
IBD in the same locality which observed an adjusted IBD prevalence of 0.39%. [2]   
The mean crude prevalence of adult IBD did not appear to correlate with the practice size. The 
mean practice size of those with prevalence less than the mean (n = 11) was about 7,800 and the 
mean practice size of those with prevalence greater than the mean (n = 7) was about 8,400. 
However, the mean crude prevalence did demonstrate greater variation depending on the 
innovation classification; early adopters and the medial cohort were similar at 0.55% and 0.45% 
respectively. However the three practices in the laggard cohort for which data was available 
yielded prevalence rates of 0.91% to 0.95%. 
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Information concerning practice payments and the number of patients who were offered and 
accepted free membership of the patient charity was not made available to me and it was unclear 
if this information had been recorded. 
4.1.5.2 Annual review audit data 
Only limited data was available from the collection of annual review audit data by the project 
team. As of 31
st
 March 2012, 44 submissions of audit data, and by direct association claims for 
payment, had been made due to a primary care annual review of an adult IBD patient. Review 
data had been submitted by 8 practices; 5 out of 9 early adopters, 2 out of the 6 medial cohort 
and, unexpectedly, one from the laggard group. That a practice from the laggard group had 
submitted review data indicated that the link between training and reviews was not fully 
implemented as nurses at that practice did not have an opportunity to undertake the necessary 
training to conduct reviews. The number of reviews per practice ranged from 2 to 12. The 
proportion of the adult IBD practice population for which a review had been conducted ranged 
from 3% to 92% (mean 14%). The highest rate of review completion was associated with a single 
practice which had conducted 12 reviews from an indicated IBD patient population of 13 adult IBD 
patients. The top six practices ranked according to proportion of reviews performed were all early 
adopter practices and the bottom ranked practice was the laggard cohort practice. Table 7 
describes the data. 
Table 7. Primary care adult IBD patient annual reviews 
Practice 
innovation 
classification 
Number of 
declared adult 
IBD patients 
Number of reviews 
completed as of 31
st
 March 
2012 Completion rate 
Early adopter 
37 4 11% 
40 3 8% 
20 12 60% 
11 3 18% 
13 12 92% 
Medial 
99 7 7% 
26 2 8% 
Laggard 76 2 3% 
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Submission of audit data, whilst technically correctly completed, was less descriptive than had 
been anticipated. For example, where practices were required to indicate whether they had 
performed assessments of quality-of-life and symptom scores it had been expected that the 
actual scores would be provided as evidence that the task had been carried out.  However, in the 
event, only one practice with seven reviews actually provided scores with all other practices 
simply indicating ‘yes’ or ‘no’ in response to the columns headed ‘Has symptom control been 
assessed?’ and ‘Has quality of life been assessed?’. There were other examples of audit data 
where similar binary responses had been provided when a more detailed response had been 
expected. Each component of the audit is considered in turn: 
Diagnosis 
Thirty-two review submissions provided a diagnosis; 17 (53%) identified Crohn’s disease, 13 (41%) 
identified ulcerative colitis, and two identified indeterminate colitis. Both of the indeterminate 
colitis diagnoses originated from the same practice which had only recorded four reviews with the 
other two diagnoses being Crohn’s disease. This raises concerns about the veracity of the audit 
data, for example ‘indeterminate colitis’ could have been selected in error in place of ‘ulcerative 
colitis’. Nonetheless, the overall figures were broadly similar to those that would be expected 
from epidemiological reports. [2]  
Aminosalicylate medication 
All 44 submissions provided a response to the question ‘Is the patient on 5-ASA medication?’  
Twenty-two (50%) were affirmative, of which 15 were linked to a diagnosis; 9 (60%) for Crohn’s 
disease and 6 (40%) for ulcerative colitis. 
Medication adherence 
Thirty-nine submissions provide a response to the question ‘Has adherence to medication been 
assessed?’  All five missing responses had been answered ‘not medicated’ to the previous 
question concerning 5-ASA medication and therefore represented a logical response to this 
question. Of the 39 responses, three were ‘no’ and 36 were ‘yes’. 
Symptom and quality-of-life assessments 
Only one practice with seven review submissions, three Crohn’s disease and four ulcerative colitis, 
provided the actual results (scores) of the symptom [179, 180] and quality-of-life assessment 
tools. [14]  Symptom scores for Crohn’s disease varied from 25 to 47 points and from 0 to 8 points 
for ulcerative colitis. The range of each score indicated that the correct assessment had been 
performed for each type of diagnosis although it would appear that the Crohn’s disease scores 
represented a single day’s score and a weekly summed score, as required, had not been 
generated. Symptom scores generally correlated in rankings with quality of life scores, for which 
the overall range was 11 to 32 points with the three lowest scores all being in Crohn’s disease 
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patients. Two reviews associated with a diagnosis of ‘indeterminate colitis’ were identified with a 
symptom assessment even though a suitable symptom assessment tool was not available for that 
diagnosis (the two symptom tools provided were for Crohn’s disease and ulcerative colitis). [179, 
180]  This indicated an inappropriate symptom assessment may have been carried out with these 
patients. Of the 37 reviews for which a quality-of-life score was not provided, 36 responses were 
‘yes’ and one was ‘no’. Similarly, for the 37 reviews for which a symptom score was not provided 
all responses were ‘yes’. 
Depression 
In response to ‘Have you screened for depression?’ all 32 responses from 7 practices were ‘yes’. A 
single practice with 12 review submissions had indicated ‘not depressed’ for 11 reviews and 
‘depressed’ for one. Further information indicated that this patient had been referred for follow-
up with a GP following the identification of depression. 
Biochemical and other monitoring 
All 44 review submission responses were ‘yes’ to the question ‘Has an annual review been carried 
out?’ and this was expected given the nature of task. The intention of this component of the 
annual review, which had undergone some local revision compared with the component which 
had been developed within the IMAGE project, was to ensure that a minimum range of 
biochemical and other monitoring tests were carried out annually. It was not clear to what extent 
the range of ten listed interventions had been completed for each patient. In addition, the review 
template required that dates were recorded for planned or previous assessment of ‘bone health’ 
and colonoscopy however the audit template on which the review data was recorded did not 
specifically request this data. It was therefore unclear whether the intended comprehensive 
biochemical, physical and health screening components were completed for all patients within 
the scope of a primary care nurse-led review appointment. The veracity of the data in this respect 
was undetermined. 
Access to specialist care 
One component of the review specifically enquired as to whether patients knew how to access 
specialist care: ‘Does the patient know how to access hospital / IBD nurse for flare ups?’ for which 
there were 44 positive responses. 
Patient information and support 
Two components of the review prompted questions about patient information and support and 
were explicitly linked in the pathway to the patient charity through provision of their information 
and local branch support group details. Again, all responses were of the binary ‘yes’ / ‘no’ type. 
With respect to provision of patient information 43 responses were positive and one was negative. 
With respect to provision of details of support groups, 42 were positive and two were negative. 
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The single negative response to the information question was also matched with a negative 
response to support group details. Both were further qualified with additional information 
indicating that the patient actively declined the information although no further explanations 
were provided. 
Smoking 
The question ‘Has advice been provided on smoking?’ elicited 43 responses, of which 31 were 
positive, one was negative and eleven stated ‘not applicable’. Of the 31 positive responses, eight 
were further qualified with information concerning the patient’s smoking history such as whether 
they had never smoked or were an ex-smoker. 
Dietician 
The question ‘Does the patient have access to a dietician?’ elicited 42 responses of which 25 were 
positive, nine were negative, and eight stated ‘not required’. Of the nine negative responses six 
originated from the same practice which had only seven submissions and for which the remaining 
response was ‘not required’. This could indicate a particular issue with access to or provision of 
dietetic services at that practice. Another practice with only two submissions also provided two 
negative responses. One positive response provided further information concerning an onward 
referral to a dietician, presumably as a consequence of the review. 
Complementary and alternative medicines 
‘Have complementary and alternative therapies been discussed?’ elicited 43 responses of which 
31 were negative and 12 were positive. None of the responses, whether positive or negative, 
were further qualified with additional information concerning the nature of the discussions or 
reasons why complementary and alternative medicines were not discussed.  
Secondary care reviews 
Annual IBD patient reviews in secondary care were intended to be delivered to the same template 
as those in primary care. However secondary care patient reviews conducted during the 
operational phase of the pathway were not systematically or collectively recorded by the hospital 
IBD team and therefore were unavailable for analysis. It was subsequently reported anecdotally 
that by the time of the evaluation close few secondary care reviews had been conducted within 
the context of the integrated care pathway and none had utilised the agreed template. 
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4.1.5.3 Prescription data 
Over the course of the 36 months from April 2009 to March 2012 there was 591,690 days’ worth 
of IBD medication prescribed from the PCT. The corresponding figure for the SHA (excluding the 
locality PCT) was 7,285,566 (table 8). The summed DDD values for the PCT and the SHA (excluding 
the PCT) were slightly greater than the corresponding ADQ values at 600,130 and 7,380,972 
respectively. Appendices 12 and 13 provide monthly breakdowns of summed ADQ and DDD 
prescribing data, respectively. 
The difference between summed ADQ and DDD values is attributable to the difference between 
the mesalazine ADQ and DDD values. Mesalazine constituted the overwhelming majority of all 
prescribing by ADQ from within the IBD basket at more than 80% in each year for both the PCT 
and the SHA. There was a trend for mesalazine to constitute an increasing proportion of 
prescribing within the IBD drugs basket over time (table 9). The rate of increase of mesalazine 
prescribing for IBD is slightly greater for the PCT compared with the SHA (excluding the PCT) 
although the absolute difference was small at less than 4%. 
Table 8. Summary of IBD prescribing by summed ADQ for the PCT and the rest of the SHA  
 2009-10 2010-11 2011-12 
PCT 
Total daily doses 183,901 198,453 209,336 
Mean doses per day 504 544 572 
Year-on-year increase*  8% 5% 
Cumulative increase*  8% 14% 
SHA  
(excl PCT) 
Total daily doses 2,292,656 2,441,432 2,551,477 
Mean doses per day 6,281 6,689 6,971 
Year-on-year increase*  6.5% 4% 
Cumulative increase*  6.5% 11% 
* : From 2009-10 baseline year. 
The IBD basket consisted of only two types, or therapeutic classes, of drug; aminosalicylates and 
steroid preparations (table 2). All aminosalicylate drugs in the basket were considered to be highly 
sensitive to IBD. Both drug classes included both oral and rectal preparations however the ratio of 
oral to rectal preparations within each therapeutic class within the IBD basket varied substantially 
(tables 10 and 11). 
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Within the PCT the overall ratio of oral to rectal prescribing, by ADQ, was 15:1 however this 
disguised opposing situations within each class, with an aminosalicylate ratio of 47:1 and a steroid 
ratio of nearly 1:5 (table 10). A notable omission from the steroid class was oral prednisolone 
which expert opinion had indicated would constitute the great majority of oral steroid prescribing 
in IBD. 
A reasonable assumption would be that the inclusion of oral prednisolone within the IBD basket 
would make the proportion of oral preparations exceed rectal preparations within the steroid 
class as with the aminosalicylate class. The steroid oral to rectal ratio would then be in the 
opposite direction. However, prednisolone, and in particular oral prednisolone, is a corticosteroid 
drug which is used for a multitude of acute and chronic inflammatory conditions. Therefore data 
relating to oral prednisolone alone without linked data relating to the therapeutic indication 
would lack specificity for IBD. Data for the SHA (excluding the PCT) is provided in table 11 for 
comparison. 
Table 9. Proportion of mesalazine within the IBD basket (ADQ) 
Period PCT SHA 
(excluding PCT) 
Difference-in-
difference 
2009-10 153,457 
(83.4%) 
1,885,500 
(82.2%) 
 
2010-11 169,276 
(85.3%) 
2,034,308 
(83.3%) 
 
Annual increase 1.8% 1.1% 0.8% 
2011-12 184,139 
(88.0%) 
2,153,129 
(84.4%) 
 
Annual increase 2.7% 1.1% 1.6% 
Three-year total 506,872 
(85.7%) 
6,072,937 
(83.4%) 
 
 
A comparison between the PCT and the SHA (excluding the PCT) demonstrated a similar pattern 
with aminosalicylates. The majority of prescribing by ADQ consisted of oral preparations and 
remained relatively stable over each of the three years in the data set. However, with respect to 
steroid preparations, although both data sets demonstrated that rectal preparations constituted 
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the majority of items within the IBD basket in each year, and both showed the proportion 
decreasing over time, the absolute levels and the attendant ratios were quite different (e.g. 83% 
vs. 72% rectal preparations over the whole period for the PCT vs. the SHA (excluding the PCT), 
respectively. Caution must be expressed against any further interpretation of this data as the data 
set for steroid use in IBD was incomplete, due primarily to the omission of oral prednisolone. 
Relatively subtle and clinically appropriate differences in prescribing could have resulted in the 
observed differences between the two groups however it can only be concluded, on current 
evidence, that the pathway had no clear or important impact on prescribing. 
Table 10. PCT prescribing for IBD by therapeutic class (ADQ units) 
Therapeutic class Period All 
prescribing 
Oral Rectal Oral:Rectal 
ratio 
Aminosalicylate 
2009-10 173,583 170,449 
(98.2%) 
3,135 
(1.8%) 
54:1 
2010-11 187,066 182,863 
(97.8%) 
4,203 
(2.2%) 
44:1 
2011-12 200,382 195,955 
(97.8%) 
4,427 
(2.2%) 
44:1 
Total 561,031 549,267 
(97.9%) 
11,765 
(2.1%) 
47:1 
Steroid 
2009-10 10,318 1,281 
(12.4%) 
9,036 
(87.6%) 
1:7 
2010-11 11,319 1,818 
(16.1%) 
9,501 
(83.9%) 
1:5 
2011-12 8,936 2,244 
(25.1%) 
6,692 
(74.9%) 
1:3 
Total 30,573 5,343 
(17.5%) 
25,229 
(82.5%) 
10:47 
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Table 11. SHA (excluding PCT) prescribing in IBD by therapeutic class (ADQ units) 
Therapeutic class Period All 
prescribing 
Oral Rectal Oral:Rectal 
ratio 
Aminosalicylate 
2009-10 2,159,071 2,093,947 
(97.0%) 
65,123 
(3.0%) 
32:1 
2010-11 2,299,891 2,234,456 
(97.2%) 
65,435 
(2.8%) 
34:1 
2011-12 2,417,609 2,346,197 
(97.0%) 
71,411 
(3.0%) 
33:1 
Total 6,876,570 6,674,600 
(97.1%) 
201,970 
(2.9%) 
33:1 
Steroid 
2009-10 133,448 33,244 
(24.9%) 
100,205 
(75.1%) 
1:3 
2010-11 141,388 36,168 
(25.6%) 
105,220 
(74.4%) 
1:3 
2011-12 113,806 44,133 
(33.0%) 
89,674 
(67.0%) 
1:2 
Total 408,642 113,544 
(27.8%) 
295,098 
(72.2%) 
5:13 
Note: Some totals do not sum to expected or previously quoted values due to individual and 
accumulated rounding errors. 
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4.1.5.4 Health episode statistics data analysis 
Following extensive probing of the HES online interface it was impossible to obtain diagnostic- or 
procedure-code specific data for a specific entity, whether that unit was a PCT or hospital trust or 
hospital site. The data that was freely available from the NHS Information Centre, which managed 
the HES online database, only provided national (England) data at grouped diagnosis and 
procedure codes, or therapeutic classification. This data was unsuitable for determining local IBD 
activity. 
However the integrated care pilots stage 2 application (March 2011) did include data relating to 
local IBD healthcare utilisation. This data was obtained by the PCT project team from their MIDAS 
system (see box 8). A detailed financial plan was included in the stage 2 application which utilised 
actual population, morbidity, acute and planned care utilisation and expenditure data. 
The project team used MIDAS to identify all admissions linked to an IBD diagnosis. Admissions 
were stratified into two groups; non-elective activity and out-patient activity. Non-elective activity 
was further distinguished between higher cost and lower cost patients with the former including 
all patients aged 70 years or older or patients with ‘complications or co-morbidities’ (annotated 
‘cc’). The lower cost group included all patients aged 69 years or younger and without ‘cc’. Out-
patient admissions were distinguished between ‘new’ and ‘review’ appointments with new 
appointments attracting a slightly higher value per episode than review appointments (see box 9). 
The data provided in the application consisted of three time periods for each type of activity (non-
elective and outpatient). The time periods used were fiscal years and included April 2006 to 
March 2007, April 2007 to March 2008, and the partial year April to November 2008 (eight 
months) which was assumed to be the most up-to-date volume of data available when the 
application was prepared. The data provided was for all of the PCT patients and indicated that 
care was delivered by one of three NHS hospital foundation trusts including two large teaching 
and tertiary referral centres. Each hospital trust itself consisted of multiple hospital and other 
sites.  The data did not provide detail at the site level only at trust (provider organisation) level. 
The data demonstrated no discernible trend with respect to IBD healthcare activity. Total non-
elective admissions were 293, 273 and 205 respectively with the latter figure representing only 
eight months of data; the equivalent expected annual rate was estimated at 308 admissions. Total 
out-patient admissions were 1,055, 1,342 and 837 (1,256 annualised equivalent) respectively.  
This data is provided to permit any future analysis which is able to utilised MIDAS data or similar 
sufficient to enable a meaningful comparison against these pre-pathway or baseline values. 
As discussed in chapter 3, the application also included a number of assumptions of cost savings 
which the pathway was expected to generate based on these levels of admissions. 
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Box 8. MIDAS  [32] 
MIDAS is an acronym for [Locality] PCT Information, Data and Statistics. 
MIDAS was a web-based software package used by a PCT conglomeration (‘cluster’) which 
included the locality PCT and three other neighbouring PCTs. MIDAS was an in-house information 
system that served as a reporting tool for the collective organisation’s data warehouse. It was 
initially designed to support Practice Based Commissioning and was claimed to empower both 
general medical practitioners and their staff and commissioning (i.e. PCT) staff to monitor and 
audit patient information relating to the clinical outcomes of patients and progress of their service 
against targets. 
The system enabled data interrogation down to the individual patient level and adjustment of 
data boundaries (e.g. PCT, practice, patient, hospital trust, political boundaries). MIDAS was a 
secure system which could only be accessed by authorised users. 
The data contained within MIDAS has its origins in the HES data generated by any hospital trust 
which has provided care or had contact with patients from the PCT cluster and this is combined 
with locally generated referral data. The majority of care was therefore provided by local 
hospitals. Standard and bespoke data reports could be generated based on diagnosis and 
procedure codes or combinations thereof. The data could be manipulated in numerous ways to 
ensure that it was useful and relevant to users and could be exported in familiar formats such as 
Microsoft Excel™. 
I was not an authorised MIDAS user and the system or data extracts from it were not made 
available to me. 
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Box 9. NHS definition of outpatient appointment classifications  [181] 
 ‘New’ and ‘review’ outpatient appointments are officially referred to as ‘first attendance’ or 
‘follow-up attendance’ respectively in the NHS payment by results tariff. The distinction between 
the two appointment types is made as 'This indicates whether a patient is making a first or follow-
up attendance.' 
Outpatient appointments are defined in the NHS Data Model and Dictionary as: 
A first attendance is the first in a series of attendances, with subsequent attendances in the 
Consultant Out-Patient Episode recorded as follow–up attendances. Follow-up attendances within 
a Consultant Out-Patient Episode are all subsequent attendances to see the same Consultant 
following a First Attendance. A Consultant Out-Patient Episode ends when the Patient is not given 
a further Out-Patient Appointment by the Consultant. 
In practical terms, a first-attendance will attract a higher charge than a follow-up attendance, 
presumably to reflect the additional resources required for the first consultation compared with 
follow-up consultations for the same episode. 
 
4.1.5.5 Combined IBD Healthcare Utilisation Metric 
The development of a single combined IBD healthcare utilisation metric was not pursued as there 
was no suitable non-drug healthcare utilisation data available to combine with the primary care 
drug data. 
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4.2 Community Pharmacy and IBD 
4.2.1 Survey 
Of the 393 surveys which were posted, 197 completed surveys were returned before the cut-off 
date. One of these was later excluded as although the registered member was an adult they were 
serving as a proxy member on behalf of their child with IBD. The responses provided in this case 
were a mixture of proxy child-patient responses and direct responses from the non-patient parent. 
In addition, a small number of uncompleted surveys were returned by adult members of the 
branch who were not IBD patients or patients who lived outside of the locality and felt that they 
were not eligible to complete the survey. A small number of completed surveys were returned 
after the cut-off date and were not included in the final analysis set. Thus the actual response rate 
was in excess of 50%, however the effective response rate was 196 out of 393 (49.9%). 
Response rates for individual questions, or parts thereof, ranged from 23% to 99%. Question 8 
was unusual in that it was preceded by a filter question and therefore only respondents who 
provided a specific response to question 7 were required to then complete question 8. With 
question 8 excluded the response rate ranged from 72% to 99%. Individual responses to each 
question are described in turn.  
Questions 1 to 8 were used to elicit baseline data concerning the extent and nature of the 
respondents’ use of various types of medication and interaction with community pharmacies. 
Questions 9 and 10 elicited information concerning patient-pharmacy interactions. 
Questions 11 to 15 elicited patient demographic details. 
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4.2.1.1 Baseline drug-related healthcare utilisation and services 
Question 1 
The results from question 1 demonstrated a high rate of prescription medication use amongst 
respondents. 
Do you currently use medicines prescribed for you for IBD? 
Response n % 
Yes 168 86.6% 
No 26 13.4% 
Not answered 2  
Multiple responses 0  
 
Question 2 
Results from question 2 demonstrated that GPs were the most common source of IBD medication 
prescriptions although prescriptions from hospital doctors were also high. Other prescribers 
accounted for much smaller proportions. The two responses received and listed as ‘other’ were 
‘Initially hospital consultant’ and ‘health care at home’, the latter being a recognised medication 
home delivery service provider. 
Who currently prescribes your IBD medication? (tick all that apply) 
Response n % 
Hospital doctor 102 52.0 
General practitioner (GP) 122 62.2 
Hospital nurse 28 14.3 
Other nurse (e.g. working in practice or district nurse) 4 2.0 
Hospital pharmacist 2 1.0 
Community pharmacist 3 1.5 
Other (please indicate) 2 1.0 
Response descriptions n % 
Not answered 30 15.3 
One response 90 45.9 
Two responses 58 29.6 
Three responses 16 8.2 
Four responses 2 1.0 
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Question 3 
A supermarket in-store pharmacy is also a type of community pharmacy therefore the true 
response rate for community pharmacy required additional calculation to account for this 
duplication. It was not possible to calculate this simply by adding the two response counts 
together as some respondents provided positive responses to both categories. Seven surveys 
answered positively to both community pharmacy and supermarket pharmacy, thus the adjusted, 
or true, number of responses for ‘community pharmacy (including supermarket pharmacies)’ was 
139 (71%). The results demonstrated that more than two-thirds of respondents received their IBD 
medication via a community pharmacy. 
Where are your IBD medicines dispensed? (tick all that apply) 
Response n % 
Community pharmacy 133 67.9 
Supermarket in-store pharmacy 13 6.6 
Hospital pharmacy 33 16.8 
General practice surgery  
(e.g. if you doctor also dispenses medicines) 
22 11.2 
Internet pharmacy 0 0 
Other (please indicate) 12 6.1 
Response descriptions n % 
Not answered 32 16.3 
One response 124 63.3 
Two responses 31 15.8 
Three responses 9 4.6 
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Question 4 
Question 4 was effectively screened by the preceding question. In question 3, 146 responses from 
139 surveys indicated that their medication was dispensed by a community pharmacy or an in-
store supermarket pharmacy and only these respondents would be expected to answer question 
4. Therefore question 4 should have been answered by these same 139 respondents. In the event, 
149 surveys provided a response and 47 did not provide a response to question 4. 133 had 
responded to question 3 with community or supermarket pharmacy or both therefore 13 surveys 
provided a response to question 4 which was unexpected. Six surveys that responded with 
community pharmacy or supermarket pharmacy to question 3 did not provide a response to 
question 4. Analysis is independent of question 3. A number of respondents indicated that they 
did not understand question 4 in addition to answering ‘not sure’ or in lieu of any response. No 
multiple responses were received for question 4. The results demonstrated that about half of 
patients always use the same pharmacy, and nearly a third usually use the same pharmacy, with a 
minority demonstrating less commitment. 
If your IBD medication is dispensed by a community pharmacy or an in-store 
supermarket pharmacy, is that at the same pharmacy? (tick only one) 
 
n 
% (as a proportion 
of all responses) 
Always 77 51.7 
Usually 42 28.2 
Sometimes 13 8.7 
Rarely 1 0.7 
Never 10 6.7 
Not sure 6 4.0 
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Question 5 
Question 5 was an open question which requested up to three written responses. The intention 
was for this question only to be answered depending on the answer provided for the preceding 
question. 149 respondents answered question four and 142 provided at least one response to 
question five. However 29 respondents (20%) who either didn’t provide a response for question 
four (n = 11) or who didn’t respond with either ‘usually’ or ‘always’ (n = 18) did provide at least 
one response for question five. Irrespective of response to question four, all responses for 
question five were analysed collectively. 
331 responses were received from 142 surveys, a mean of 2.35 responses per responding survey, 
or a mean of 1.70 responses from all 196 returned surveys in the analysis set. 80 surveys provided 
three responses, 30 surveys provided two responses, 31 surveys provided one response and 54 
surveys did not provide any response. 
Responses were not requested to be, nor were they necessarily, ranked although the construct of 
the question could have led to an assumption of this nature by respondents. The actual responses 
received did not indicate any obvious or apparent ranking by respondents and analysis has not 
therefore considered any ranking. 
A thematic analysis of responses using text-based analysis was undertaken using a framework 
analysis approach. [182]  Themes were identified based on prior knowledge of community 
pharmacy and relevant published research. These themes were refined and validated by an 
experienced pharmacy practice academic from a neighbouring institution with a small number of 
relatively minor amendments. Each theme was classified into one of five induced categories 
which were further defined as either external to the influence of the pharmacy, or internally 
influenced attributes. 
Twenty-two distinct themes were identified which were subsequently classified into five main 
categories. Details of the themes, categories and frequency counts are provided in the table 12. 
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Table 12. Thematic analysis of responses to question 5 
If your prescription is usually or always dispensed at the same pharmacy, what are the factors 
that influence that decision? List the three most important. 
Category Theme n Influence 
Geographical 
Proximity to GP 40 
159 External 
Convenient 104 
Restricted choice 7 
Proximity to parking 8 
Business and 
Staff attributes 
Familiarity with staff 3 
96 
Internal 
Internet (online) prescription service 3 
Service quality 14 
Staff attributes 44 
Waiting time 11 
Information 10 
Loyalty not otherwise specified 10 
Opening hours 1 
Pharmaceutical 
services 
Prescription collection and delivery service 23 
42 
Repeat prescription service 14 
Provision of monitored dose system 1 
Provision of medicines use review, or other 
medication review 
2 
Emergency supply 2 
Drug specific 
Provision of preferred medicine brand(s) 1 
22 
Stock-holding 21 
Pharmacist 
attributes 
Helpful 5 
11 
Confident 2 
Pharmaceutical/medical knowledge 1 
Professionalism not otherwise specified 2 
Dispensing accuracy 1 
Other Recommended by GP 1 1 External 
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Question 6 
Question six was expected to return one response per respondent who reported receiving 
prescription IBD medication (question 1) and the results correlated accordingly.  
‘Other’ responses included ‘wife’ for which the respondent had already indicated ‘family member’, 
‘infliximab infusion at hospital every eight weeks’, ‘military nurse’, and ‘delivered by chemist if not 
well’ for which the respondent had only indicated ‘you’. These results were all counted separately. 
Who usually collects your prescription once it has been dispensed? (tick only one) 
 n % 
You 129 65.8 
Family member 28 14.3 
Friend or neighbour 1 < 1 
Social services carer 0 0 
A health care professional (e.g. district nurse) 1 < 1 
It is delivered 18 9.2 
Other (please indicate) 4 2.0 
 n % 
Not answered 30 15.3 
One response 154 78.6 
Two responses 9 4.6 
Three responses 3 1.5 
 
Question 7 
This question was potentially independent of question 1 as it related to non-prescription 
medication and similar items. This meant it was the first question which respondents would 
encounter which would not be related to prescription medication. The results demonstrated that 
a significant minority of respondents did report taking non-prescription IBD medication. 
Do you take other medicines for IBD which are not prescribed for you? This might include 
medicines that you buy from a pharmacy, supermarket or grocery store, or herbal or 
vitamin preparations. 
 n % 
Yes 45 23.0 
No 145 74.0 
Not answered 6   3.1 
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Question 8 
Question 7 was explicitly intended to serve as a filtering question for question 8, therefore only 
respondents who had answered ‘yes’ to question 7 were expected to provide a response to 
question 8. Forty-five surveys responded ‘yes’ to question 7 and 46 surveys provided at least one 
response to question 8. All 45 surveys which responded ‘yes’ to question 7 provided a response to 
question 8. The additional response to question 8 was from a survey which had not provided a 
response to question 7. The ‘other’ response indicated direct supply to the patient from a clinical 
trial centre. 
If you answered ‘yes’ to question 7, where do you obtain these medicines? (tick all that apply) 
 n % % 
Community pharmacy 9 19.6 4.6 
Supermarket (including the in-store pharmacy) 15 32.6 7.7 
General store (e.g. local convenience store) 3 6.5 1.5 
Health food, herbal or vitamin store  
(e.g. Holland & Barrett) 
22 47.8 11.2 
Internet / online 7 15.2 3.6 
Mail order, or from a magazine or television advert 6 13.0 3.1 
Given to you by family or friends 0 0 0 
Other (please indicate) 1 2.2 < 1 
 n % % 
No response 150  76.5 
One response 32 69.6  
Two responses 11 23.9  
Three responses 3 6.5  
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4.2.1.2 Patient satisfaction with pharmaceutical care and pharmacy 
Question 9 
Respondents were required to recall experiences relating to the pharmacy that they usually use or 
otherwise their most recent visit to a community pharmacy. Fifteen respondents did not recall 
visiting a community pharmacy, 14 of whom did not provide any response to the 20 statements 
which constituted this question. The question was preceded by a filter statement to eliminate 
respondents who could not recall visiting a community pharmacy. One respondent who indicated 
that they could not recall visiting a community pharmacy still provided a response to each of the 
20 statements. The reporting and analysis of responses has been conducted irrespective of 
response to the filter question and other questions. 
The response rate for individual statements varied from between 81% to 88%. The response 
matrix is provided in table 13. The question order presented in the results is not that which was 
used in the survey (see appendix 4) as items for each constituent scale incorporated into the 
question have been grouped together in the results. The ‘no opinion’ response was extensively 
used, ranging from 0 to 24% within FE items and 18 to 43% within MT items. 
Calculation of FE and MT scores required a complete set of responses excluding ‘no opinion’ 
within each scale. A complete set of required responses for FE was available from 89 surveys and 
for MT from 61 surveys. 
The range of individual FE and MT scores was 1.0 to 5.0, corresponding to the mean score over all 
items within each scale. The overall mean FE score was 3.80 (standard deviation 0.96; 95% 
confidence interval 3.61 to 4.00). The overall mean MT score was 3.31 (SD 1.25, 95%CI 2.99 to 
3.62). The difference between mean FE and MT scale scores was significant using a two-sided test 
and an alpha value of 0.025 to give an overall significance level of 5%; difference in mean scores 
was 0.49 points (p = 0.01). 
There were some limited examples which indicated that responses had not been properly 
considered with responses presented in an obvious pattern. This was most commonly 
demonstrated by responses inserted into the same vertical column for all 20 items. Analyses have 
not been adjusted to account for seemingly irrational or non-properly considered responses. 
Responses corresponding to ‘no opinion’ were the third most common response overall, 
accounting for one-fifth of all responses. However there was a striking difference between scales, 
with ‘no opinion’ accounting for 9.8% of all FE responses and 33.9% of all MT responses. The most 
common response for eight out of nine MT items was ‘no opinion’.  
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Table 13. Response matrix for survey question 9  
Scale Item 
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The professional appearance of the pharmacy 3 7 44 67 51 1 173 
The availability of the pharmacist to answer your questions 2 14 34 52 52 15 169 
The pharmacist’s professional relationship with you 6 16 31 51 43 19 166 
The pharmacist’s ability to advise you about problems that you might have with your medications 5 7 34 41 39 36 162 
The promptness of prescription drug service 6 19 42 46 58 0 171 
The professionalism of the pharmacy staff 4 12 43 53 57 1 170 
How well the pharmacist explains what your medications do 11 13 30 37 35 40 166 
How well the pharmacist instructs you about how to take your medications 11 18 37 30 35 34 165 
Your pharmacy services overall 3 17 48 48 56 1 173 
How well the pharmacist answers your questions 5 11 38 32 43 35 164 
The courtesy and respect shown to you by the pharmacy staff 5 13 48 41 65 0 172 
Total 61 147 429 498 534 182 1851 
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The pharmacist’s interest in your health 18 23 29 22 23 50 165 
How well the pharmacist helps you manage your medications 15 16 27 22 20 61 161 
The pharmacist’s efforts to solve problems that you have with your medications 8 14 29 25 25 63 164 
The responsibility that the pharmacist assumes for your drug therapy 16 14 17 26 19 67 159 
The pharmacist’s efforts to help improve your health or stay healthy 17 14 22 23 16 69 161 
The privacy of your conversations with the pharmacist  26 34 22 26 30 30 168 
The pharmacist’s efforts to assure you that your medications do what they are supposed to  14 13 24 26 17 64 158 
How well the pharmacist explains possible side effects 27 16 31 22 22 45 163 
The amount of time the pharmacist offers to spend with you 27 17 27 24 21 47 163 
Total 168 161 228 216 193 496 1462 
Grand total 229 308 657 714 727 678 3313 
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Question 10 
This question consisted of 12 statements, each assessed on a Likert scale. The responses matrix is 
provided in table 14. Some statements were deliberately designed to contradict other statements 
to provide a measure of intra-responder reliability. 
No response was received from 13 surveys and a full response (i.e. a response for each of the 
twelve statements) was received from 158 surveys (81%). Twenty-five surveys (13%) provided 
between one and 11 responses each. 
Responses were not scored but ranged from negative to positive agreement. The skew of 
responses was informally assessed by visual inspection of the data. The highest level of positive 
agreement was statement 4, with 128 respondents indicating agreement (73%). The highest level 
of disagreement was with statement 9, with 139 respondents indicating disagreement (79%). 
Some statements demonstrated bimodal levels of agreement due to relatively few mid-range 
responses of ‘neither agree nor disagree’. Specifically, these were the 2
nd
, 7
th
, 11
th
 and 12
th
 
statements, with mid-range responses ranging from 25 to 43 against an overall range of 19 to 70. 
Statements for which the mid-range response was the most common were the 3
rd
, 6
th
, 8
th
 and 10
th
 
statements although some of these still demonstrated an overall skew in the spread of responses. 
The results can be interpreted as cautiously positive for community pharmacy with more 
respondents agreeing to statements which support a role for pharmacy and disagreeing to 
negative statements. However, there is a considerable degree of heterogeneity in responses and 
nearly one-quarter of responses were ambivalent. Of particular note was that relatively few 
patients reported problems with managing their medication although those who did agree with 
the statement that they struggled with their medication still accounted for over 10%. 
 
124 
Table 14. Response matrix for survey question 10 
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When I visit a community pharmacy I feel that I can discuss medication issues with the pharmacist 7 23 29 88 29 176 
My community pharmacy lacks privacy for me to discuss issues with the pharmacist or other staff 25 41 30 56 22 174 
I would like my community pharmacist to be more involved in the overall management of my condition 20 48 70 27 9 174 
If I have a question about my medicines the pharmacist is always available 1 15 32 104 24 176 
There is no need for a pharmacist to be involved with the management of my condition 14 34 37 65 27 177 
My community pharmacist does not have the time to discuss medication related issues with me 28 52 60 23 8 171 
I would be happy to have my medication monitored in a community pharmacy 19 47 43 58 12 179 
Pharmacists are suitably qualified to take on a bigger role in the management of my condition 19 40 67 35 14 175 
At times I struggle to manage my medication 62 77 19 14 5 177 
I would not feel comfortable with a community pharmacist being more involved in the management of my condition 14 40 54 49 22 179 
If I have a question about one of my medicines I ask my pharmacist first 27 69 25 44 12 177 
My community pharmacy has a suitable place for me to discuss confidential issues if I need to 26 33 26 65 26 176 
Total 262 519 492 628 210 2111 
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4.2.1.3 Baseline disease and demographic data 
Questions 11 to 15 constituted the final section of the survey and consisted of five questions 
designed to collect baseline demographic and disease characteristics. 
Question 11 
Question 11 obtained information concerning the gender of respondents. The overall response 
rate was very high, with only three survey respondents omitting a response to this question. The 
results demonstrated that almost two-thirds of respondents were female. 
Are you N % 
Male 70 36.3 
Female 123 63.7 
Not answered 3  
 
Question 12 
Question 12 obtained information concerning respondent age. The overall response rate was high 
with only two survey respondents omitting a response to this question. The results demonstrated 
that the majority of respondents were ‘middle aged’, in the range 40 to 69 years, however 
significant numbers of responses were received from younger and older patients.  
One returned survey indicated that the respondent was aged under 18 years. This contravened 
ethical approval for the study and the survey and all associated data was removed from the 
analysis set. The survey respondent indicated that they were a proxy adult member for their child 
with IBD. 
Which age group are you? n % 
Under 18 years 0 0 
18 to 29 years 16 8.2 
30 to 39 years 22 11.3 
40 to 49 years 36 18.6 
50 to 59 years 45 23.2 
60 to 69 years 40 20.6 
70 to 79 years 26 13.4 
80 to 89 years 9 4.6 
Older than 89 years 0 0 
Not answered 2  
 
126 
Question 13 
This question sought to obtain a self-declared diagnosis. 185 surveys provided one response, two 
did not provide any response, and nine provided two responses. Of those which provided two 
responses, two stated that they had Crohn’s disease and ulcerative colitis, two that they had 
Crohn’s disease and another IBD diagnosis other than ulcerative colitis, and five stated that they 
had ulcerative colitis and another IBD diagnosis other than Crohn’s disease. 
What form of inflammatory bowel 
disease do you have? 
n % 
Crohn’s disease 104 51.2 
Ulcerative colitis 86 42.4 
Other IBD diagnosis 13 6.4 
Not answered 2  
 
Question 14 
This question sought to obtain a self-declared assessment of disease severity. 191 respondents 
provided one response, one respondent provided two responses (indicating moderate and 
severe), and four respondents did not answer this question. 
Most patients stated that their disease was mild or moderate although a significant minority, 
almost 1 in 4, stated that their disease was ‘severe’. 
Regardless of your official diagnosis, how 
would you personally describe the 
severity of your IBD 
n % 
Mild 60 31.4 
Moderate 89 46.6 
Severe 42 22.0 
Not answered 4  
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Question 15 
This question required a text (written) response from respondents relating to their residential 
location. 
What is the first part of your postcode? e.g. TS17, DL3 ………. 
Nine respondents did not answer this question. 186 respondents provided a single answer 
consisting of the first three or four characters of their postcode, i.e. the postcode district. 181 of 
the postcode districts were immediately local and 5 were near-local. One postcode was from a 
remote location and this respondent indicated that they used a relative’s address within the 
group locality for their membership and registration with the patient charity, hence they were 
assigned to that particular branch.  
Further analysis of postcode data was compromised by misjudged data collection. A full post code 
or any further information than requested, for example the next numerical characters denoting 
post code sector, was not obtained so as to maintain respondent confidentiality. However 
postcode data is correlated with, for example deprivation scores or other socioeconomic 
characteristics, at the postcode sector level of granularity which is one level further than the 
district level collected. Consequently further analyses were terminated. The post code district 
data was not entirely redundant as it did confirm the geographical spread of respondents which 
corresponded closely to that expected with the sample derived from a geographically-defined 
branch of a national patient charity. 
4.2.2 Summary of survey responses 
The overall findings from the survey data of adult IBD patients were that: 
• The condition was managed extensively with prescription medication 
• The condition relied upon a significant element of primary care management 
• Patients regularly visited community pharmacies themselves 
• Patients chose their community pharmacy due equally to external and internal factors 
• Use of non-prescription medicines was relatively high and these were purchased from a 
diverse number of sources including community pharmacies 
• Satisfaction with current levels of pharmaceutical care was generally good, with 
satisfaction with care relating to ‘friendly explanation’ being greater than that relating to 
‘managing therapy’ 
• Adult IBD patients valued pharmacists for information-providing roles but were less 
welcoming of pharmacists becoming more involved in the management of their condition 
• Few patients reported current problems in managing their medication 
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4.2.3 Focus groups 
By 12
th
 January 2011, 76 recipients of survey packs had returned a completed focus group enquiry 
(appendix 6). Two of these were participants declining to participate. Of the 74 respondents who 
indicated they were willing and able to potentially participate, focus group information packs 
were sent by post to 49 individuals and via e-mail to 25. 
From the 74 packs distributed, 25 replies were received either by return of consent form or 
through other correspondence, most often e-mail. One individual was ineligible for participation 
as she was not an IBD patient although she was an adult member of the local branch of the 
patient charity as a proxy member for her child who did have IBD. Three respondents 
subsequently withdrew consent or were unavailable for the proposed focus group dates. 
Confirmed invites were sent to 21 individuals for one of three focus groups as indicated in  
table 15. 
Table 15. Focus group stratification, invites, and attendance 
 Focus group 1 Focus group 2 Focus group 3 
Planned 
patient type 
Younger (age ≤ 50 years) 
ulcerative colitis patients 
Older (age > 50 years) 
ulcerative colitis patients 
Crohn’s disease 
patients 
Date and time 
Wednesday 23rd February 
2011.7 to 9pm 
Sunday 27th February 
2011. 1 to 3pm 
Sunday 27th 
February 2011.  
4 to 6pm 
Invited 6 7 8 
Attended 2 5 2 
 
In order to accommodate the specific requirements of some participants, and in reflection of the 
confirmed participant response rate, the proposed stratification was not strictly adhered to. In 
particular, two patients with Crohn’s disease attended the second focus group and both 
attendees of the first focus group were aged over 50 years. 
The focus groups were semi-structured although the structured element was not proscriptive or 
strictly adhered to. Questions were generally presented in an open manner and as facilitator I was 
conscious of permitting participants to discuss amongst themselves rather than interjecting with 
too many questions. During the focus groups several of the scenarios (appendix 9) arose 
incidentally at various times. In these situations the scenarios, or the specific steps within them, 
were not re-interrogated although they were taken as a starting point for interrogation of a 
particular scenario. In the event each focus group endured for most of the allotted two hours. 
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Table 16. Focus group attendees 
Participant code Focus group Details 
11 1 Female, UC 
12 1 Male, UC 
21 2 Female, UC 
22 2 Male, CD 
23 2 Male, CD 
24 2 Male, UC 
25 2 Female, UC 
31 3 Male, CD 
32 3 Male, CD 
CD: Crohn’s disease UC: Ulcerative colitis 
Ultimately, for each theme, a single document was generated which would contain text relating 
to a single specific theme. Some sections of text featured within multiple different themes if it 
was deemed that more than one theme was clearly included within that section. Thematic 
iterations underwent some revisions to yield the themes identified in table 17. Each is considered 
in turn. 
Table 17. Themes identified from community pharmacy-IBD focus groups 
Theme Notes 
Pharmacists* As individuals, professionals and healthcare providers 
Pharmacies The environment and facilities (including staff) 
IBD The condition, being a patient, social impact 
Medication Importance in the management of IBD condition, use 
of non-prescription medicines 
Boundaries of care Relationship with key providers, relationships 
between providers 
Medication adherence* Identifying the boundaries of care with respect to 
community pharmacy, willingness to accept specific 
care from community pharmacies 
Medication monitoring* 
Choice of medication* 
Nutritional support* 
Managing a relapse* 
Associated healthcare needs and 
services* 
* : Theme identified a priori and specifically queried. 
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4.2.3.1 Pharmacists 
This particular theme was specifically investigated and served as the opening topic within each 
focus group. Participants typically described their interactions with community pharmacists and, 
by extension, the pharmacies and other staff. The majority of comments were positive. In general, 
participants recognised community pharmacists as healthcare professionals, with expert 
knowledge about medicines, but perceived their current level of healthcare provision as limited 
and constrained. Participants were concerned that pharmacist’s knowledge would not extend to 
non-drug aspects of IBD. 
Participants expressed concerns about how well integrated community pharmacy was with their 
overall healthcare management, and were particularly concerned that if pharmacists were making 
disease management decisions this would be difficult to communicate to GPs and specialists. The 
existing role of community pharmacists was perceived as largely technical as opposed to clinical. 
Some participants were clearly aware of actual or perceived clinical hierarchies and felt that 
pharmacists were less important that GPs in such hierarchies, and that shifting some elements of 
care to community pharmacists was tantamount to deskilling of healthcare provision. 
Pharmacists were perceived as being busy; participants were not inclined to consult a pharmacist 
particularly as the pharmacist was removed from the patient interface (e.g. pharmacists were 
located away from the pharmacy counter) and participants were reluctant to interrupt a busy 
professional. 
4.2.3.2 Pharmacies 
The community pharmacy environment and experience, i.e. the ‘shop’, emerged as a theme in the 
focus groups. Community pharmacies were perceived as convenient and accessible places. 
Participants reported community pharmacies as busy environments where the pharmacist was 
often occupied.  Some participants expressed feelings of guilt if they wished to speak to the 
pharmacist as they were distracting the pharmacist from the task of dispensing. Concerns were 
expressed about confidentiality as the patient interface (the pharmacy counter) was public. This 
was a particular concern given the embarrassing nature of the condition. Several participants 
were aware of private consultation rooms within pharmacies but were not sure about how to 
access them or the pharmacist. Some participants were unaware of private consultation facilities. 
None reported actually using a pharmacy consulting room with respect to IBD. Waiting times in 
pharmacies could prove problematic given the nature of the condition and a potential need for 
frequent and urgent toilet visits. The pharmacy counter was perceived as a physical barrier 
inhibiting interaction with pharmacy staff and pharmacists. Pharmacy staff were generally 
considered to be helpful. 
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Overall, despite some issues, participants appeared to be satisfied with their community 
pharmacy experiences. 
4.2.3.3 IBD 
Another theme that emerged consistently in focus groups was the perception and handling of the 
diagnosis. Participants reported being embarrassed about having IBD and keeping the diagnosis 
secret from family and friends. Concerns were expressed about public misunderstanding of the 
condition and not wanting to be thought of as ‘sick’. This seemed to be more common amongst 
male participants. This in turn imposed some constraints on interacting with community 
pharmacists as these interactions were at least initiated or even wholly conducted in public. 
24 ‘ … it’s [IBD] not something that I talk about …. ‘ 
25 ‘ … one of the problems with IBD, it’s not a talked about illness is it?’ 
11 ‘Not if there’s somebody in the queue behind you!’ 
The need to visit a toilet frequently and promptly was a restriction for some participants, 
particularly with respect to, for example, prescription waiting times. There seemed to be a great 
fear of experiencing another relapse and a feeling of being lucky that their own condition was not 
as bad as others of which they had knowledge. During a relapse some patients reported a loss of 
self-confidence particularly with respect to social interactions. 
A few participants referred to the actual or perceived impact of the condition on their 
employment, which was consistently negative. One participant explicitly stated that he kept his 
diagnosis secret for as long as possible due to the macho working environment he operated in 
and the potential effect on his employment. 
4.2.3.4 Medication 
A general theme concerning medication also emerged beyond those issues which were 
specifically raised within the scenarios. Participants reported extensive experience of medication 
rotation over time i.e. having tried a number of different types of drug for their IBD. There 
appeared to be a common ‘trial and error’ approach to medication prescribing for IBD with 
patients directly associating symptom relief or recovery with the drug that they happened to be 
taking at that time. Participants also reported that after taking their medication for a period of 
time the efficacy waned or was in some way diminished. Some participants reported hoarding 
prescribed medication to self-manage their condition in the event of a relapse and one participant 
undertook this activity with the co-operation of their GP. 
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A number of participants reported concerns about the adverse effects of drugs, that this 
information had only been presented in print, e.g. the patient information leaflet accompanying 
dispensed medication, and that it was not presented in a balanced or risk-appreciated manner. 
25 ‘I wasn’t warned of the side effects that could go with it, … . I mean, I was really quite 
spaced out on them so, you know, stopped driving myself ‘cos I was, I felt as though I wasn’t 
safe to be driving but nobody warned that I could feel like that.’ 
All groups reported a degree of intentional non-adherence and this appeared to be common for 
all participants. This finding agrees with a contemporary postal survey conducted with nearly 
1,900 members of a national (UK) patient charity. [37]  One-third of those respondents reported 
intentional non-adherence with IBD maintenance therapy. Participants also reported considerable 
experience of having tried several medications over long periods of time before settling on a 
combination that ‘works’. For example there was a consistent desire to reduce or eliminate need 
for medication. 
25 ‘I think I got to the stage you see, a few years ago when I was in remission, like you, I was 
taking the six a day and I thought “no, I’m going to try and get off these”.’ 
This appeared to be implicitly associated with dissatisfaction with the efficacy of conventional 
medicines. A significant amount of interest in and some direct experiences of use of non-
prescription ‘alternative’ medicines (e.g. herbal, vitamin, health food-type products) was reported 
although direct experience of such preparations was limited. 
Information about medicines was obtained from a variety of sources particularly the IBD nurse, 
Crohn’s and Colitis UK (formerly the National Association for Colitis and Crohn’s disease), and the 
internet. Although a community pharmacist was recognised as an accessible expert on medicines 
few participants reported actually consulting, or initiating a discussion with, a pharmacist for 
information about their medicines. 
4.2.3.5 Boundaries of care 
A more subtle theme that emerged was that relating to the boundaries or responsibilities for care, 
specifically where it was suggested or posited that a community pharmacist could provide a 
particular service and with respect to the boundary between specialist and generalist provision of 
medical care. With respect to the latter, there was a difference in experiential view expressed 
between participants. A few participants reported they had confidence in their general medical 
practitioner for the management of their IBD and they would seek to consult their GP when a 
problem arose. However, a more common experience reported was of the opposing stance, 
whereby there was a lack of confidence in generalist care and a heavy reliance on specialist care, 
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whether provided by an IBD specialist nurse or a consultant. This reliance on specialist care was 
often fostered by the specialists themselves. 
25 ‘No, well I can just go straight, direct to my specialist at [hospital name]. You can just ring 
straight up.’ 
32 ‘Because I have like a, there’s a consultant that’s always at the end of the phone. It’s hard 
getting through to him sometimes but I tend to find, if I’m poorly and steroids take days and 
days to work, don’t they? Weeks in fact, so I want to speak like, to the main person, type thing. 
I want to cut out …., I don’t want any middle man.’ 
24 ‘…. but if I need to see them before then I can usually ring and speak to the consultant’s 
secretary and they can usually squeeze you in.’ 
25 ‘We hold those consultants in high regard, don’t we?’ 
25 ‘I’ve never had particular faith in just going off to any GP to talk about it; you end up back 
with the consultant. You always do.’ 
32 ‘I’d go straight to me consultant; because consultants, I don’t know if yours do, sort of like, 
encourage you to contact them.’ 
32 ‘[The consultant] sort of like, he took me to one side and he said “there’s me number, any 
problems, phone me direct”. So I used to phone him, direct. I remember I was going on holiday 
or something, I went “oh, should I take me tablets with me?” He phoned me back, like, within 
half an hour so I’ve always, I’ve always, I don’t know, it always seems to be consultants saying 
“there’s me number, I will get back to you” and, by and large, I’ve only ever had a couple of 
queries, they’ve always got back to me, probably within the hour.’ 
22 ‘I’ve found that my GP is, you know, she’s more a…, I mean I’ve actually been in to, when 
they’ve had junior doctors in, to talk about my problems, to go through things like that and 
she’s very good. When I am ill … “straight across the road to the hospital”.’ 
Although some participants felt that expansion of IBD care into community pharmacies might be 
more convenient in terms of access concerns remained about information integration and the 
limited authority and autonomy of pharmacists. The boundaries and level of care that participants 
were comfortable with did not reach consensus within or across groups and was highly 
individualised 
4.2.3.6 Scenarios 
The latter part of each focus group, typically the second of two hours, involved the presentation 
of scenarios (appendix 9) relating to pharmaceutical care services which could, in theory, be 
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delivered by community pharmacists for adult IBD patients. These were sometimes explicitly 
revealed to participants, and other times subtly woven into each discussion. On several occasions 
elements of the scenarios arose spontaneously without any specific propagation from the 
facilitator. The following syntheses were derived irrespective of the manner in which the 
scenarios were presented. 
A. Medication adherence 
Participants were generally positive about community pharmacists taking an active role in 
improving medication adherence including active monitoring of actual compared with expected 
prescription volumes. There was general acceptance of this role to a relatively high level through 
passive provision of information, targeted delivery of specific information to active monitoring 
and provision of specific devices to aid adherence. Some participants reported that they felt these 
tasks were already performed by community pharmacists although in an ad hoc fashion as 
opposed to a systematic and integrated model. 
22 ‘That’s what I’ve been picked up on about because I’ve gone in for some medication and 
it’s obvious that I haven’t been taking it because it’s the length of time between, since I had 
them and I’ve ordered the next one. It’s obvious that I’m not taking the correct dosage. They 
pick it up.’ 
Interviewer ‘Who picked you up on that?’ 
22 ‘Well the doctor did initially, but as I say, this pharmacist who’s retired, he used to pick it 
up all the time, because he used to say “well, I haven’t seen you for a while, what’s happened? 
Have you been taken off them” and then I’d give him the prescription and he’d look at it and 
say “it’s a while since you’ve had these”.’ 
And from the same focus group: 
25 ‘It’s a very up and down illness, so you do learn to adjust your own.’ 
24 ‘It is really, because it’s a self medicating illness really, that’s what the GPs say, ‘you can 
manage it better than we can’ because, I mean, you know what to do better than the GPs.’ 
Although the extent or nature of non-adherence to prescribed medication regimens was not 
specifically investigated either in the patient survey or focus groups, it was referred to, often 
indirectly, by participants in each focus group. Findings regarding non-adherence were in common 
with published evidence. A systematic review of 17 studies of medication adherence in IBD  
(n = 4,322) found that non-adherence was reported at up to 72% of patients with most studies 
reporting a rate between 30 and 45%. [29] The authors reported that none of the commonly 
reported demographic and clinical characteristics were consistently associated with non-
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adherence. A trend was identified for more complex treatment regimens to be associated with 
greater rates of non-adherence as was psychological distress and doctor-patient discordance. [29] 
B. Medication monitoring 
Only a small number of participants had direct experience of being prescribed a medicine which 
required regular monitoring. In general participants were in favour of a role for community 
pharmacists in the monitoring of medication to a relatively advanced degree, for example in 
taking test samples and making dose adjustments. Some participants felt that their current 
process with significant patient responsibility functioned adequately and they could see little 
need for a community pharmacist to be involved.  
Some reported that the regular contact with their general medical practice due to monitoring 
visits was reassuring and provided an opportunity for them to engage with primary medical 
providers concerning their IBD and that this could be missed. A more common concern was with 
regard to information sharing and the mechanisms by which a community pharmacist would 
communicate test results both to the hospital IBD team and general practice. Concerns were 
expressed that the existing two-way communication between secondary and primary care was 
often imperfect and adding a third party into this system could complicate the situation. Concerns 
about the ability of a pharmacist to extract, for example, a blood sample were expressed by some 
participants. The suitability of the pharmacy premises for such services was not explicitly 
expressed. 
This excerpt from the second focus group highlights some of these issues: 
25 ‘… but at the minute it’s between the consultant and the GP, if you start with the 
pharmacy as well you’re not going to know which direction you’re going in, it might be a bit 
confusing.’ 
Interviewer ‘And what about, you know, thinking if this [medication monitoring] got a bit 
more involved now. What about if the actual sample itself could be taken in the pharmacy and 
sent off to be measured?’ 
24 ‘Well, that’s what I was thinking would be quite convenient, or could be convenient, as 
long as those results were going to the hospital and to the … ’  [interrupted by 22] 
22 ‘They’d have to go back to your GP. I’ve just had mine done’ 
24 ‘… go to the GP and go to the hospital, you know.’ 
21 ‘It would be handy for other people, like, wouldn’t it? But as you say, for us, as you said, 
we get ours checked.’ 
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And from a different focus group: 
Interviewer ‘With the monthly blood tests that you have [name], at the GPs’ surgery, is that 
an inconvenience when you have to go to the GPs for that?’ 
32 ‘Oh no, it, to tell you the truth it makes me feel quite well in meself, do you know, that 
I’m doing something about it. I go to get me bloods done. ‘Cos I’d probably even say the blood 
tests sometimes are not a waste of time, …’ 
Concerns were also expressed about the patient impact of being informed of a problem with a 
test result by someone who was potentially unable to do anything about the problem as might 
occur within a partial pharmacy-based monitoring system, or if bad news was delivered to a 
patient in a community pharmacy. This was a particular concern expressed at the first focus group: 
12 ‘I think if it was going to be something like a liver function and there was a problem with 
your liver, then if, if you’ve got the pharmacist saying “you’ve got a problem with your liver” 
then you’d rather be there at the doctors to say, “ok, so how do we approach, you know, how 
do we deal with it?” Where psychologically you get told by the pharmacist “oh, you’ve got a 
liver problem” then it’s “oh I’ll have to get in to the doctor’s” and then it’s “oh God what’s 
wrong?” ’ 
11 ‘No, I would say no, I agree with you [participant 12]. You’re there and you get a test 
result back, and “yes, you have cancer”, well, or you have a question, even if it’s not clear, you 
know this is not “we think you should see your doctor” you know, and immediately anxiety 
level goes straight up because we are just human and we immediately think all the wrong 
things and I think, I would actually say that’s the wrong setting [community pharmacy].’ 
Overall, with respect to the monitoring medication scenario, consensus across and within focus 
groups was not achieved. Although participants were generally positive, there were disparities 
concerning the level of community pharmacy involvement, and perceived need. Many barriers 
were identified by participants and any advanced level of involvement would likely require 
suitable information technology infrastructure before it was acceptable to IBD patients. 
C. Supplemental and enteral feeds 
Participants reported little direct experience of use of such products. Some reported experience 
of friends who had used them, or having personally used such products only during in-patient 
stays, or having read about them. One aspect that was considered useful by most participants 
would be for community pharmacists to provide samples for patients to try before they 
committed to ordering larger quantities on prescription. 
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Interviewer ‘And what about if the pharmacist was to provide samples of products? Because 
there’s quite a large range available.’ 
24 ‘Yeah, that would be a good idea.’ 
21 ‘Yes, it would, wouldn’t it?’ 
Interviewer ‘So if a pharmacist, say, would provide samples of products for you to take away 
and try and then come back and say “yes, these I liked, I would like some of these”.’ 
All (focus group 2) ‘Yeah.’ 
From the third focus group: 
32 ‘… ‘cos like I was saying, when I was in hospital, I didn’t get that. I was getting “have this, 
it’s going to build you up” and I’m thinking “I haven’t had a solid stool in six weeks” do you 
know what I mean?  ….. So that would be much more welcome, have a sample, take ‘em home, 
see how you get on with them, come back and then, like I say, … yeah … definitely to that.’ 
Participants were generally positive about the involvement of community pharmacists in the 
management of supplemental and enteral feeds although an obvious need was not clear and 
there appeared to be little interest in this aspect of treatment. 
D. Choice of medication 
There was general acceptance among participants for community pharmacists to have a limited 
level of involvement in medication choice. For example, provision of information about different 
dose formulations or different drugs within the same class and the types of medicines which are 
available. Involvement beyond a limited level was generally unenthusiastically or negatively 
received by participants, as the following excerpt demonstrates: 
11 ‘I mean your doctor, yeah, has to look up what to give you and the pharmacist, perhaps, 
would have maybe a better understanding of what’s available out there, better than the 
doctor, … but I don’t know.’ 
In particular, it was felt that community pharmacists would be encroaching too far into the role of 
a medical prescriber: 
31 ‘Yeah, I mean, my thought is that here we’ve got pharmacists treading on the toes of GPs 
and consultants and I think it’s got the makings of problems. In my opinion, if they go down 
the track, in our condition, or with our condition, that they would say “well, I think you should 
change from whatever you’re on, to this that might be better” because who then carries the 
can if it all goes pear shaped?’ 
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32 ‘I personally, would rather have just one person to hold responsible for the medication.’ 
However participants did not recollect having had discussions with their doctors regarding 
medication choices. Many participants reported having tried a number of preparations and types 
of drug over time. Some participants did report specific preferences for types of formulation: 
12 ‘I’d been prescribed with suppositories and when I saw the consultant for a colonoscopy 
he said “oh, we’ll put you on these suppositories” and then when I went and saw the [GP], and 
I’m not quite sure what happened, but she prescribed a different type of suppository and the 
other ones were easier to administer given the shape and I keep thinking I must get, … when I 
hand these in, … I might go “oh, by the way, could I go on to the ones that were prescribed 
from the hospital?” So, … and it was actually when I handed in the prescription at the 
pharmacist I saw the ones I was on and then I got these new ones and I thought “oh, are they 
the same type of things?” but they’re still, … so something like that would [be good].’ 
Although patients reported little or no involvement in decisions about choice of medication in the 
past, few reported this was a problem despite having tried many different medications over time. 
E. Managing a relapse 
Participants were generally positive about the involvement of pharmacists in helping to manage a 
relapse particularly where it could result in the expedient access to appropriate medication. 
Concerns were consistently raised regarding information sharing between the pharmacist, 
hospital and GP. Some participants reported holding their own supply of oral steroids for relapse 
management, sometimes with the agreement of their GP: 
25 ‘Because what I have, what I actually do is, I’ve got a good GP and if I’m going on holiday, I 
do quite a bit of holidays, and I’m going away for three weeks, I have said to him in the past 
“would you be able to let me have some prednisolone to take with me?” So I usually have a 
little supply tucked away.’ 
Interviewer ‘Ok. And is that something that many of you have?’ 
25 ‘But if I thought I could just have access to it, at the pharmacy over the road, I wouldn’t be 
so concerned about having my little pot at home.’ 
Other concerns raised were whether a pharmacist could be expected to have the knowledge and 
ability to contribute appropriately: 
12 ‘In theory yes, but as [participant 11] said, has mentioned before, have they got time to 
do this? Because pharmacies are very busy places and would, … I mean, I’ve got the IBD but 
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there’s all the other, you know, chronic illnesses that are going about. If it, I mean, … I’m all for 
it, yes if there was somebody … .’ 
Other concerns were that relapse medication was not always provided in isolation, for example a 
blood sample might be taken: 
24 ‘Well usually, if I start a flare up I phone the IBD nurse and she prescribes some 
prednisolone but she always wants a blood test first to see, you know, the extent of the 
inflammation. Although she does give me the prescription, you know she takes a blood test at 
the same time so the pharmacies probably wouldn’t have that facility would they? Or they 
wouldn’t do that, they’d just …’ 
F. Associated healthcare needs 
Many participants were not aware of the associated healthcare needs of IBD such as increased 
risk of depression and osteoporosis. There were few smokers were present and discussion of 
smoking cessation services targeted at IBD patients received little comment. One participant was 
particularly interested in the association between smoking and IBD symptoms which made him 
question his past actions and disease history. Generally, participants were receptive to the idea of 
pharmacists providing targeted advice and additional services for IBD patients. Some concerns 
were expressed about whether pharmacists would have the time and the facilities to deliver such 
services, but the overall response was positive. Participants were, in the main, commenting 
speculatively as they had no personal experience or in many cases knowledge of the associated 
health needs with IBD. 
For example, many participants reported that they were non-smokers: 
11 ‘… these are all additional things that, yeah, perhaps a pharmacy could get into. Again, I 
wouldn’t be too pleased about having all that with a queue of people behind me, you know?’ 
Interviewer ‘Right, so it’s about whether the pharmacies have, a, the facilities but, b, also the 
time?’ 
11 ‘The time, facilities, the privacy, you know, that’s quite a lot to ask of a pharmacist, I think, 
personally, but …’ 
12 ‘Well that, I mean, yes, it’s more convenient if you can go along rather than sit going to 
your doctor and trying to get an appointment …’ 
Privacy was consistently raised: 
32 ‘I’d have no objection to that [bone densitometry, being delivered in a community 
pharmacy], definitely not.’ 
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31 ‘Once again, I think it would have to be done [in private].’ 
32 ‘Yeah, definitely.’ 
A degree of confidence was also expressed in discussing associated healthcare needs with 
community pharmacists: 
Interviewer ‘But you feel you could speak to a pharmacist [about feeling depressed] then?’ 
21 ‘Yeah, I’d speak to a pharmacist if I really felt down and I wanted any problems … or I was 
really worried about anything, … I would, yeah.’ 
4.2.4 Focus groups summary 
The focus groups provided useful information, particularly on the boundaries of care which adult 
IBD patients would find acceptable to receive from a community pharmacy. Due to the small 
number of groups conducted and overall low numbers of participants no single point is claimed to 
have reached saturation in terms of thematic analysis. [182] Therefore data from the focus groups 
by itself is formative only.  
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Chapter 5: Discussion 
5.1 Integrated care pathway 
5.1.1 Integration of care and related processes 
The pathway was described as an ‘integrated care pathway’ although the nature of the 
integration was never explicitly defined. 
A number of real and non-physical IBD-care-related boundaries existed within the locality which 
patients, clinicians, information and funds had to cross. These are broadly categorised and 
described. 
Geographical 
Healthcare related to IBD was provided at different sites, locations and buildings. For 
example, primary care medical practices, hospital outpatient clinics, gastroenterology 
wards, accident and emergency departments, patient’s own homes. 
Environmental 
There were different facilities available in different locations. In general, more facilities 
were available in secondary care settings than in primary care settings, for example 
diagnostic and imaging apparatus was only available within hospital sites. Overnight nursing 
care was only available to patients who were willing to stay in hospital.  
Personnel 
Due largely to other factors, specific care locations defined geographically and 
environmentally, were associated with their own distinct care providers. For example, 
consultant gastroenterologists and specialist IBD nurses who were employed by the 
hospital trust were not known to have delivered care within a primary care medical practice. 
Informatics 
Within the locality there was no shared information source or database that could 
contribute to the care of IBD patients. The principal information sources relating to IBD 
patients were distinct between primary and secondary care. Primary care medical records 
were generally electronic and inaccessible to secondary healthcare personnel. Secondary 
care medical records were typically paper-based. Information transfer between primary 
and secondary care was usually by hard copy and clinical information was often transferred 
only from secondary to primary care and less often in the other direction. 
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Financial 
Primary and specialist healthcare budgets were separately held by distinct statutory 
organisations. Specialist healthcare providers were essentially customers of primary care-
based budget holders. 
5.1.1.1 Extent of integration in the IBD pathway 
The pathway that was eventually designed for implementation (figure 1) would not result in any 
change to the locations of where care was delivered (i.e. geographical integration) even though 
the nature of the care being delivered in primary care in particular would change. Neither would 
the pathway result in any changes to the facilities or personnel which were available in care 
locations (i.e. environmental integration). For example, members of the hospital IBD team would 
not be required to deliver care outside of the hospital. 
However, the pathway could, potentially, have had an impact on the financial and informatic 
boundaries and these are described in-turn. 
5.1.1.2 The pathway’s effect on the informatic boundary 
The informatic boundary is a significant hurdle to integrating care within any healthcare system. 
Typically, within the NHS, primary care providers hold their own information concerning patients 
on a single electronic system whereas secondary care holds patient information across multiple 
providers and in multiple separate systems. A single paper-based file (the ‘medical record’) is held 
by the principal secondary care provider. Information generally flows from secondary care 
providers, often by hard copy, to the patient’s nominated primary care provider with less 
information moving in the opposite direction. [183] 
The pathway would help to diminish this boundary primarily through bilateral sharing of annual 
review information. The pathway was intended to provide for triplicate hard-copy summaries of 
the previously defined patient annual review. The final specification of the patient review 
summary is provided in appendix 1.  The summary report had been agreed by the project board 
with significant contributions from all parties. The project management team undertook to 
arrange printing of triplicate forms with the annotated (top) copy being held by the review 
provider whether primary or secondary care, the middle copy being sent to the other care party 
(e.g. if the review was conducted in primary care then the middle copy would be sent to the 
hospital IBD team, and vice versa) and the bottom copy provided to the patient. 
An unresolved issue arose which related to reviews carried out in primary care for patients who 
were not under the care of the participating hospital IBD team. It was not clear whether primary 
care providers were required to communicate the review to the hospital IBD team or to the 
patient’s current specialist if they were so registered. This presented two issues: 
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1. The first issue concerned the communication of reviews to the hospital IBD team for 
patients who were not or never had been under the care of that team. This 
communication could breach patient confidentiality as well as being of minimal clinical 
value to the hospital team. The only benefit from the provision of this information to the 
hospital IBD team was that the patient could be recorded on the IBD database held by the 
team which could then be expanded to include all IBD patients in the locality regardless of 
the specialist care provider. 
2. The second issue was essentially the reverse of the first and concerned the 
communication of reviews to a non-locality hospital consultant. Such an individual would 
not be expecting nor would they be familiar with the review and it could cause confusion 
to all parties. A partial solution to this particular issue was proposed; the consultant 
gastroenterologist member of the project board was requested to contact his colleagues 
at neighbouring hospitals and inform them about the project so that they would not be 
surprised or confused if they received a review summary from a patient’s GP. However 
these issues, as with several others, were not properly resolved despite being queried 
again by the clinical champion at the project board meeting in December 2011. It was not 
confirmed whether the consultant gastroenterologist did contact his colleagues in 
neighbouring trusts. 
In addition to these unresolved issues the project management team, which had undertaken to 
arrange the printing of triplicate review summaries, did not complete this task for reasons which 
were not explained by the team or queried by the project board. Instead it was known that at 
least one practice, and potentially others, had incorporated the summary into their electronic 
practice systems. The practice appeared to have undertaken this task without support from the 
project team. Electronic copies of the summary such as this could help practices with record 
keeping and in accessing the necessary paperwork for the reviews. It could also help with 
electronic communications where such arrangements were in place although it was not believed 
that appropriate arrangements were in place with respect to the IBD pathway project. 
Due to the immature state of the pathway at the close of the evaluation, there was no 
opportunity to properly evaluate the information flow between primary and secondary care 
within the IBD pathway. Anecdotally, the hospital IBD team had reported they had not received 
any copies of review templates from primary care medical practices and the same team reported 
that it was not conducting patient reviews according to the agreed template and was not using 
the agreed summary. It therefore appeared that patient clinical information flow across the 
primary and secondary care interface was not actually changed by the pathway in its earliest 
operational phase. The pathway as designed did, however, have some limited potential to 
integrate informatics across the primary and secondary care interface. 
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Informatic integration within the IBD pathway project had generated discussion at some of the 
earlier project board meetings. The earliest idea was presented at the project board meeting of 
June 2010 and involved making use of the patient-held summary care record, a separate project 
which developed within the NHS National Programme for Information Technology (NPfIT). [184] 
However some members of the project board had reported negative experiences with other 
related components of NPfIT and ultimately the NPfIT summary care record was not delivered 
within timescales which would have been compatible with the IBD pathway project. The idea was 
therefore not developed within the IBD pathway project. 
A later idea presented at the project board meeting of October 2010 was for the hospital 
gastroenterology department to serve as a pilot site for an imminent national IBD patient 
database project which was being supported and promoted by the patient charity. [185] However 
this idea was presented in the absence of anyone from the hospital and it was not known whether 
it was ever communicated to them. At the following project board meeting in November 2010 an 
action was noted for the chief executive of the patient charity (project board member D) to 
discuss the IBD patient database pilot with the consultant gastroenterologist (project board 
member B). However both individuals were absent from the meeting and it was not known 
whether this discussion did take place. It does appear that the hospital did participate in the 
database pilot to some degree. At the following project board meeting in February 2011 the 
consultant gastroenterologist (B) was present but did not refer to the database pilot at points in 
the meeting where this would have been relevant and appropriate. The chief executive of the 
patient charity (D) was not present at the project board meeting in February 2011. The last 
project board meeting at which both individuals were present was in September 2010 although 
there were a number of e-mail communications after this date. 
Had these relatively ambitious plans relating to the informatic boundaries been realised within 
the IBD pathway project they would have been complementary to the IBD Standards. [1] 
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5.1.1.3 The IBD pathway’s effect on the financial boundary 
The financial boundary remained in place despite the pathway. A single, shared, IBD-specific 
budget, which would have represented full financial integration, was not created. Financial 
considerations were frequently referred to during project board meetings. Primary and secondary 
care parties were willing to discuss the impact of the pathway, or specific components thereof, on 
their respective financial positions. Even the chief executive of the patient charity (D), a patient 
representative and non-NHS party, appeared to have an in-depth understanding of how the 
pathway could affect an organisation’s financial position. On occasion this led him to raise such 
issues in advance of other board members. One particular example related to the hospital IBD 
service discharging patients to primary care but being able to readmit patients to the service 
expediently as defined within the pathway. There was a concern that this would not be counted 
as a full discharge so that if a patient was readmitted the hospital would be funded at a lower 
‘follow-up’ appointment rate whereas under existing arrangements the admission would often 
attract a higher ‘new patient’ appointment. This issue was negotiated relatively easily by all 
parties with a specific time-point defined after which any subsequent admission or appointment 
would be paid at the higher rate. 
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5.1.2 Relation to other integrated care initiatives 
During the evaluation, from October 2009 to March 2012, there were some important healthcare 
policy changes within the English NHS. The most significant resulted from the Government White 
Paper ‘Liberating the NHS’ published in 2010 [186] which led to a fundamental change in the 
organisation of commissioning within the NHS in England. Although this resulted in substantial 
local upheaval and reorganisation, particularly with respect to primary care commissioning and 
support, [187] the general policy direction for integrated care, both locally and nationally, 
remained. [188, 189]  One of the most important exponents of integrated care within the NHS, 
and whose report led directly to the Department of Health integrated care pilots programme, 
[190] commented that long-term commitment was still needed from the Department of Health to 
integrate care as well as more exploration of integration between primary care and hospitals 
(vertical integration). [191] The general healthcare policy direction, of which integrated care in its 
various guises was a key component, had already persisted for a number years through numerous 
political changes and health service reorganisations.  It is likely that healthcare integration will 
remain a key policy. Therefore projects and evaluations such as the IBD pathway will continue to 
have immediate relevance to the English NHS and other health economies. 
There is a growing body of evidence relating to the integration of healthcare, accepting the 
caveats concerning inconsistent and shifting terminology and foci, and crucially the different and 
often subtle contextual differences. [112, 192]  A review of integrated care reported health 
economic benefits [193] although these depended upon the approach used, how well it was 
implemented and the environment in which it was introduced, including the financial 
environment. The conclusion of the Department of Health’s integrated care pilots evaluation 
concurred, whilst also noting that few if any such effects had actually been demonstrated in the 
first two years of observation. [108] An important aim of the IBD pathway was to deliver cost 
savings to the local health economy, primarily from reduced hospital admissions and outpatient 
care. A review of an integrated care project by the Nuffield Trust observed that ‘the importance of 
reducing avoidable hospital costs means it attracts a high degree of policy attention and profile’ 
and ‘ … a target of reducing admissions is often a prerequisite for funding and support [for 
integrated care projects]’. [194]  This was also identified as a key objective in many of the projects 
included within the Department of Health integrated care pilots programme. [108] As the IBD 
pathway had only just entered the operational phase at the point of the evaluation close there 
was no realistic prospect of health economic effects observed over the course of the evaluation 
being attributed to the pathway. In addition, such outcomes as would impact on rates of 
healthcare utilisation are recognised to be more likely longer-term outcomes requiring at least 
two or three years from operation to become apparent. [194] However a rational and objective 
review of the IBD pathway designed within this project (figure 1) would lead to a reasonable 
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expectation that it could deliver the reductions in healthcare utilisation expected and the 
attendant savings.  
Reports of integrated care have often identified a diverse range of enabling and disabling, i.e. 
barrier or inhibitory, attributes to the successful implementation and operation of an assorted 
range of integrated care models. [187, 192, 195, 196] 
In place of specific enabling attributes some reports have instead identified the processes that 
need to be done or put in place to facilitate successful integrated care initiatives. An example of 
this was a joint report from the Nuffield Trust and the King’s Fund published in 2011 which 
identified several points to overcome barriers to integrated care including evaluation of the 
impact of integrated care. [43] 
5.1.2.1 Comparison with the Department of Health integrated care pilots evaluation 
The IBD pathway was originally planned for inclusion within the Department of Health integrated 
care pilots project which commenced in 2009. A comparison is therefore made between the 
methodology and outcomes of this evaluation with the Department of Health evaluation of the 
integrated care pilots. [108, 197] 
Methodology 
The evaluation plan for the IBD Pathway was formulated in isolation of the Department of Health 
evaluation. Despite this the two evaluation strategies bore more similarities than differences 
(table 18). 
Table 18. Comparison of the evaluations of the Department of Health integrated care pilots and 
the IBD integrated care pathway 
Attribute IBD Pathway 
Department of Health  
integrated care pilots 
Theoretical framework Realist Not stated, but general and specific 
contextual elements were considered 
Methodological strategy Mixed methods Mixed methods 
Duration (planned) Two years Two years 
Duration (actual) 2½ years Two years 
Focus Single locality and 
disease target, health 
providers only 
Sixteen individual integrated care projects 
across England each being distinct, several 
included social and community care 
providers 
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Even within the broad methodological strategy identified in table 18 there were similarities in the 
nature of the mixed methods employed. For example, with respect to isolating changes 
associated with the intervention from contemporaneous background changes both evaluations 
made use of a differences-in-differences approach. Both evaluations also utilised interviews with 
key actors and non-participant observation of meetings as components of the qualitative 
evaluation strategy.  
Outcomes 
The Department of Health integrated care pilots evaluation was an overarching evaluation of 16 
distinct and diverse individual projects. The evaluation primarily reported overall findings as 
opposed to specific individual project outcomes. The quantitative component of the Department 
of Health evaluation was more detailed and was able to draw more robust conclusions relating to 
healthcare utilisation than this evaluation. Of the key outcomes reported in the Department of 
Health evaluation none could be identified as corresponding to any outcome identified in this 
evaluation. This may relate more to the differences in the scope of the evaluations (multiple 
diverse projects vs. single disease-specific project) than any underlying differences in 
methodology. 
Enablers and Barriers 
The Department of Health integrated care pilots evaluation team described the barriers and 
enablers to integrating care that were identified across the evaluation. [197]  A summary of these 
is described in table 19 [108] and a full description is provided in appendix 14. [197] 
Many of these enablers and barriers are common to the field of change management, some are 
specific to the healthcare field, some may be specific to the NHS structure and culture, but many 
are specific to the contemporaneous implementation of integrated healthcare in England. Those 
indicated with an asterisk (table 19) were also identified, either explicitly or indirectly, within this 
evaluation. 
Of the barriers identified as common to the IBD Pathway project some were inherent in the 
design of the project (e.g. multiple partners), others were foreseen but unsuccessfully overcome 
(e.g. IT solutions and information sharing), others were unrecognised (e.g. organisational culture, 
sub-optimal training), and others had not been foreseen and arose incidentally (e.g. concurrent 
internal reorganisations). With respect to unforeseen incidental barriers the response of the 
project team was sub-optimal. Better project management, which was itself impaired by the 
organisational culture, may have meant that barriers could have been identified and successfully 
mitigated or managed. Sub-optimal project management was not identified as a barrier in the 
Department of Health evaluation although notably the included projects each received external 
project management support. [198] 
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The Department of Health evaluation identified many enablers and barriers across the overall 
evaluation (table 19 and appendix 14) although it did describe the manner in which individual 
projects sought to manage barriers either prospectively or reactively. 
Table 19. Enablers and barriers to integrating care identified in the integrated care pilots [108] 
Enablers Barriers 
Strong leadership Large-scale, complex integrations  
Pre-existing relationships at a personal 
level across organisations * 
Roles or professional identity of staff under threat 
Shared values; collective communicated 
vision * 
Changes to staff employment involving TUPE 
(Transfer of Undertakings Protection of Employment) 
regulations 
Investment of effort in widespread staff 
engagement; staff can see clear benefits 
Unrelated organisational changes; unexpected 
budgetary changes * 
Provision of education and training specific 
to service change * 
National policies, processes and legislation; NHS and 
local government bureaucracy (e.g. pooling 
budgets) 
 Poor IT connectivity between systems and 
organisations * 
 
The Department of Health evaluation may have been expected to identify more enablers and 
barriers to integrated care than were identified in this evaluation as it was the sum of findings 
from 16 different and diverse integrated care projects. 
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5.1.2.2 The North West London Integrated Care Pilot 
A widely reported contemporaneous project which had a number of similarities with the IBD 
Pathway project was the North West London Integrated Care Pilot. [199]  Although similar in 
some respects a key difference was a broader remit, focusing not only on a single long-term 
condition (diabetes) but additionally and more broadly all patients aged 75 years or more. The 
project also included mental health, social and community care providers as well as primary and 
acute (secondary) care. Nonetheless, there were more similarities between them as the London 
project also focused on a single locality and the evaluation utilised a similar methodological 
approach. For example, it was a mixed-methods evaluation albeit initially over just the first 12 
months with a less intensive longer-term evaluation. The evaluation included quantitative 
analyses of healthcare utilisation across a specific and identifiable patient cohort, as well as 
qualitative analyses which included observations and interviews. [200]  
Despite initial results reporting reductions in hospital admissions, from which substantial financial 
savings were estimated, [201] more robust subsequent reports of the first 12 months did not 
report the same findings. [200, 202]  No significant overall effect on emergency (unplanned) 
admissions was observed. [199]  However the project did result in modest improvements in care 
processes such as provision of care plans for patients with dementia, as well as improved patient 
access and reduced waiting times for care. [199, 202]  Some limited improvements in clinical 
parameters were also beginning to emerge, for example measures of blood glucose levels in 
diabetic patients. Less tangible but no less important positive outcomes were achieved relating to 
the process of integrating care. For example, communication with and between various 
healthcare professionals improved, as well as partial solutions to shared governance and finance 
arrangements. Several tensions and hurdles were overcome and clinicians were generally 
committed to the project. A particular barrier which had not been overcome was that relating to 
sharing clinical information via a single information technology platform. Not only had this not 
been delivered but it created and failed to resolve the various tensions and consequent barriers 
relating to its continued absence. One-year evaluations concluded that positive progress had been 
made but that “a minimum of three to five years is needed for such initiatives to show impact in 
relation to activity, patient experience and outcomes”. [199, 202] 
Given that such a timeframe was stated as the minimum required to demonstrate an impact on 
healthcare activity it was not clear why the project had initially planned to deliver substantial 
financial savings in its first year relating directly to reduced healthcare utilisation. It concluded 
that “policy-makers and National Health Service managers expect too much too soon when 
testing initiatives”. [199]   
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5.1.3 Middle range theory 
Middle range theory was described by Pawson & Tilley in their seminal 1997 text as: [63] 
‘ … “theory that lies between the minor but necessary working hypotheses …and the all-
inclusive systematic efforts to develop a unified theory that will explain all the observed 
uniformities of social behavior, social organization and social change” (Merton, 1968). In 
essence, “middle range” refers to the degree of abstraction and can refer to programme 
theory, generative mechanisms, CMOs, formal theories etc.’ 
Thus this evaluation can seek to identify and empirically establish the existence of the specific 
theories, the middle range theories, and the highly abstract and generalisable theories. [203]  The 
former were taken to be the enabling and disabling factors which are reported in this section, the 
middle range theories are intricately and necessarily linked to these, and the latter is taken to be 
the theories of change. The theories of change identified are each considered separately in 
subsequent sections. A middle range theory is derived from the enabling and disabling factors. 
5.1.3.1 Balance between enabling & disabling factors 
There was, and will likely remain, an on-going tension between enabling and disabling (barrier) 
factors faced by the IBD pathway. The net effect of this tension will be a dynamic balance which 
will vary at different stages of the project and therefore at different points of time, i.e. at times 
the enabling factors will dominate and at other times the disabling factors will dominate. The 
enablers and barriers which affected the IBD pathway project and which were identified by the 
close of the evaluation were: 
5.1.3.2 Enablers identified in the IBD Pathway project 
• Motives and aims aligned with local and national healthcare policies and priorities 
• Utilisation of pre-existing communication networks and relevant partnerships 
• Financial incentives for primary care providers 
• Credible and legitimate patient / user representation and involvement 
• Sponsorship from a commercial party for a defined component of the project 
5.1.3.2 Barriers identified in the IBD Pathway project 
• Lack of consistent and effective strategic leadership 
• Initially at least, sub-optimal project management 
• Delayed introduction of effective and nominated clinical leadership 
• Lack of effective communication strategy including sub-optimal clinician education and 
training 
• Absence of effective communication and data sharing tools 
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• Lack of a defined role for patient / user representatives 
 
The enabling factors were predominantly of a generative nature, i.e. they exerted their influence 
more in the initial phases at the commencement of the project; they enabled the project to 
commence although some will have had a longer-term impact on the project, such as third-party 
sponsorship and use of networks and partnerships. 
At the point of closure of the evaluation the project was still active and delivering some planned 
components to variable degrees which indicate that the overall balance at that point was in 
favour of the enabling factors. The barriers had either been accommodated or overcome. The 
accommodation of disabling factors would appear to add significant delays to the expected or 
planned progress of the project.  
The key enablers and barriers which influenced the IBD Pathway project and which have been 
identified were themselves composed of a number of different components which have been 
described in more detail elsewhere. These specific, descriptive, and granular enablers and barriers 
can be considered as the middle range theories identified by the evaluation of the IBD Pathway. 
The middle range theory identified within this evaluation of the IBD pathway is summarised 
singularly and succinctly as: 
The progress of change for a specific component of care within a large and complex 
healthcare system is determined by the sum effect of multiple enabling and inhibitory 
factors. 
The enabling and inhibitory factors may exist internally, or be external to the change process. The 
overall balance of factors will be dynamic and some specific factors will be only transitory in 
nature. Therefore the future progress of the project cannot be easily predicted from its’ position 
at a single point in time. 
5.1.4 Theories of change 
Using the perspective of Weiss, [204] it was assumed that several theories of change implicitly 
existed within the IBD pathway project, although some were more subtle than others. As stated 
by Stame, theories of change in social programmes such as the IBD project are seldom explicit or 
formally stated. [88] Instead they more often take the form of assumptions and tacit 
understandings, often for the same theories within the same programme. The theories are 
themselves linked to certain practical mechanisms which will potentially deliver the intended 
outcomes. [205] 
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The theory of project management was identified with explicit evidence of its existence within the 
project. Two other theories of change were identified implicitly within the pathway which was 
itself the outcome of the pathway design phase; those of patient empowerment and clinician 
empowerment. These also manifested themselves as a component of the pathway design process 
although to a lesser degree than their presence as a component of the designed pathway. Thus, 
three theories (project management, patient empowerment, and clinician empowerment) were 
identified within the IBD pathway project and each is described in turn. This list may not be 
exhaustive although every effort has been made to identify all the theories of change which 
existed within the project. 
The contextual attributes which enabled or inhibited the observed outcomes were primarily 
design- and implementation-phase related outcomes. At the point of the evaluation close the 
project was probably too immature to have demonstrated the desired operational outcomes 
especially regarding hospital admissions and other measures of healthcare utilisation, and 
attendant costs. This is reflected in the CMO configurations presented in the following sections. 
The literature on complex health service change generally concurs that anything less than two 
years, and often more, is too short a period of time in which to observe meaningful changes in 
healthcare utilisation and other quantifiable outcomes relating to complex interventions such as 
new models of integrated care.[194, 197]  With respect to the evaluation of such projects, the 
Nuffield Trust concluded in its evaluation of integrated care that ‘A pilot may work partially and 
learning from that partial success is important. Or it may be, of course, that the beneficial 
outcomes were not measured or were measured too early.’ [194] This evaluation has identified 
what has worked (enablers) and has not worked (barriers, inhibitors) within the IBD pathway 
project and has sought to identify and explain these. Their expression in the realist paradigm 
framed as Context-Mechanism-Outcome scenarios is thus presented. 
5.1.4.1 Project management 
The project management literature appears to be predominantly concerned with methods and 
processes and comparatively little was identified concerning the underlying theories of project 
management. Two reports that highlighted this point suggested that project management theory 
should be broken down into the combination of separate theories of ‘project’ and ‘management’ 
with the latter consisting of sub-theories relating to specific elements of management. [206, 207] 
However, this perspective appears unnecessarily complicated and relies upon some abstract 
concepts of project management. The theory of project management could be considered more 
simply and succinctly as: Projects are more likely to succeed on time and more efficiently if they 
are managed according to a defined and structured process than if they are managed on a less 
structured and somewhat ad hoc basis. This is the theory which was implicit within the IBD 
154 
pathway project and it is this theory which was essentially tested in the context of the PRINCE2 
project management processes.  
Project management theory was a constant presence throughout the evaluation as it permeated 
all phases. Key components of PRINCE2 that would have been particularly applicable to the IBD 
project were: [175] 
• Constitution of a project board with defined membership 
• Nomination of a project manager and if necessary other members of the project team 
• Proper recording of project board activities with minutes of meetings 
• Proper and advanced scheduling of project board meetings 
• Production of a project plan with identification of deliverables alongside deadlines and 
nominated individuals or teams for each deliverable 
• A defined mechanism for reporting exceptions and changes to the project board 
The pathway design process was largely conducted through, and during, project board meetings. 
The project board was not formally constituted nor was it officially nominated as such, instead it 
grew and developed organically into the project board role. The project board consisted of a core 
membership supplemented by occasional other members or participants. 
With respect to chairing project board meetings only, a senior individual from the host or sponsor 
organisation (the PCT) could have been a good choice for several reasons: 
• Maintaining a focus on the strategic aims of the project, particularly with respect to its 
relationship with a contemporaneous local healthcare project. 
• Providing greater external and internal credibility and lending a gravitas to the project. 
• Ensuring that the project was managed according to best practice given the PCT’s 
commitment to PRINCE2 methodology. 
In addition to a lack of leadership at project board meetings, meetings also tended to be poorly 
organised, especially in the first half of the evaluation. Meetings often lacked agenda, minutes, or 
actions. This was, unfortunately, not an inadvertent oversight. As early as the fourth project board 
meeting in March 2010 the project manager declared to the board that he did not intend to 
organise meetings formally by, for example, taking minutes but instead he preferred to allow 
meetings to flow and only make a note of the actions required. No one disagreed with or 
contested this arrangement. That the IBD pathway project was managed sub-optimally has been 
objectively demonstrated with reference to the pre-defined project management methodology 
that was to have been applied to the project. The Department of Health integrated care pilots had 
structured professional project management support and it is noteworthy that poor or sub-
optimal project management was not identified as an issue with its evaluation. [108, 197] 
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It is hypothesised that a vicious circle may have been in existence in respect to the project 
management aspect of the IBD Pathway (figure 4). Essentially, sub-optimal project management 
would lead to the project being less likely to succeed and this would in turn, through missed 
milestones and slipping deadlines, reinforce the decision to manage the project sub-optimally. 
This hypothesis remains untested and is presented as a possible explanatory hypothesis.  It is 
postulated that factors outside of the vicious circle may also reinforce each factor within the cycle 
independently.  
Figure 4. The hypothesised vicious circle of sub-optimal project management 
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Context-Mechanism-Outcome configurations relating to project management 
Four unique CMO configurations were identified through a repeated and iterative process  
(figure 5). A relatively high level of abstraction has been incorporated into the resulting 
configurations although a more granular level of detail is provided concerning each configuration 
separately. In total two contextual factors, two mechanisms and three outcomes were elucidated. 
Figure 5. CMO configurations relating to project management within the IBD pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
Red boxes are contextual factors, orange are mechanisms and outcomes are in green. The four 
configurations are: (C1+M1 = O1), (C1+M2 = O2), (C2+M1 = O3), and (C2+M2 = O3). 
C1 was a generative and motivational contextual factor which led to the project being created and 
led to positive outcomes. C2 was an inhibitive context which led to a negative outcome. O1 and 
O2 were positive outcomes, O3 was a negative outcome. O3 was only generated when combined 
with C2. O1 and O2 were only generated when combined with C1. The mechanisms yielded 
positive and negative outcomes depending on the contextual factors which they were subjected 
to, thus the same mechanism could have different outcomes depending on the context and this is 
an important message for the generalisability of this and similar research. 
Each ‘C’ and ‘O’ component of the CMO configurations and their combinations are described in-
turn. 
C1: General healthcare policy at national and local level supporting 
greater involvement of primary care in the management of chronic 
medical conditions and a general shift of management of chronic 
conditions out of specialist/secondary care. This was also shared by 
the patient/user representative organisation, the only non-NHS 
party, and reflected in a published standard-of-care document 
from the same organisation. 
M2: Project management according to a defined and systematic 
process. 
M1: Private sector funding to hire a project leader (clinical champion). 
C2: Organisational and operational culture 
within the organisation responsible for 
project management. 
O3: Project not delivered to planned 
timescales. Some relatively small 
components of the project were absent. 
Many components of the project were not 
explicitly agreed. 
O1: A ‘clinical champion’ who was also a 
practicing general medical practitioner 
within the locality was recruited and 
appointed. 
O2: Project 
delivered to 
minimum 
specification. 
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C1: For multiple reasons, it has long been governmental and health department policy in the NHS 
and many other health systems in other countries, for chronic or long-term conditions to be 
managed less in acute settings by specialists, such as hospital-based consultants, and more in 
primary and community care settings. [130, 178, 179]  These polices were in turn reflected in the 
local Momentum project [59] and the IBD Standards. [1] It was this general policy environment, 
shared by all parties, which led to the creation of the project and provided the strategic 
motivation and remit for the project to continue. 
C2: The organisational and operational culture of the project management organisation, the PCT, 
did not appear to have been conducive to permitting effective project management or at least not 
to the defined standard. This was a negative contextual influence which inhibited the progress of 
the project. It was exemplified through several observable aspects: 
• Lack of leadership and contributions from senior operational management 
• Unsystematic and untargeted selection of project management team 
• Lack of robust governance and supervision of the project management team 
• Lack of strategic resource planning for the project management team 
Due primarily to a combination of the above points, less tangible cultural inhibitors were 
identified through observation and supported through interview data. Specifically, the strategic 
aims of the project and the objectives appeared to be disconnected from the project 
management team, or vice versa. 
The project management team appeared to approach the project as another task that had to be 
completed and had to be fitted into their flexible and variable daily workload. In that respect, they 
did not appear to have subscribed to what the project was trying to achieve, the strategic aims of 
the project, and saw each outcome as a task in its own right as opposed to an interconnected 
series of tasks which were intended to operate synergistically towards a defined set of 
complementary objectives. 
A rational approach for a project team to take is not to commit full effort to a project until it can 
be certain that the project will succeed or survive. This logical and rational decision can be 
described by game theory and the project management team is in effect applying a ‘maximin’ 
strategy. [208] Using this strategy the team was attempting to maximise the minimum outcome 
achievable. The choices which the team could make were either to apply full effort to the project 
from the outset, or commit only the minimum effort which the organisation would permit the 
team to commit. This can be described with a payoff matrix (figure 6). [208]  The scores assigned 
to each outcome-combination in figure 6 are arbitrary and essentially represent a ranked position. 
The matrix demonstrates that the best outcome would be for the project to survive with 
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minimum effort from the team. The worst outcome would be for the project not to survive 
despite the team committing full effort. The matrix is valid until such time that the project team 
can identify whether the project will survive or not, at which point the team is assumed to commit 
full effort. Regardless of the effort committed by the project management team, project survival 
is a positive outcome and the non-survival of a project is a negative outcome for the team. 
If the project team committed full effort from the outset, without knowledge as to whether the 
project will survive or not, the net expected payoff is -1. However if the team committed 
minimum effort the net expected payoff is +1. The rational strategy is therefore to commit 
minimum effort, at least until the team can identify whether a project will survive or not. 
Figure 6. Payoff matrix for a project management team with imperfect information concerning 
project survival (ranked scores) 
Project outcome → 
Project team approach ↓ 
Survive Not survive 
Net expected 
payoff 
Full effort 1 - 2 - 1 
Minimum effort 2 - 1 1 
 
Project management teams may not operate in total informational ignorance as the payoff matrix 
may be affected by some knowledge or experience of the underlying risks, or probabilities, of 
each project outcome. For example, if a project management team has experience of greater 
probability of project non-survival then the team will be more likely to choose the minimum effort 
strategy as this will maximise the expected minimum payoff. The opposite, however, is not 
necessarily true because even if experience demonstrated that project survival is the dominant 
outcome, a team might still opt for minimum effort as the maximum outcome is preferred to that 
with the full effort strategy. This indicates that the rational strategy under different conditions 
could still be ‘minimum effort’. Therefore project management teams may require external 
constraints to abandon a minimum effort strategy for a full effort strategy. This is particularly 
important because there may be a negative feedback mechanism between the efforts committed 
by a team and the probability of a project outcome; survive or not survive. In essence, the simple 
payoff matrix in figure 6 does not show a potential negative feedback between the survival of a 
project and the effort from the project management team, i.e. the two attributes are not 
independent and a project may be more likely to survive if the team commit full effort, and less 
likely to survive if the team commit only minimum effort. 
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An in-depth analysis of game theory and an attempt to prove its applicability to this situation is 
not attempted. Instead, it is presented as a hypothesis to explain why a well remunerated, 
resourced, externally credible and experienced project management team opted to work sub-
optimally. Other attributes which have not been explicitly considered within the payoff matrix 
are; internal motivation (e.g. self-motivation from individual project team members, pride in own 
work), individual recognition within a larger team or organisation, the length of time required to 
determine whether a project is successful or not, and other factors. 
It is postulated here that an organisational or operational culture within the project management 
organisation, the PCT, permitted, enabled, or encouraged the project management team to select 
the minimum effort strategy for project management. This was contrary to external commitments 
made by the same organisation. 
Another aspect of the organisational culture which impacted negatively upon the project was in 
relation to the receipt of funds from a commercial party where a potential conflict of interest 
existed with respect to local NHS business. Despite extensive guidance for the NHS from the 
Department of Health concerning such arrangements, [209] the PCT appeared to be in a state of 
bureaucratic paralysis. The organisation did not respond swiftly or decisively to expediently 
resolve what was a relatively straight-forward issue. Knowledge of the availability of ex-NHS 
funding for the project existed at an early stage, for example detailed discussion ensued at the 4
th
 
project board meeting in March 2010. Even at this meeting contractual and financial 
arrangements were raised as a potential issue although they were not discussed in detail. Another 
risk which was included in the project plan was if the funding source either did not deliver the 
funds at all, or withdrew the funding at a later point. The solution to this risk was stated 
‘approach other sources for funding’. In the final project plan update of October 2010 the plan 
stated that the funding had been confirmed and the only outstanding issue was ‘Still awaiting 
approval of sponsorship’. The new project management team reported at their first project board 
meeting in February 2011 that the issues had been resolved although this had taken almost 12 
months. The precise nature or details of the issues were not explicitly stated; one issue related to 
the organisation being required to agree a contract which would outlast its own existence. Details 
were not reported by the project management team concerning how the issues were resolved. 
M1: This mechanism represents the availability of a source of private funding specifically to 
recruit a project leader, known within the project as the ‘clinical champion’. 
M2: The second mechanism presented represents the approach of the project management team 
in using a defined and systematic project management process, specifically PRINCE2. 
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Outcomes 1, 2 and 3 are described in the context of the contextual attributes and mechanisms 
which produced them. 
C1+M1 = O1 and C2+M1 = O3 
These CMO configurations are related to the recruitment of a ‘clinical champion’ for the project. 
The role of clinical champion was discussed at a relatively advanced level at the second project 
board meeting in March 2010. At the 13
th
 project board meeting in December 2011 the board was 
introduced to the clinical champion. That a clinical champion was successfully recruited and 
appointed was a significant achievement of the project (labelled as outcome 1). The major 
enabler to that achievement was considered to have been the provision of non-NHS funding, 
labelled as mechanism number 1. It was not clear whether such a post could have been filled 
without that funding, either through voluntary participation or from another funding source. It 
was highly unlikely that the post could have been filled through voluntary participation alone 
given the pressures on GP time and resources, especially as any GP undertaking the post during 
normal working hours would likely put pressure on colleagues. It was also unlikely that the post 
could have been funded using other NHS funds, e.g. from funds allocated to the practice-based 
commissioning group, as the amount of funding secured, approximately £15,000, would have 
represented a substantial investment for an unproven and non-essential role. If the post had been 
filled through voluntary participation or NHS funding then it may not have permitted the level of 
commitment secured with the private funding which equated to about one day per fortnight. 
Although an individual was appointed, this only occurred after a substantial time-lag in excess of 
12 months. The main reason for this delay, as explained repeatedly at project board meetings, 
was reported to be external to the project board; the PCT finance department was reluctant to 
accept and agree non-NHS funding for a post which would be arranged and contracted through 
the PCT. These issues were presented as being bureaucratic and engendered disparaging 
responses from the project management team when reported at project board meetings. 
However, the real extent of this issue was not clear. An alternative interpretation was that this 
issue may have served as a convenient distraction and deflected attention from the project 
team’s own inactivity and overall lack of progress with the project. The continued delay to 
appointing a clinical champion was a repeated frustration to members of the project board and 
was frequently cited as a negative aspect of the project process during interviews. It is impossible 
to confirm the impact that this delay had on the project as there was no counter-factual scenario 
or control group. However, the project clearly lacked leadership for a prolonged period and would 
likely have benefitted from a recognised primary care clinical lead without a history of having 
been contracted to work for the PCT. The clinical champion would have been ideally suited to 
fulfil such a role. The delay to recruitment of a clinical champion was a negative attribute of the 
project management process and earlier recruitment could reasonably have been expected to 
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have had a positive effect on the project. The only advantage to the delay to recruitment of the 
clinical champion was that there would be a corresponding delay to the date at which the 
funding, available for two years from the date of appointment, expired. 
C1+M2 = O2 
The positive generative policy context which promoted the general aims of the project (C1) 
combined with a systematic and active approach to project management, however suboptimal 
(M2), did produce a pathway design which could be described as having met the minimum 
requirements of all parties (O3). The minimum requirements of each party can only be inferred 
from observations and notes as the project did not have any agreed aims or objectives. The 
pathway did not contradict any of the IBD Standards and would directly and indirectly contribute 
to local attainment of many of the standards. [1] 
C2+M2 = O3 
This was the most fundamental CMO configuration underpinning the progress of the project. 
Essentially, a project of this scope and scale was intended to have been managed according to a 
recognised and approved project management methodology, that of PRINCE2 (labelled as M2). 
However, the actual project management strategy employed could not be recognised as PRINCE2 
and appeared at times to be haphazard, reactive and generally disorganised. For example several 
of the early meetings had no agenda or minutes of previous meetings. Actions were infrequently 
noted and even less frequently followed up, and consequently several actions were never 
completed or completed substantially behind schedule. There was a noticeable shift in project 
management style when the new project management team took over in January 2011. This 
change in project management style was particularly noticeable in the management of project 
board meetings with more advance notice of meeting arrangements, agenda provided, and 
minutes/actions noted. In addition, the new project management team progressed rapidly with 
organising the first training event and, somewhat slower, in recruiting a ‘clinical champion’. 
However the fundamentals of PRINCE2 project management such as a project initiation 
document, overall project plan, and a formally defined project management board, had already 
been omitted from the outset and these would be difficult to retrospectively apply at the point at 
which the new project management team took over. In addition, the lack of a project plan, action 
plan, minutes and other essential project records meant that the new project team experienced 
difficulties in taking the project forward. The new project management team was even less 
purposefully appointed to the project than the first team. 
Project teams were faced with a predicament in identifying projects which will survive and those 
which will not, possibly due to external factors beyond the project team’s control. Of all the 
projects which a team, or team members individually, are involved with some will not survive for 
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reasons beyond the project team’s control; i.e. even with optimal project management, for 
example full application of PRINCE2 methodology by the project team, some projects will ‘fail’. 
The predicament therefore is in identifying at the outset which projects will survive and which 
won’t. There is a considerable trade-off for teams and individuals as applying the effort required 
for full or even extensive application of PRINCE2 will be more time consuming than not, at least in 
the early stages of a project, and yet the result could be the same – a failed or uncompleted 
project. Therefore the project team collectively, or its members individually, must decide on the 
resources that they will, collectively or individually, put into a project. A rational strategy under 
certain circumstances is to apply minimum effort to a project until it becomes clear whether the 
project will survive. Once a team is able to identify, or feels confident that, a project will survive 
then it is assumed that the team will commit greater or even full effort to the project. If the 
project, however, does not survive then the team or its individual members have, in retrospect, 
chosen the optimum strategy from the outset. These are rational decisions in the context of a 
resource constrained and strained environment, i.e. the organisation is required to deliver more 
projects than it can actually deliver if all work was to be completed at optimum levels. Such a 
strategy can lead to a self-fulfilling vicious circle developing in which sub-optimal project 
management from the outset can itself make a project more likely to fail thereby justifying the 
decision to apply sub-optimal resources to a project. Projects which do survive will then share 
characteristics which can become the norm, such as sub-optimal project management, and weak 
governance and leadership. This was observed in the IBD pathway project but it is not known 
whether other projects managed by the same organisation shared such attributes. Optimal 
project management does not necessarily mean that a project will survive but a project which is 
managed sub-optimally is more likely to experience: 
• Products, or project milestones, which are delayed, or otherwise delivered behind 
schedule. 
• A project delivered to a lesser specification than that desired including the 
abandonment of specific components or products. 
• A project which exceeds its budget or fails to achieve budgetary milestones. 
One mechanism by which PCT senior management could have better overseen the project was 
with a substantive role on the project board such as chairing project board meetings. This may 
also have had an impact on the project team as they would be more closely observed by their 
senior managers. For example, an individual from the PCT board of directors such as the Director 
for Health Systems Development and Estates Development, who had been involved with the 
original integrated care pilots bid, was named as a core member of the Momentum programme 
team [59] and was a direct line manager to the project team, would have been an appropriate 
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candidate. However securing the commitment of such a senior individual may have been difficult 
and may not by itself have been sufficient to ensure optimal project management throughout. 
A key feature resulting from the sub-optimal project management was that there was no single 
statement of the aims or objectives of the project or any specific part of it. This was demonstrated 
by none of the project board members or project team being able to succinctly and consistently 
describe the aims and objectives of the IBD pathway project. 
The PCT appeared to struggle with the duplicate role of performing the project management 
function and providing strategic in-put with the latter role more severely affected. The two roles 
were not entirely complementary; that of a project overseer and decision maker, as given 
collectively and individually to members of the project board, and that of project ‘doer’ and 
delivery, as given to the project team. Conflict may arise where the same individuals are called 
upon to perform both tasks. Both project managers (project board members H and I) dealt with 
this dual role in a similar manner albeit to differing degrees. Both tended to favour the decision-
maker role to the detriment of the project management function. Both sought to obtain a third 
party to carry out the day-to-day project management functions; for the first project manager this 
came with the temporary assistance of two ‘organisational development managers’ between 
September 2010 and January 2011 (J and K), and for the second project manager such an 
individual was already in place (L). The conflict between the decision-maker and project 
management function may have led to or contributed to suboptimal project management as 
described under CMO configuration 1 and can be considered as an effect stemming from a lack of 
leadership or senior level input from the project management organisation. 
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5.1.4.2 Patient empowerment 
Four unique CMO configurations relating to the theory of patient empowerment were identified. 
These involve one contextual factor and three distinct mechanisms (figure 7). Data relating to two 
sets of outcomes, affecting two CMO configurations, were not obtained within the evaluation and 
therefore these CMO configurations have been identified but have not been evaluated. Each ‘C’ 
and ‘O’ is described in-turn as well as the resultant CMO configurations relating to the theory of 
patient empowerment. 
C: The context within which the theory of patient empowerment existed was one of a general 
policy shift within the NHS nationally for greater influence and power for patients with respect to 
individual cases and also service developments. [47]  This policy direction was reflected in the 
local Momentum programme and by extension the PCT and hospital trust partners who owned 
the programme. In addition, the policy was reflected and strongly supported by the patient 
organisation as embodied in the IBD Standards which the organisation had published with other 
parties. Thus, the theory of patient empowerment was enabled by a long history of top-down 
policies devised specifically to realise the theoretical benefits of empowered patients. All parties 
of the IBD pathway project were supportive of these policies. This was a positive contextual factor 
which enabled and promoted patient empowerment within the project. 
M1: The first mechanism by which patients were empowered was reflected in the representation 
of patients or service users within the pathway design process and in the resulting pathway 
design. This mechanism, when combined with the contextual background, yielded two groups of 
observable outcomes, one set relating to the design process and one set relating to the pathway 
as was designed. 
M2: The second mechanism by which patients were empowered was reflected by the provision of 
information to patients, with the majority of the defined sources originating from the patient 
organisation or other patient organisations. This latter aspect further reinforced the involvement 
of patients and patient representatives within the pathway. Outcomes associated with this 
mechanism, whilst observable in the pathway design (figure 1), have not been evaluated. 
M3: The third mechanism was that of patient choice and the actual extent to which patients could 
exercise choice within the pathway design. As with the second mechanism, this mechanism was 
observable in the pathway design (figure 1) and associated pathway descriptions but could not be 
evaluated due to the limited operation of the pathway. 
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Figure 7. Context-mechanism-outcome configurations relating to the theory of patient 
empowerment within the IBD pathway project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As previously, red boxes represent contextual factors, orange represent mechanisms and 
outcomes are in green. However, dark green boxes represent outcomes which have not been 
evaluated within this evaluation.  
C: Government policies promoting patients as free market consumers  
(i.e. exercising choice, informed, equal partners, rights). 
M1: Substantial patient 
representation in fundamental 
aspects of project. e.g. on project 
board and via patient panel, and 
with the patient-organisation 
sponsored IBD Standards used as 
the implicit aims of the project. 
M2: Specific disease, service and 
advocacy information supplied by 
patient organisations, and 
provided to patients. 
M3: Patient choice incorporated 
into pathway. 
O1: Patient (user) representation 
on project board constituted about 
one-third of the board. 
Project board members and the 
patient panel made numerous 
small, but cumulatively significant, 
contributions to the project board 
meetings and project actions.  
At least one patient representative 
attended every project board 
meeting and each significant event. 
Three patient panels were 
convened although participation 
numbers were low and 
opportunities to contribute were 
limited. 
O2: Pathway designed was largely 
complementary to the IBD 
Standards although many of the 
standards were not met. 
O3: 
i. Take-up rate of membership of 
patient organisation: Proportion 
of free memberships claimed out 
of the number of free 
membership vouchers distributed 
to patients. 
ii. Proportion of newly diagnosed 
patients who are provided with 
patient information. 
iii. Proportion of patients who are 
provided information about the 
hospital IBD service. 
iv. Qualitative views of patients 
concerning service and disease 
information provided within the 
pathway. 
04: 
i. In primary care, the proportion 
of patients who attend for an 
annual IBD review out of the 
number of patients who are 
invited to attend. 
ii. In secondary care, the 
proportion of patients who opt to 
have an annual review in primary 
care out of all patients who are 
offered the choice of having their 
annual review in primary care or 
secondary care. 
iii. Qualitative views of patients 
concerning their degree of choice 
regarding selection of their care 
providers and identifying the 
attributes which may promote or 
prevent patients exercising 
choice. 
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C + M1 = O1 
User representation within the pathway design process was extensive. Patient representatives 
constituted a considerable proportion of the project board and contributed significantly to board 
meetings and project events. There was further representation directly from actual local patients 
via the patient panel although this did not operate optimally. 
C + M1 = O2 
The designed pathway would deliver, fully or partially, twelve of the IBD Standards, six of which 
related entirely or principally to patient empowerment, each described in turn. 
IBD Standard C1. Information on the IBD service 
All IBD patients should have information describing the IBD Service and how it can be 
accessed. This should include information on how patients who have concerns about their 
condition or their care can request discussion of their case at the IBD Team meeting or 
request a second opinion. It should also explain how patients can give feedback on the 
care they receive or participate actively in service development. 
The pathway did stipulate that all patients under the care of the hospital IBD team including 
newly diagnosed patients should be provided with a leaflet describing the hospital IBD service. A 
draft leaflet was produced and discussed by the patient panel. A final version of the leaflet was 
never presented to the project board and it is not believed that any such leaflet is available within 
the pathway. 
IBD Standard C2. Rapid access to specialist advice 
There should be a clear process for patients to obtain access to specialist advice and 
support from a named specialist nurse/ stomatherapist by the end of the next working 
day. Ideally there should be a choice of telephone and email contact. 
The pathway did provide patients with direct communication with the hospital IBD team via a 
telephone helpline and a dedicated e-mail account. The pathway did not provide for direct patient 
access to a stomatherapist. The pathway did not stipulate a deadline by which e-mails and 
telephone calls would be answered. 
IBD Standard C4. Supporting patients to exercise choice between care strategies for outpatient 
management 
Patients may prefer continuing hospital management, shared care with their GP or 
supported self-management and they may wish to choose a different option at different 
stages in their illness. The appropriate administrative and clinical infrastructure must be in 
place to support these different strategies and patients should have written information, 
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preferably a care plan, explaining clearly what arrangements have been agreed with them 
for their care. 
Within certain limits, the pathway permitted patients to exert a degree of choice concerning the 
management of their condition. The pathway did not make specific arrangements or reference to 
administrative and clinical infrastructure to support different care strategies. Primary care 
clinicians were required to undertake specific education and training to be able to participate in 
the pathway and therefore receive and manage patients who might opt to be managed in primary 
care. A care plan was not included in the pathway despite being discussed on several occasions by 
the project board. 
IBD Standard C5. Involvement of patients in service improvement 
Patients should have a voice in the development of the IBD Service. The service must be 
able to demonstrate that mechanisms are in place to obtain and respond to patient 
feedback about their IBD Service and to provide opportunities for more direct 
involvement. 
Patients were represented on the project board by three members from the same patient 
organisation, although none of the individuals were themselves IBD patients and none lived in the 
locality. A patient panel was convened on three occasions and all members were local IBD 
patients and believed to be residents of the locality. No specific mechanisms for patients to 
provide feedback or to provide other modes of involvement with the IBD service were addressed 
by the pathway. 
IBD Standard D1. Provision of information 
All patients must be offered appropriate information about their care, treatment options 
and condition at all stages of their illness. Information should be appropriate to the age, 
understanding and communication needs of the patient and carers. 
This point is assumed to refer to verbal communications which were not specifically addressed by 
the IBD pathway. 
Written information about IBD in straightforward English should be provided in 
outpatient clinics, ward, and endoscopy areas. 
The pathway defined specific information products which were provided by the patient 
organisation and also defined the points in the pathway and patient journey at which these 
products would be provided. The IBD Pathway was only for adult patients and all information 
products, both draft and complete, appeared to be appropriate for adult patients. The external 
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information products from the patient organisation had been validated by them for adult 
patients. 
Information should be available in languages other than English where the catchment 
population requires this. 
Standard D1 was not specifically addressed by the pathway. Some of the information products 
from the patient organisation were available in numerous other languages. 
Communications relating to informed consent should be written in clear, straightforward 
language and staff should ensure they are understood by the patient before signing. 
This was not specifically addressed by the pathway. 
Patients being considered for surgery, especially pouch surgery or ileostomy, should be 
offered written and/or audiovisual information, and where possible the option to talk 
with patients who have had pouch surgery or a permanent ileostomy. They should also be 
provided with information about their post-operative care, including histology. 
This was not specifically addressed by the pathway. 
Information should be provided to all inpatients about their care following discharge and 
the arrangements for follow up. 
Provision was made within the final pathway design to ensure that patients under the care of the 
hospital IBD team were provided with information concerning the IBD service. However, although 
draft versions of a hospital service patient information leaflet were produced, a final version was 
not ready by the point of the evaluation close. The leaflet was intended to address the necessary 
points. 
IBD Standard D3. Information about patient organisations 
All patients should be provided with contact information for the relevant patient 
organisations. 
This standard was specifically addressed by the pathway although attainment was incomplete. 
The pathway specifically defined that information from the patient organisation was provided to 
newly diagnosed patients and this also included a voucher which patients could use to claim a 
free membership of the organisation for the first year. The draft hospital IBD service leaflet also 
provided contact information for the patient organisation. Other information products from the 
patient organisation would contain contact details for the patient organisation. 
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C + M2 = O3 
This configuration relates to an outcome-based evaluation, both quantitative and qualitative, of 
the various ways in which the pathway could be expected to deliver patient empowerment. It 
should be noted that, due to the relatively immature state of the pathway at the evaluation close, 
none of these specific outcomes were evaluated and are instead stated here to support a future 
evaluation of the pathway. Useful and informative outcomes could include: 
• The take up rate by newly diagnosed patients of the offer of free membership for one 
year of a specific patient organisation. For completeness, the evaluation should also 
include a measure of the number of vouchers provided or distributed against a baseline of 
the number of opportunities for provision of the vouchers. A descriptive analysis of the 
voucher distribution process should also be included particularly as late-emergent 
anecdotal evidence suggested that the distribution process had evolved in a manner 
which was not foreseen or intended by the patient organisation. 
• A quantitative and descriptive evaluation of the provision of patient information to newly 
diagnosed patients as specified by the pathway design. The evaluation should include 
temporal measures relating to the sequential appointment at which information was 
provided (e.g. first vs. second appointment, etc.) and the overall time from confirmed 
diagnosis. A similar analysis should be conducted regarding the provision of information 
to patients about the hospital IBD service where this is specified in the pathway. 
• Importantly, an evaluation should include the qualitative views of patients concerning the 
various service and disease information products provided within the pathway. Ideally, 
such an evaluation would address the appropriateness of the point at which the 
information was provided in the patient’s disease journey, as well as the scope and 
content of the information and factors relating to its source and the manner in which it 
was provided. It would be useful if a qualitative evaluation could inform improvements to 
any aspect of provision of information to patients. 
C + M3 = O4 
A crucial element of empowering patients is in the expression of patient choice and the pathway 
did make explicit provision for patients to exercise choice within the pathway. This CMO 
configuration relates to obtaining outcomes from the contextual background and the collective 
patient choice mechanisms within the background. However, as with the previous CMO 
configuration, the pathway was not at a mature enough stage to reliably evaluate these aspects of 
the pathway at the evaluation close. Therefore these specific outcomes were not evaluated and 
are instead stated here to support a future evaluation of the pathway. Useful and informative 
outcomes relating to the evaluation of patient choice would include: 
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• The proportion of patients who attend for an annual IBD review out of the number of 
patients who are invited or otherwise eligible to attend. Patients should be differentiated 
by the invite sender and the actual review location (i.e. primary vs. secondary care in both 
cases). This would provide a measure of the opportunity to express choice and a measure 
of the expression of that choice. 
• Importantly, the evaluation should include the views of patients concerning their planned 
and actual degree of choice regarding selection of their care providers. This could be 
useful in identifying the attributes which promote or prevent patients exercising choice. 
Whether patients were genuinely empowered, and the extent of any such effect, was not 
identified within this evaluation. However there are several features of the IBD pathway which 
could reasonably be expected to deliver patient empowerment, including some features 
supported by sound evidence. Some components of the pathway would meet the requirements of 
the IBD Standards with respect to patient empowerment and related aims although there 
remained considerable room for improvement in that respect. 
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5.1.4.3 Clinician empowerment 
One contextual factor was identified which influenced the application of the theory of clinician 
empowerment within the pathway. This contextual factor is described singularly as relating to 
explicit and prioritised healthcare policy for clinician-led commissioning, particularly primary care 
clinician-led commissioning, [210] and in tandem the on-going pre-eminence of the practice and 
implementation of evidence based medicine. [211] In this respect evidence-based medicine has 
been subjectively classified as a clinician-led initiative and is therefore itself an aspect of clinician 
empowerment. Four mechanisms were identified through an iterative process and seven 
outcomes were associated with these mechanisms. One of the outcomes links to two context-
mechanism pairs hence there are eight unique CMO configurations. Three of the outcomes were 
not evaluated within this evaluation but they have been prospectively identified and stated to 
support any future evaluation. 
Mechanism one (M1) related to the (implicit) aims of the pathway being founded in an initiative in 
which clinicians of various professional backgrounds were fundamentally involved and which, in 
part, was founded in evidence-based medicine, i.e. the IBD Standards. [1] 
Mechanism two (M2) related to the actual or real application of care which was itself defined in 
large part by evidence-based medicine. 
Mechanism three (M3) related to the gateway process by which a clinically-led group had the 
ultimate control, at least in a budgetary sense, to approve or otherwise the on-going funding of 
the project. 
Mechanism four (M4) related to the roles which clinicians had, both in the pathway design 
process and in the outcome of that process, the pathway. 
Outcomes are described in detail under separate headings for each of the eight unique CMO 
configurations. 
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Figure 8. Context-mechanism-outcome configurations relating to the theory of clinician 
empowerment within the IBD pathway project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
C: Healthcare policies which promote clinically-led commissioning and evidence-based medicine. 
M1: The implicit aim of 
the pathway was the 
implementation of the 
IBD Standards which 
were in turn developed 
with multidisciplinary 
clinical input from 
recognised clinical 
representative groups 
and several of the 
specific standards 
originated from 
evidence-based sources. 
M4: Clinicians had 
substantive roles within 
the project including the 
project board and 
delivered components of 
the project. 
M3: Approval of, and 
funding for, the project 
was required from the 
primary care clinical 
commissioning group. 
M2: Sources of evidence-
based medicine were 
utilised in the pathway 
components which 
defined the nature of 
care received by 
patients. 
O2: The designed 
pathway would deliver, 
fully or partially, six of 
the IBD Standards which 
related to important 
clinical or evidence-
based roles. 
O7: Substantive roles 
existed for clinicians 
within the pathway 
design process  
(e.g. project board 
membership) and a 
primary care clinical peer 
was recruited to act as 
the project leader. The 
majority of care was to 
be delivered by 
clinicians. 
O5: The primary care 
commissioning group 
approved on-going 
funding and support for 
the project.  
O3: The IBD Standards 
themselves utilised 
evidence-based sources 
and the Map of 
Medicine®, an evidence-
based clinical resource, 
was used to define 
primary to secondary 
care referrals for known 
IBD patients. 
O4: The care of IBD 
patients should be 
audited against the IBD 
Standards and the Map 
of Medicine® care 
pathway. 
O1: An in-depth audit of the annual reviews 
differentiated by primary and secondary care providers 
to include; completion rates for individual 
components, quantitative regression analyses of 
patient-reported outcomes.  
Temporal analyses to develop with respect to whole 
cohorts at specific intervals and individual patients 
after specific intervals or events. 
O6: A quantitative 
evaluation of the wider 
impact of the pathway 
on healthcare and 
associated resource 
utilisation with direct 
consideration of cost 
implications from 
different perspectives 
should be undertaken. 
As previously, the red box represents a 
contextual factor, orange boxes represent 
mechanisms and outcomes are in green. 
Darker green boxes represent outcomes 
which have not been evaluated within 
this evaluation. 
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C + M1 = O1 
This configuration would yield quantitative outcomes relating to the internal performance and 
patient-reported outcomes of the patient annual reviews. It is important to note that, at the 
evaluation close the number of completed annual reviews was insufficient for formal evaluation. 
Therefore none of these outcomes have been robustly evaluated; this configuration remains to be 
evaluated and is stated for the purpose of supporting a future evaluation. 
Internal performance indicators relating to the completion of annual reviews including temporal 
measures (i.e. the rate at which individual practices, and secondary vs. primary care, undertook 
reviews). Performance would also include a descriptive analysis of the overall review completion 
rate and individual component completion rates. Of greater interest, especially externally to the 
project, would be the actual review data. For example, the reviews required quality-of-life and 
symptom scores for most patients. These could in-turn be described and analysed, potentially via 
regression analysis, by different patient cohorts based on, for example, diagnosis, disease 
severity, principal care provider (self-care vs. primary vs. secondary), gender, etc. Whole cohorts 
could be followed up over time, from one year to the next using arbitrary cut-off points, or 
individual patients could be tracked anonymously and trends relating to changes in underlying 
quality-of-life or symptom scores could be identified. Any consistent trends could be associated 
with the pathway. At the least, such an analysis would provide a useful and informative 
epidemiological cohort. 
The analytical and policy impact of such data could be potentially significant and would 
demonstrate, primarily, the clinical outcomes of the pathway from which cost impacts could also 
be derived. 
C + M1 = O2 
The designed pathway would deliver, fully or partially, twelve of the IBD Standards, six of which 
related entirely or principally to clinician empowerment. The relevant standards are each 
described in turn. 
IBD Standard A4. Referral of suspected IBD patients 
Guidance should be developed for the identification and referral of symptomatic patients 
in whom IBD is suspected. 
This was not specifically addressed by the pathway. 
GPs should be prepared periodically to review their diagnosis in patients with 
unresponsive, atypical or troublesome abdominal symptoms. 
This was not specifically addressed by the pathway. 
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A communication pathway must be agreed for referral of possible IBD patients to the IBD 
Service for rapid consultation and assessment. Such patients should be contacted within 2 
weeks of referral and seen within 4 weeks, or more rapidly if clinically necessary.  
The pathway defined specialist assessment within 4 weeks following primary care referral and this 
was complementary to this part of the standard. The pathway did not define deadlines for 
contacting patients or make allowance for more rapid assessment if clinically needed. 
Newly-diagnosed IBD patients for whom surgery is not an immediate consideration and 
who have initially been referred to a surgeon should normally be transferred to the care of 
the medical gastroenterology team. 
This was not specifically addressed by the pathway. 
IBD Standard A11. Outpatient care 
All patients with confirmed IBD should have their details maintained on the Register of IBD 
patients even when they are no longer regularly attending outpatient clinics. 
The pathway required that patients were properly ‘coded’ on primary care electronic patient 
records so that they could be readily identified. The only ‘register’ in local use was that held by 
the Hospital IBD team and maintained by the Specialist IBD Nurse. The pathway required that 
even patients who were not currently managed or under the care of that specific Hospital IBD 
team (i.e. patients managed at other hospitals, or managed entirely in primary care) would be 
notified to the Hospital IBD team so they could be recorded on the hospital database. Issues 
relating to patient confidentiality and communication strategies for patients who were not or had 
not been under that hospital’s care were not conclusively resolved. 
All IBD patients who are not under immediate or on-going care, including those in 
remission, should have an annual review and basic information recorded. This may be 
undertaken in a hospital or community clinic or by telephone follow-up, and should be 
done by a healthcare professional with recognised competence in IBD. 
One of the key components of the pathway was the provision of an annual patient review for all 
patients with information recorded on practice records, shared with the Hospital IBD team for the 
patient’s medical record, and audited by primary care commissioners. The review could be carried 
out in a number of settings and the option of a telephone review was discussed although this was 
not specifically included in the final pathway. The competence of healthcare professionals was 
assured through verified completion of specific education and training and on-going support from 
the Hospital IBD team. In addition, the clinical champion and primary care commissioning team 
established a network for primary care nurses conducting IBD reviews. 
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The criteria for annual review should be agreed by the IBD Team, but would normally 
include assessment of the need for colorectal cancer surveillance, renal function and bone 
densitometry. 
The review components were derived from a project which had developed and tested an IBD 
annual review for use in primary care. The content of the IBD pathway review was then refined by 
the project with significant contributions from the Hospital IBD team. The IBD pathway review 
template included additional assessments for cancer surveillance, renal function and bone 
densitometry in accordance with this standard. 
All IBD patients who have a concern or questions about their IBD should have access to a 
dedicated telephone service (IBD Helpline) that is either answered or has an answerphone 
facility providing a response by the end of the next working day. 
The pathway provided access to the Hospital IBD team, specifically the specialist IBD nurse, via a 
telephone helpline. This was also available to patients who had been formally discharged from the 
hospital IBD service. The helpline was connected to an answerphone and arrangements were in 
place with hospital IBD team administrative (non-clinical) staff to manage the helpline at times 
when it was not directly managed by clinical staff. The pathway did not define a specific deadline 
by which responses were provided. 
Patients experiencing a possible relapse of their IBD should have access to specialist 
review within a maximum of 5 working days. 
The pathway specifically defined that a relapse for patients managed in primary care, or any other 
indication for an existing patient which required specialist review, would be seen or consulted by 
a specialist within five working days. 
IBD patients should be able to choose from a range of arrangements for their outpatient 
care. These should include attending hospital as an outpatient, guided self-management 
with access to support when required, and care in a primary or intermediate care setting 
with defined links to the IBD Team. 
The pathway would permit a limited degree of choice for patients with stable disease and in 
remission to choose their care provider. Patients who were currently managed in primary care or 
not under any formal care arrangements were not provided choice within the pathway. This was a 
specific suggestion from the patient panel. Patients who were currently managed in secondary 
care could choose to stay under the care of the Hospital IBD team or to be managed in primary 
care. Patients with unstable or active disease could not choose their care provider and were 
expected to remain under the care of the hospital IBD team until such time that their disease was 
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stabilised and in remission. The pathway did not make any provision for intermediate care. The 
pathway promoted and supported self-management through specific provision of information 
and sign-posting to, and promotion of, credible patient organisations. 
IBD Standard B1. Arrangements for shared care 
The arrangements and scope for shared care and the circumstances in which the patients 
should be referred back to hospital care must be clearly defined between the hospital staff 
and the GP. They must be explained verbally to the patient and written information on this 
provided to the patient, ideally as a care plan. 
Referral arrangements within the pathway from primary to secondary care were defined by the 
Map of Medicine®. The pathway did not make a specific requirement for referral arrangements to 
be communicated to patients. A written care plan, although discussed on several occasions by the 
project board, was not included in the pathway. A final version of the IBD service leaflet, which 
was being produced by the Hospital IBD team as part of the pathway, was not delivered within 
the pathway. 
A system for sharing of information about test results or treatment changes should be in 
place through the use of IT, written communication between the GP and hospital or a 
patient-held record. 
The pathway did not make any changes to communication processes for clinical data, the majority 
of which would occur via hard (i.e. paper) copy. Primary care communication to secondary care 
was largely absent prior to the pathway and the pathway could have stimulated such 
communication as copies of primary care reviews were to be communicated to secondary care. 
There were already systems in place for electronic sharing of biochemical clinical data from 
secondary to primary care. A patient-held record or care plan was discussed on several occasions 
by the project board but was not included in the final pathway. 
Treatment with immunosuppressive or biological therapies should only be initiated by 
clinicians with expertise in their use for IBD. Shared care protocols should be developed to 
support the on-going prescribing and monitoring of these drugs in general practice. 
The pathway did not make any specific changes to arrangements for management of specific 
therapies. 
Arrangements should always be made in discussion with the patient. 
The pathway did not make any specific changes to arrangements for discussing treatment 
decisions with patients. However, better informed and empowered patients which were one of 
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the implicit aims of the pathway could rationally lead to patients being involved in discussions 
about their treatments. 
IBD Standard E1. Register of patients under the care of the IBD service 
Every IBD Service should maintain a local Register of all diagnosed IBD patients in the 
catchment area (including those who have been diagnosed but are not currently being 
managed in secondary care) recorded on a searchable database and with adequate 
clerical support to maintain this. 
This standard was not specifically addressed by the pathway although the pathway did reinforce 
the importance of the pre-existing database created and maintained by the Hospital IBD service. 
In addition, the pathway sought to ensure that the hospital database could obtain information 
concerning local IBD patients who were not or had not been under its care. This standard is 
similar to the first point of standard A11 which has been described previously. 
IBD Standard F1. Training and education 
All members of the IBD Team should be expected and enabled to participate in local and 
national professional education to maintain their competence and knowledge in a fast 
developing subspecialty. 
The ‘IBD team’ in this point is taken to include all primary and secondary care practitioners 
involved in the delivery of care for IBD patients. In that respect, the pathway did achieve this 
standard, principally through the provision of specific and mandatory education and training 
events for practice staff with verified and remunerated attendance. In addition, the pathway 
required a named GP lead in each participating practice to undertake a specific online educational 
package, the completion of which was verified and remunerated. Another outcome of the 
pathway which began to emerge at the end of the evaluation, and under the direction of the 
clinical champion, was an informal network for primary care practice nurses. 
Advanced nursing practitioners within the IBD Team should have access to medical 
support as well as nursing supervision. 
This point was not specifically addressed by the pathway. It was already covered by the Hospital 
IBD team which was the only IBD team within the locality known to have an advanced nursing 
practitioner. 
The IBD Team should provide IBD awareness and education opportunities for GPs. These 
should focus on the initial presentation of IBD, as well as its treatment. A lead GP should 
be identified to assist in this. 
178 
This point was specifically addressed by the pathway. The project board provided two education 
and training events which were open to voluntary attendance from GPs and other primary care 
clinicians to attend. Participating practices were required to identify a GP to act as lead for IBD 
and this individual was required to attend one of the education and training events, as well as at 
least one practice nurse from participating practices. The content of each education and training 
session covered the specific criteria stated in the points and both sessions had contributions from 
the primary care medical lead and other clinicians. It was not clear whether there would be an on-
going education and training commitment within the pathway after the initial events. 
IBD Standard F3. Service development 
IBD Teams should participate in local and national activities intended to improve the 
quality of IBD care and services. 
The pathway itself and participation in the evaluation represented attainment of this point. The 
pathway did not mandate any specific contributions to this point. 
IBD Teams should take an active part in clinical network arrangements and events with 
neighbouring IBD Services. 
The pathway did not specifically address this point. The pathway did stimulate a recognised need 
for the Hospital IBD team to communicate with neighbouring hospital gastroenterology 
departments although it was not clear if these communications occurred. The academic adviser 
did allude to having communicated details of the IBD pathway to other healthcare organisations 
within the region. 
IBD Teams should be encouraged to hold an Annual Review Day to reflect on their service 
and where appropriate to consult with relevant stakeholders. 
This point was not specifically addressed by the pathway and no such event is known to have 
been planned after the pathway was launched. 
C + M2 = O1 
As with the other CMO configuration relating to outcome one (O1), this was not realised within 
this project evaluation. In this configuration outcome one was interpreted to also provide 
information about the realisation of mechanism two (M2), subject to the background context (C), 
both previously described. In this respect the configuration could inform whether the 
expectations of the impact of evidence-based care can be realised under the specific local 
conditions such as the context (C) and other objectively identifiable factors. 
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C + M2 = O3 and C + M2 = O4 
Both of these CMO configurations relate to the local application of evidence-based medicine in 
IBD (M2). Evidence-based medicine is itself a clinically-led movement viewed as the highest 
quality expression of clinical care. It has therefore been interpreted as a form of clinician 
empowerment for the purposes of this evaluation although this is not necessarily a universally 
accepted interpretation. 
The first of these configurations (C + M2 = O3) related to the pathway design and in that respect it 
was concluded that evidence-based medicine was incorporated into the pathway. This was 
achieved by defaulting to the application of the IBD Standards as the implicit aims of the pathway 
and the partial attainment of those standards, and by defaulting to the Map of Medicine® to 
define patient referrals from primary to secondary care. Both sources were themselves 
embedded in evidence-based medicine. 
The other CMO configuration relating to the second mechanism (M2) of evidence-based medicine 
(C + M2 = O4) was not evaluated within the project evaluation and the associated outcomes are 
instead stated to support a future evaluation. In that respect a future evaluation of this 
configuration should involve an in-depth audit of the actual care delivered against the IBD 
Standards and the Map of Medicine® IBD care pathway. Both of these potential audit standards 
are founded in evidence-based medicine and by direct association an audit against them would be 
an indirect audit on the application of evidence-based medicine. 
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Box 10. Evidence-based medicine within the IBD Standards  
IBD Standards [1] 
Introduction 
….  In developing the standards the Working Group has drawn on NACC’s work identifying 
patients’ needs and wishes, on existing evidence-based guidelines for the clinical management of 
IBD, the strategic report Care of Patients with GI Disorders published by the BSG in 2006 and 
evidence-based service statements produced by the various professional groups. 
Standard F. Evidence-based practice and research 
…. The principle of a knowledge-based service requires that necessary research should be 
identified and prioritised. …. 
 
Box 11. Evidence-based medicine within the Map of Medicine® 
Map of Medicine® [212] 
Editorial methodology 
…. Map of Medicine® specifically searches for well-reputed secondary evidence – systematic 
reviews, meta-analyses based on systematic reviews, and guidelines. … 
Every care map is peer-reviewed. Peer-reviewers are asked to consider the evidence base used, 
the practice-based knowledge added, and the clinical usability. …. 
 
C + M3 = O5 
An indicative budget had been prepared by the project management organisation, the PCT, as 
part of its application for the Department of Health integrated care pilots. This budget plan was 
based principally on the estimated number of patients using standard prevalence rates multiplied 
by the cost of individual components of care under an assumption of eventual 100% take-up by all 
parties (patients and primary care medical practices). This budget plan estimated comprehensive 
take-up by 26 practices with 842 IBD patients. The direct project costs for the first year were 
therefore estimated at £13,000 for practices and £29,470 for conducting patient reviews; total 
cost £42,470. It was not clear whether these were expected to be recurrent costs; certainly the 
cost for conducting patient reviews would be expected to be recurrent as would the additional 
£120 per practice (total £3,120) for submitting data pertaining to the reviews. The costs for 
clinician training, at £380 per practice (£100 per GP and £280 per practice nurse), may not have 
been recurrent. 
Fundamental to the project was an assumption that the pathway would create savings based on 
reduced use of specialist, secondary and emergency care. The net effect of these savings was 
estimated at £154,140 per annum based on standard healthcare values for 2008-09. This figure 
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was itself based on a number of unreferenced or unclear assumptions. For example, the stated 
prevalence of IBD was 4.4 per 1,000 giving an estimated patient population of 842. However this 
figure was slightly greater than that found in an earlier epidemiological study from a similar 
locality of about 3.88 per 1,000. [2] A similar figure of 4 per 1,000 was reported in the IBD 
Standards. [1]  The practice agreement which participating practices were required to sign for 
participation in the project used a figure of 9 per 1,000 (appendix 11) the basis of which was 
unclear. The budget plan assumed that 500 of the 842 patients (59%) were managed by specialists 
with an average of 1.5 outpatient attendances per annum (750) and there would be a 30% 
reduction in the number of outpatient attendances (i.e. 225 fewer attendances). The figure of 750 
outpatient attendances per annum was based on actual local data. An increase of 20 new 
outpatient appointments was also factored-in along with the attendant costs. The majority of the 
estimated savings originated from reductions in emergency admissions, for which actual data 
indicated about 200 admissions per annum at higher cost tariffs plus 100 admissions per annum 
at the lower tariffs. The budget plan assumed a reduction of 10% in the former and 80% in the 
latter, yielding savings of £40,860 and £98,640 respectively. 
The net budget impact was based upon a number of assumptions for resulting levels of healthcare 
utilisation which were not stated or referenced and appeared to have been arbitrarily elucidated. 
Nonetheless, it was this budget plan, which may have been periodically updated with new tariff 
values, which formed the basis of the financial argument for the project. The budgetary case was 
referred to implicitly and explicitly at several points during the project by both project managers. 
It was clear during project board meetings that the budgetary argument was crucial in securing 
on-going support and up-front funding for the project.  
During the course of the project the ownership, or budgetary responsibility, shifted from a 
Practice-Based Commissioning (PBC) group budget to a GP commissioning consortium budget. 
The PCT would still provide strategic support and project management however on-going support 
for the project was required from the GP commissioning consortium board. This change coincided 
with the introduction of the new project management team in early 2011. The pathway launch 
was made to the PBC group board in November 2010. One of the first tasks undertaken by the 
new project manager, who took up the role in early 2011, was to secure on-going funding for the 
project from the GP commissioning consortium board. At the 10
th
 project board meeting in May 
2011 the project manager alluded to some issues relating to transfer of funding oversight 
although little detail was provided. At the 11
th
 project board meeting in July 2011 it was reported 
that funding of £60,000 had been secured for the nine practices which had already signed-up to 
the pathway and any extra practices which subsequently agreed to participate in the project. As 
of the 31st March 2011 the direct project costs were estimated at £8,780, based on 21 practices 
signed-up, eight GP’s and 14 nurses having undertaken the required training, and 44 annual 
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reviews completed. Therefore the actual costs which were estimated to have been incurred were 
substantially less than the funds which had been allocated. However the direct project costs do 
not include the cost of project management support and other operational expenses. 
C + M3 = O6 
As with outcomes O1 and O4, outcome six (O6) was also remained unevaluated. The individual 
outcomes which could be included within O6 related primarily to data which was readily available 
and already routinely recorded within local and national NHS data infrastructure. However the 
crucial step to making the data useful was being able to relate it to specific diagnoses or 
indications, or by linking it directly to patients defined by a specific disease such as IBD. This step 
was not readily achievable with current data sets or the available access to them and presented a 
substantial barrier to the useful evaluation of the data. 
Assuming that this barrier could be overcome, outcome six (O6) would represent a collection of 
relevant and potentially correlated quantitative outcomes routinely collected as part of patient 
care and NHS systems. Such outcomes would take a certain amount of time to be realised, most 
likely measured in years as opposed to months, but would also be of paramount interest to 
healthcare commissioners and others with similar influence or interests. 
The individual outcomes could include: 
• Unplanned (emergency) admission rates 
• Elective (planned) admission rates 
• Procedure codes identifying specific procedures carried out for IBD patients or for the 
purpose of treating IBD 
• Primary care medical and nurse consultation rates 
• Secondary care medical and nurse consultation, and other contact, rates 
• Prescription drug use analysed according to various standardised reference measures 
This CMO configuration could help to identify whether the budget plan assumptions described 
under outcome five (O5) were realised and to the extent they were realised. 
C + M4 = O7 
As with user involvement, the pathway design process and the outcome of that process, the 
pathway to be delivered, included a substantial role for clinicians, both medical and nursing 
clinicians, and primary and specialist care. It could justifiably be said that the pathway was 
dominated by clinicians and the project could be described as ‘clinically led’. There were many 
examples of clinician empowerment within the pathway both during the design process and with 
respect to the pathway which was actually designed. 
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• Project board: Of the eight regular project board members or roles, two were exclusively 
of a clinical background (the consultant gastroenterologist and the specialist IBD nurse).  
A further two members had substantial past (academic adviser) or current (primary care 
medical lead) clinical experience which frequently influenced their contributions to the 
project and project board meetings 
• Project board meetings: Despite no special dispensation to ensure hospital clinician 
attendance and their consequent irregular attendance, the majority of board meetings 
were chaired by a clinician. All clinician representatives, with the exception of the 
specialist IBD nurse, contributed substantially to project board meetings. The specialist 
IBD nurse only attended two project board meetings and whilst there contributed 
comparatively little to discussions, although her presence alone was a positive 
development and may have had an impact on other project board members. 
• Launch event: The individual who took the lead at the launch event was the primary care 
medical lead, also a practicing local GP (project board member ); the audience consisted 
of GPs and practice managers being the ‘[Locality] GP commissioning forum’.  
• Clinician education: The pathway design required that primary care clinicians, both 
general medical practitioners and practice nurses, undertook formal and verifiable 
training and education. Clinicians were also involved in delivering the bespoke training 
and education meetings within the pathway. 
• Clinician to clinician communication: The pathway, if fully realised, would enhance 
communications and information-sharing between clinicians, primarily across the 
primary-secondary care interface. This aspect of clinician empowerment was not formally 
evaluated. Clinicians, both primary and secondary care, reported improved 
communication with colleagues in the other sector when interviewed. Anecdotal reports 
indicated that communication, particularly in the direction of primary care to secondary 
care, had increased. 
• Clinician peer-to-peer leadership: Although a missed opportunity for significant and 
substantial clinician empowerment during much of the evaluation, the ‘clinical champion’ 
role was fulfilled and would provide a good example of clinical empowerment. This role 
was fulfilled by a primary care medical clinician recruited to work for, lead and promote 
the pathway amongst primary care clinical peers. However opportunities for the clinical 
champion to contribute to the initial design processes and significant events such as the 
launch event were missed due to delayed recruitment. 
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Clinical champion 
The requirement for, and the eventual recruitment of, a clinical champion within the pathway was 
another example of clinical empowerment within the pathway and this was reflected in the CMO 
configuration C + M4 = 07. 
Limited use of the term ‘clinical champion’ was identified in UK-orientated health literature. 
However one useful example was an article published in the Health Service Journal in 2009. [213] 
This described an initiative within a single PCT which co-incidentally was also located in the same 
SHA. In this example clinical champions were appointed by the PCT although not necessarily 
recruited from primary care. The posts were created to help the PCT develop clinical priorities and 
strategy, promote ‘practice based commissioning’, promote evidence-based care, and to act as 
focal points for communications. The clinical champions were expected to have direct 
involvement with clinical pathway and planning groups and service review and redesign 
mechanisms. [213] 
The Royal College of General Practitioners has appointed ‘clinical champions’ for specific 
therapeutic and related fields since at least 2008. The college’s description of the role described 
the aims and objectives as: [214] 
• To pro-actively raise the profile and awareness of the clinical priority area among general 
practitioners, the wider primary health care community, and patient-related 
organisations and groups. 
• To spearhead collaborative and partnership working with both internal and external 
stakeholders. 
• To promote best clinical practice and develop the range and quality of training, 
educational and information resources in the priority area. 
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5.2 Community Pharmacy role in managing IBD 
The survey and focus group analyses combined were generally supportive for the potential 
involvement of community pharmacy in the management of IBD for adult patients. The results of 
the survey also indicated a considerable opportunity for community pharmacists to be involved in 
the management of adult IBD patients given the high rates of prescription and non-prescription 
medication use, and the majority of patients regularly using community pharmacies. 
5.2.1 Survey analysis 
5.2.1.1 Baseline drug-related healthcare utilisation and services 
The survey results demonstrated that this group of adult IBD patients had a high use of use of 
prescription medication for their IBD with 87% reporting current use. This was not an unexpected 
result given what was known about the management long-term conditions more generally. [215]  
However it was somewhat at odds with data published in 2000 which found in a similar locality 
that the rate of medication use for IBD amongst a general practice IBD patient population was 
46%. [2]  Data from an American database in 1997 found that 88% of nearly 4,500 paediatric and 
adult IBD patients were using any prescription medicine, although only 57% were using drugs 
specifically targeted at the alimentary system such as 5-aminosalicylic acid drugs. [216] Therefore 
the survey results in this respect should be interpreted cautiously as responses may not have 
been as intended and could relate to any indication not just IBD. 
The relatively large difference between the rates of prescription IBD medicine use found in this 
survey and in the earlier work of Rubin [2] could be explained by a number of factors. Some of the 
more plausible include: 
• Changes in disease management over time resulting in wider use of medication for IBD in 
general. 
• Rubin’s work focused on a general practice IBD patient population whereas this survey did 
not discriminate on this basis. Therefore the survey result could be inflated by a proportion 
of patients under specialist care, in turn associated with a different rate of medication use.  
• Rubin’s work was objectively verified from patient notes and practice records whereas 
these survey results were self-completed by patients and may be subject to recall bias or 
fabrication. 
• Although the survey question specifically enquired about IBD medication respondents could 
have misinterpreted this, intentionally or unintentionally, and may have included other 
non-IBD medications thus inflating the apparent IBD-specific rate. Rubin’s work focused 
only on a specific range of medicines commonly, but not exclusively, used for IBD. The 
evidence from the American database would support this notion. [216] 
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The survey results also demonstrated that responsibility for prescribing IBD medication appeared 
to be equally shared between primary and secondary care. Secondary care prescribers (hospital 
doctor, nurse or pharmacist) accounted for 50% of responses, and primary care prescribers (GP, 
practice or district nurse, or community pharmacist) accounted for 49% of responses. The most 
common prescriber was a GP with 62% of respondents indicating their IBD medication was 
prescribed by their GP. There were a relatively large number of multiple responses to this 
question which could indicate uncertainty or misinterpretation of the question amongst 
respondents. It was also possible that responses related to the professional who initiated a 
particular prescription as opposed to the professional who prescribed the medication, with this 
relatively subtle distinction not apparent to respondents. For example, hospital specialists will 
often initiate a new drug treatment and once the patient has stabilised with a maintenance dose 
prescribing is transferred to the patient’s GP. 
The survey results showed that the majority of prescriptions were dispensed in primary care with 
community pharmacies accounting for 75% of responses and GP’s (assumed to be dispensing 
doctors) a further 11%. Hospital pharmacy accounted for a significant proportion at 17%. It was 
interesting that despite about one-half of respondents indicating that a hospital-based prescriber 
was responsible for prescribing their IBD medication only one-sixth of respondents reported 
obtaining their medication from a hospital. This disparity could be real, on the basis that hospital 
prescribers can prescribe drugs which can be dispensed by community pharmacies. However the 
size of the disparity supports the notion that responses to the preceding question were 
misrepresented in some way.  
Of those who stated they collect their prescriptions from a community pharmacy, and allowing for 
a small number of responses from non-community pharmacy patients, the majority stated that 
they ‘always’ or ‘usually’ collected their prescription from the same pharmacy (80%). This data 
supports the notion that a specific community pharmacy could build-up a comprehensive 
medication record, at least with respect to IBD medication, and enable pharmacy staff, including 
the pharmacist, to develop a professional relationship with, and knowledge of, a particular patient. 
Where the rate for continuity of dispensing agent is high, as indicated in these survey results, a 
case for their involvement in the management of those patients is supported. However consistent 
use of the same pharmacy does not necessarily mean that a patient will have contact with the 
same pharmacist. Community pharmacy relies on a large locum work force [217] and therefore 
individual patients may often see different pharmacists at the same establishment.  
The reasons why respondents were selecting the same pharmacy most of the time, termed 
patient loyalty, were evenly split between external factors outside of the pharmacy proprietor’s 
control or influence (48%), and internal factors which could readily be influenced by the 
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proprietor (52%). The most frequently cited theme was for ‘convenience’ relating to some 
element of geographical proximity. The most popular category was similar, relating to 
‘geographical’ reasons for patient loyalty. This category included the most popular single theme 
as well as others relating to parking, lack of choice, and specifically due to proximity to the 
patient’s GP. Nonetheless, internal factors such as the conduct of pharmacy staff and provision of 
additional services accounted for just over half of all responses. Customer service themes such as 
‘service quality’ and ‘stock holding’ were cited more frequently than clinically orientated services 
such as the provision of medication use reviews. Overall, these results were encouraging for 
community pharmacy as they indicated that considerable influence could be exerted by 
community pharmacy staff and proprietors in achieving customer loyalty, at least with respect to 
this survey sample. Attributes which pharmacy proprietors should focus on to build patient loyalty 
might include the potential provision of additional services, both clinical and practical, staff 
training in general customer care, and holding adequate stocks of prescription medication. 
Little relevant research was identified relating to reasons for customer or patient loyalty with 
community pharmacies. A survey of nearly 400 members of the public aged 20 to 69 years in 
Estonia in 2005 found that ‘appropriate location’ was the most frequently cited reason for the 
choice of a pharmacy, accounting for 24% of the sample. [218]  Although this result was similar to 
the findings of this survey, it is not clear how the question was presented to respondents. In 
addition, respondents to the Estonian survey may not have been actual patients, yet alone IBD 
patients, and may have submitted responses relating to attendances at a pharmacy for non-
health purposes. A survey of Australian community pharmacy customers identified stronger 
feelings of loyalty in pharmacies which were identified as providing a high-level of drug 
information to patients compared with pharmacies identified as low information providers. [219]   
The survey responses detailed a high level of prescription medication use, which was managed 
(prescribed and dispensed) predominantly in primary care, with most prescriptions being filled at 
community pharmacies and with high levels of customer or patient loyalty to those pharmacies. 
The survey also provided evidence that IBD patients usually collect their own prescriptions once 
dispensed. Although this data did not specifically relate to community pharmacies the most 
common place to obtain prescriptions for IBD medicines had already been indicated as a 
community pharmacy. Combined, this data supports the notion that community pharmacies 
provide an opportunity for patients, should they so wish, to engage regularly with a healthcare 
professional, i.e. a pharmacist. The reverse is also true inasmuch that community pharmacists 
would have regular opportunity to engage with IBD patients if necessary. 
The survey identified a relatively high rate of non-prescription medicine use at about one in four 
patients (23%). The question included examples relating to the purchase of non-prescription 
188 
medicines for IBD, of which there were none known to be specifically licensed in the UK, as well as 
alluding to medicines commonly referred to as complementary and alternative medicines (CAM). 
The relatively high rate of non-prescription medicine use was not entirely unexpected. A review of 
CAM use in adult and paediatric IBD populations identified nine articles published between 1998 
and 2006 which provided prevalence estimates on the use of CAM in North American and 
European IBD populations. [220]  These estimates ranged from 11% to 34% for current use and 
from 21% to 60% when past use was included. [220]  Two UK-based clinical surveys were included, 
one which reported current use at 28% and the other which reported current or past use at 50%. 
[220]  These results were broadly in-line with the result obtained in this survey. A high rate of 
non-prescription medicine use, whether licensed medicines or unlicensed CAM-type medicines, 
might indicate an area of unmet need relating to either the reasons why patients resorted to such 
therapies, or in providing information about the medicines. In addition, such use is often 
unrecorded and unknown to physicians and creates an important gap in the patient medical 
record which community pharmacies could fill. [221] 
When it came to purchasing non-prescription medicines the data indicated that most purchases 
were made at health food or vitamin stores accounting for 48% of respondents. This could reflect 
that a large proportion of non-prescription medicine use may be of the CAM-type rather than 
over-the-counter pharmacy medicines. Only 20% of respondents cited a community pharmacy as 
the place where they obtained such medicines although one-third indicated they obtained them 
from a supermarket including the pharmacy. Of interest was the proportion of respondents who 
obtained their non-prescription medicines from the internet or via mail order or catalogue 
companies (28%). The purchase of medicines via the internet creates the possibility that 
prescription-only or other regulated medicines are being purchased as these are widely available 
illegally from non-UK based operators. [222]  Purchase via impersonal mediums means that 
patients have limited opportunities to ask questions about the item they are purchasing and any 
potential interactions with existing medication. Although CAM use amongst adult IBD patients in 
the survey population appeared to be relatively high, and there is evidence that patient records 
relating to CAM are often incomplete, community pharmacists have a limited capacity to 
intervene due to a significant proportion of non-pharmacy based purchases. 
5.2.1.2 Patient satisfaction with pharmaceutical care and pharmacy 
The overall completion rate for the patient satisfaction instrument was relatively high which 
provided a useful sample. A few surveys showed evidence of false or poorly considered responses 
indicated by an obvious pattern in responses such as all responses being placed into the same 
vertical column. As these surveys constituted a relatively small proportion of the overall sample, 
and it was not possible to objectively determine which were subject to this bias, they were 
retained in the overall sample for analysis. However this has created a weakness and potential 
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bias in the analysis. Response rates were generally higher for friendly explanation (FE) items than 
for managing therapy (MT) items and the ‘no opinion’ response was used more extensively for MT 
items compared with FE items. This was not an entirely unexpected outcome as the MT items 
related to a higher level of pharmaceutical care than FE items and a level of care which was felt 
might be less familiar to the sample population. 
The mean FE score in this study was 3.80 compared with a mean of 4.31 when the instrument was 
initially developed in a rural mid-Western American population following a specific interventional 
programme aimed at improving pharmaceutical care. [161] The mean MT score was 3.31 
compared with a mean of 3.94 obtained when the instrument was initially developed. [161]  Both 
of these examples found the mean FE score to be about 0.5 points greater than the mean MT 
score. The difference between the FE and MT scores in this study, 0.49 points, was statistically 
significant (p = 0.01). 
Interpretation of the pharmaceutical care satisfaction survey results was limited by the small size 
of the sample which constituted each dimension. Nonetheless, taken at face value, the results 
demonstrate a high degree of satisfaction with pharmaceutical care with most responses 
corresponding to either ‘very good’ or ‘excellent’. Community pharmacists and interested others 
should consider putting resources into improving satisfaction with aspects of pharmaceutical care 
which relate to MT as this is associated with statistically less satisfaction compared with FE where 
there is less overall scope for improvement. 
As well as the pharmaceutical care satisfaction instrument [161] the survey included twelve 
statements about pharmacists, pharmacies and medication. The overall impression from these 
results was less clear than that provided by the satisfaction instrument largely due to one of the 
most common responses being ‘neither agree nor disagree’. However, in general terms, the 
overall results were more positive than negative with respect to pharmacies and pharmacists. 
Statements associated with a clearer trend related to coping with medication and dialogue with 
pharmacists. Statements which related to an information role for pharmacists and the availability 
and ease of access of pharmacists demonstrated a favourable trend for the profession. One 
statement relating to patient preference for pharmacists as a source of medication information 
did not demonstrate an obvious preference. Further exploration of the barriers to IBD patients 
actually seeking information from community pharmacists was not included in the survey. 
However this was explored to a degree in the focus groups. Statements which related to a greater 
role for pharmacists in managing IBD demonstrated an overall negative agreement distribution 
although the response trend was not consistently clear or strong. Statements relating to the 
expertise of pharmacists, monitoring of the condition in community pharmacy, and the privacy or 
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suitability of the community pharmacy environment all demonstrated little obvious trend in the 
results. 
5.2.1.3 Baseline disease and demographic data 
The demographic and disease characteristics of this survey sample were broadly in-line with other 
UK-derived samples and this provides some validity to the sampling. An earlier sample from a 
similar locality was 53% female, with a mean and median age of about 50 years; 59% had 
ulcerative colitis & 35% Crohn’s disease. [2]  A postal survey of 1,900 members of Crohn’s and 
Colitis UK (a national patient charity) found that 63% were female with a mean age of 50 years; 47% 
had ulcerative colitis, 43% had Crohn’s disease, and 6% had an ‘other’ diagnosis. [37] 
5.2.2 Summary of combined survey and focus group data 
The survey and the focus groups combined were undertaken as exploratory work to identify 
whether there was a need or desire for pharmacy involvement in the management of adult IBD 
patients, and what services could be delivered. In addition some baseline data relating to current 
provision of pharmaceutical care was obtained. The evidence demonstrated that there is 
significant potential for pharmacy involvement but this may not extend to a definite clinical need. 
It would appear that, although IBD patients frequently adjust their medication, often use or show 
an interest in non-prescription medication, and may have questions relating to their medication, 
they do not perceive there to be much if any unmet need in these respects. IBD patients appear 
to be quite confident in managing their medication and use a variety of information sources. The 
extent of medication non-adherence amongst IBD patients would indicate a high degree of need 
for interventions to improve adherence. 
Evidence from the department of health integrated care pilots programme did not support 
community pharmacy involvement in models of integrated care. [108]  One of the 16 pilots 
involved screening for cardiovascular disease (CVD) in community pharmacies in Greater 
Manchester. However, uptake of pharmacy-based screening was lower than expected, and lower 
than local health checks which also included CVD screening. [223] On this basis the Tameside and 
Glossop CVD pilot ceased pharmacy-based screening during the evaluation period because of 
patient reluctance to attend for health care services at pharmacies. 1[108, 223]  There was a 
presumed patient preference for pharmacy-based screening on the basis of access and 
convenience however this was not borne out in practice and demonstrated a note of caution for 
any future pharmacy-based services delivered for the purposes of access and convenience alone. 
UK-evidence from five focus groups of patient perceptions of clinical services provided by 
community pharmacies has been published. [224] Patients were recruited from groups of young 
mothers, older persons (age 52 to 94 years) and men, all from Glasgow (UK). In general these 
191 
patients reported little knowledge of clinical services provided by community pharmacies, 
recognised a hierarchy in which pharmacists acted subserviently to GPs, and pharmacists were 
often considered to be inaccessible due to being ‘in the back’ of the dispensary. Community 
pharmacies were also seen to be compromised by overt commercial interests. Consequently, trust 
in GPs was greater than that in pharmacists and the authors suggested that gaining GP support for 
extended pharmacy services could build public trust. [224] Some of the sentiments expressed in 
these focus groups also arose in the focus groups in this study although patient trust was not 
specifically probed. This evidence is useful in highlighting the need for GP support of pharmacy-
led initiatives from the patient’s perspective, which complements findings from the professional 
and system perspective. [225, 226] 
Other evidence for the involvement of community pharmacies in the management of long-term 
conditions is provided by international experiences of initiatives focused on osteoporosis. A 
systematic review found three randomised controlled studies with, in each example, a degree of 
patient-identification or risk-stratification involved. [227] Nonetheless, the review identified 
modest benefits with increased service utilisation including medication adherence and surrogate 
measures of disease activity although the evidence base was limited and subject to bias. 
Encouragingly, each example included within the review involved a degree of integration between 
the pharmacy and other healthcare providers, most commonly the primary care medical 
practitioner. [227]  
An audit conducted by the Royal Pharmaceutical Society of Great Britain identified a role for 
community pharmacies in the early detection of bowel cancer. [228] Over 70% of 223 pharmacies 
identified at least one patient based on the inclusion criteria, which identified the potential for 
patients to discuss bowel-related symptoms with community pharmacists. This audit provided 
evidence that pharmacists are considered appropriate healthcare providers by patients with 
bowel-related symptoms. Analysis of pharmacist actions also indicated that pharmacists were 
able to adequately discern the most appropriate course of action for patients and that the 
pharmacy environment provided an opportunity for imparting health messages and advice. [228] 
Where enhanced levels of healthcare provision via community pharmacies have been utilised 
within the NHS previously a significant barrier was found to be the level to which pharmacists felt 
they were integrated within the primary healthcare team. [225] Specifically, access to patient 
information such as medical records and co-location with primary care medical professionals and 
facilities were found to substantially enhance the provision of pharmacist-led interventions. [225] 
These are aspects of care provision which should be considered and, where available, 
incorporated if pharmacy-led interventions for IBD are to be implemented successfully. 
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A Swedish study which involved patient and professional focus groups to elicit views and 
experiences related to specialist dermatological care [229] reported that all respondents, both 
patients and professionals, identified poor care and service co-ordination with the most apparent 
‘gap’ being that between community pharmacists and other providers. In addition, pharmacist 
provision of support was constrained by the lack of privacy afforded by the community pharmacy 
environment and the lack of access to a patient clinical history. [229] Again, the lessons which 
could be learnt here for any successful implementation of a community pharmacy-led 
intervention for IBD would be to ensure that pharmacists can access the relevant patient 
information and that they have appropriate facilities, especially with respect to privacy and 
confidentiality, to provide the intervention. 
5.2.3 Limitations of the community pharmacy evaluation 
The potential limitations relating to the community pharmacy evidence identified in this 
evaluation must be acknowledged. These included two consecutive steps of self-selection with 
the group of patients having first selected to join the national patient charity which was used for 
sampling and then self-selecting themselves to complete and return the survey. Thus those who 
actually responded to the survey could be distinctly different to other or general IBD populations. 
However the disease and demographic characteristics did not demonstrate gross deviations in 
those respects. [2, 37]   
Although most of the survey questions were specifically about IBD and IBD medication it is 
possible that this was not understood by respondents or in some cases respondents could not 
differentiate IBD-specific experiences from other health experiences. Additional data about non-
IBD medication use and co-morbidities was not collected so any associations of these factors 
cannot be assessed.  
Another issue was that of defining a ‘community pharmacy’ which was integral to the survey. The 
term ‘community pharmacy’ has a specific meaning in the provision of healthcare and is distinct 
from dispensing doctors, both legislatively and professionally. This aspect was considered a priori 
and consequently a bespoke lay-person definition was included on the front page of the survey. 
However respondents may have simply regarded any dispensing activity as a pharmacy and 
answered questions irrespective of whether it was a community pharmacy or dispensing doctor. 
This was not identified as an issue during pilot testing. Another concern was that some members 
of the public may not perceive a supermarket pharmacy as being a community pharmacy. 
Therefore, to further assist respondents, a distinction was made between a ‘community pharmacy’ 
and a ‘supermarket pharmacy’ even though, in both legislative and professional terms, a 
supermarket-based pharmacy is a community pharmacy. 
193 
Additional potential for misunderstandings or misinterpretation of terms used within the survey 
may also have existed. For example, two external reviewers of the survey identified the term 
‘manage’ or ‘managing’ in relation to IBD as having potentially multiple meanings or 
interpretations. Consequently a bespoke lay-person definition was added to the front page 
(appendix 4). Other definitions included on the front-page were for ‘IBD’ which was abbreviated 
throughout, and ‘monitoring’ which was also considered as having potentially multiple 
interpretations. 
With respect to the focus groups, again these were limited by multiple factors: 
• Only three groups were convened involving nine participants which constituted a small 
overall sample size. 
• None of the themes identified reached what could be considered saturation. 
• As with the survey, the sample was a self-selected group of a self-selected group.  
i.e. participants had first chosen to join the patient charity and had then volunteered to 
participate in a focus group. This particular group of patients might be unrepresentative of 
other adult IBD patients. 
• All participants were aware that the group facilitator and assistant were both registered 
pharmacists and the research was part-funded by a pharmacy research charity. Therefore a 
subtle influence due to a feeling of expectation to please cannot be ruled out. 
5.3 Reflections 
In conducting this doctoral research project I have encountered a considerable volume of new 
learning and experiences. With respect to my own conduct, I was expected to act impartially as a 
non-participant observer, aiming to exert as little influence on the project as possible. However 
this was not always achieved and may have arisen in ways so far unnoticed. 
This presented a particular issue for the project’s academic adviser who, whilst being an integral 
member of the de facto IBD pathway project board, was also my lead academic supervisor and by 
inference part of the research team. This created the incongruous position whereby I was 
evaluating my own supervisor’s role in the pathway. In the event this dichotomous relationship 
did not appear to have a negative impact either within the research team or with the project 
board. 
A similar albeit less overt and conflicting relationship arose in my interactions with patient 
representatives, particularly the chief executive of the patient organisation to which all three 
were allied. The patient organisation had provided substantial funding to the evaluation of the 
pathway which would lead to me having to, in part, evaluate the actions of an organisation which 
had contributed to my academic funding. In addition the patient organisation would have 
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influence over the evaluation. In the event this did not present any significant or obvious barriers. 
On a few occasions I was requested to provide brief and informal updates to the patient 
organisation with respect to the progress of the project. These were honestly presented and well-
received. 
Towards the end of the evaluation observation period a new relationship emerged between a 
member of the project board (B) and the University when the consultant gastroenterologist was 
appointed as an honorary lecturer. However this appointment appeared to have arisen through 
separate relationships between these parties and did not present any obvious conflicts in 
conducting the evaluation. The gastroenterologist did not have any involvement in the evaluation 
other than via his role on the project board and as part of the hospital IBD team. 
Other professional relationships existed and developed between myself and members of the 
project board & other actors within the scope of the evaluation, as might be expected for a 
relatively small team working together over a protracted period of time. For these reasons it 
would not be accurate to claim that the evaluation process was wholly independent of the subject 
under evaluation. However, neither would it be an accurate reflection to describe the evaluation 
as subject to undue internal influences or bias. Despite the various overt and subtle relationships 
that existed between the various parties the evaluation was largely independent of the IBD 
project under scrutiny. 
As to whether I was able to maintain the desired outcome of non-participation, again in the main 
this was the case however there were examples where I strayed from these bounds. In one 
example, after specific questions had been directed during a project board meeting, I delivered a 
frank and honest summary of the project management up to that point. The effect of this report 
to the project manager was immediately apparent and there followed a noticeable upshift in 
project management activities and practice recruitment. General project management functions, 
particularly in relation to managing board meetings, also improved. My intervention was an 
example of a researcher moving beyond the non-participant observer role. Other examples 
included provision of advice to the second project management team which related to the 
previous phase of project management and included provision of some project documents. More 
subtly, I engaged in numerous conversations outside of the formal project meetings where the 
project was discussed in more liberal terms however on each occasion comments remained 
tactful and considered. More obvious were meetings with my lead supervisor during which the 
project was often discussed in frank terms. I also undertook more active roles with the hospital 
patient panel, a group which counted two project board members within its membership. 
However the influence of the panel on the project board was itself somewhat limited and passive. 
On each occasion that I undertook activity which could exert influence it was considered and 
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undertaken in full recognition of the potential impact on the evaluation and the project. My 
experiences up to the end of the evaluation observation period indicated that my judgments were 
fair. 
A more significant reflection is that the evaluation plan had been designed primarily to collect 
outcomes, and the contextual affecters of them, from the operation of the IBD pathway. In 
hindsight it was optimistic to expect that such a pathway could be designed by multiple agents, 
implemented across a defined health economy with multiple agents (GP practices, GPs, nurses, 
and hospital services), and be operationalised to such an extent that the desired outcomes could 
be identified within the time frame available. In the event the evaluation, even with an extended 
observation period, was only able to evaluate the pathway design and implementation phases 
with little relating to its operationalisation. This subtle but important change in focus of the 
evaluation could have been identified at an earlier point in time and plans amended accordingly, 
focusing exclusively on the design and implementation phases. This could in turn have negated 
the use of patient focus groups which proved limited in the information revealed. The outcomes 
of the evaluation and the extent of pathway ‘success’ should therefore be considered in the 
context of reasonable timeframes for such projects. In that respect, the pathway was designed 
and implemented, largely from scratch, in less than two years. Outcomes relating to healthcare 
utilisation and associated with the operational phase of the pathway would only appear at a later 
point in time and after a significant time lag. This would appear to be consistent with other 
evaluations of projects of health system changes. 
The patient focus group conducted within the context of the pathway evaluation was 
disappointing. Although it may appear that little useful information about the actual impact of the 
pathway was obtained, seemingly because it had had no impact and many of the participants had 
no knowledge of it, this was itself a useful finding. But that finding was perhaps a poor return for 
the efforts of both the researchers and crucially the participants, and this could have been 
elucidated by other means. Other findings from the focus group, whilst interesting and 
enlightening concerning the local management of IBD and real patient experiences, were not of 
direct relevance to the evaluation. 
With respect to data collection, one important strand was the collection of all relevant electronic 
mail communications for analysis. I had made an explicit request to be copied into all such 
communications so that a complete record could be created. However, reference to specific 
communications at various meetings indicated there was a volume of potentially useful 
correspondence that I was not party to. Therefore the collection of e-mails as an important source 
of data was incomplete and the extent of the missing data is unknown. An additional 
consideration is my notes relating to project board meetings. The project board meetings were 
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important events during the evaluation however several were not supported by any official 
minutes or notes and when such were available they were often scant in detail. Therefore my 
notes became the primary record of these meetings however this left them open to significant 
subjective and unvalidated interpretation. 
With respect to conducting the pharmacy-oriented research component of the doctoral research 
project, a number of specific learning experiences were gained. Firstly there were practical 
learning aspects such as designing and constructing a postal survey, and conducting patient focus 
groups. In addition, the pharmacy component provided a first experience of dealing with a 
research ethics application and committee. This provided experience in learning the practical and 
theoretical steps required to ensure a successful application. Particular consideration had to be 
given to the course of actions that would ensue if a focus group participant subsequently decided 
to withdraw. This was an interesting conundrum which was considered with the co-operation of 
the research ethics committee chair. The likelihood of such an occurrence, its implications on the 
overall research, and dealing with it in a practicable way were all considered. 
The pharmacy project also provided a salutary experience in dealing with one’s own prior 
assumptions about a defined population, in this case members of a patient organisation. It had 
been assumed that all (adult) members of the local branch of the national patient charity:  
• Resided in the locality 
• Were themselves a current adult IBD patient 
This second assumption, although apparently true for the majority, was found to be erroneous 
due to a number of reasons, specifically:  
• Proxy patient members, such as parents taking membership as a proxy for a child with IBD 
• Healthcare professional members, such as nurses and dieticians 
• Members who had been effectively surgically cured of IBD and were therefore no longer 
an IBD patient but who retained membership of the group 
My own professional experiences of working within community pharmacy inhibited a full 
consideration of some aspects of being an IBD patient such as receiving medicines from hospitals, 
having medicines administered in hospital, and receiving items other than medicines (e.g. medical 
devices, dressings or appliances) on prescription. This expressed itself in subtle ways for example 
in the construct of some questions both in the survey and focus groups, but was only realised 
during data analysis. On a purely technical basis, an error was made in collecting postal code data 
and linking this to other post code-sensitive data sets. 
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With respect to the pharmacy focus groups, these provided a useful learning experience both 
within the pharmacy project but also in preparation for the focus groups which was subsequently 
undertaken within the IBD pathway evaluation. Within the pharmacy project there was a clear 
and steep learning curve from the first to the third (final) focus group convened. In the first focus 
group I, as the facilitator, accounted for a significant proportion of the conversation. This may 
have been in part due to the particular participants of that group and because only two 
individuals were present. With the second group, which consisted of five participants, I ensured 
that all participants had a fair and equal opportunity to contribute even if they did not wish to 
exercise it. In the third focus group, also with two individuals, I felt more relaxed and allowed the 
conversation between participants to flow more easily and extensively. I was still able to subtly 
incorporate the desired questions and topics into the general conversation. In particular, with the 
first focus group the service scenarios were presented in a formal and step-wise manner with 
printed guides shown to participants in a similar fashion to a slide presentation. At subsequent 
focus groups the scenarios were more subtly introduced and were not formally presented in this 
way. 
Working with the local branch of the patient charity was rewarding. The response rate to the 
survey was about 20% greater, in absolute terms, than anticipated which was welcome especially 
as it was distributed at a busy period of the year and at a time when many people are away. 
However the response rate could support an argument that the sample or target population was 
in some way unrepresentative. By comparison a contemporary survey which was also about 
medicines, and included questions of similar construct, posted to 5,900 members of a national 
IBD patient charity achieved a response rate of 32%. [37] However the initial interest in focus 
groups was relatively low and fewer individuals followed up that initial interest by making 
arrangements for a focus group, and fewer again actually participated in a focus group. The 
reasons for this lack of interest and attrition were not clear and it is an area to consider for further 
improvement should similar research be conducted in the future. 
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Chapter 6: Conclusion 
6.1 The IBD integrated care pathway 
Whether the IBD integrated care pathway was successful or should not be answered with a simple 
‘yes’ or ‘no’.  The process under evaluation included the design, implementation and operational 
phases of the pathway and each should be considered on its own merits. 
With respect to the design, the project can be considered to have been successful as a pathway 
was designed which was acceptable to all parties, concordant with the IBD Standards, and which 
was founded on clinical evidence and relevant experience from an earlier project. The pathway 
design underwent much refinement during the evaluation. Some specific products required to 
ensure that the designed project could be operated were, however, not delivered. 
With respect to implementation the pathway appeared, superficially at least, to have been 
successful with almost all eligible practices making an explicit and affirmative choice to 
participate. The majority of practices and many primary care health professionals attended a 
training and education session. However behind these headline figures lie details which 
demonstrated that the pathway launch was delayed, practice participation took longer than 
expected, that although agreement for participation had been secured actual pathway-related 
activity appeared to be much less, and there were some deficiencies in the training and education 
sessions. 
With respect to the operational phase of the pathway, initial results would appear to indicate that 
only a small volume of the expected work had been delivered and that communication between 
clinical teams across the interface had not been effective. In addition, certain aspects of the 
pathway did not appear to be operating as intended and communication about the project to 
patients was poor or non-existent. Consequently none of the expected health service benefits 
from the pathway, such as reduced admissions and burden of disease, could be identified. 
However success must be considered alongside temporal parameters. For example, the problems 
with the operation of the pathway may, in the longer term, transpire to be mere ‘teething 
problems’ but only observation for a longer period of time will reveal which. 
Objectively, the IBD pathway did not deliver a significant degree of integration. The area in which 
it had the greatest potential to deliver a more tangible level of integration, informatic integration, 
appeared not to have been realised in the pathway’s operation, or at least not in the early stages 
of operation observed by this evaluation. However, the pathway did deliver integrated care, as 
opposed to integration, in more subtle ways. Integrated care for IBD patients might not 
necessarily result in the removal of boundaries but easier and clearer negotiation across the 
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primary and secondary care interface. In this respect the pathway can be considered to have 
delivered integrated care although there was still plenty of scope left for further gains. Examples 
of attainment of integrated care were the stipulation of deadlines for access to specialist care, 
expanded access to the IBD specialist nurse including the introduction of novel modes of 
communication to the hospital IBD team, and standardisation of a key component of care through 
consistent application of the annual review in both primary and secondary care.  
A less tangible, but no less important, aspect of integrated care which the pathway did generate 
was greater communication between primary and secondary care clinicians. The project board 
could serve as the basis for a local IBD clinical network. Both primary and secondary care clinicians 
reported, anecdotally, improved levels of, and confidence with, communicating with their 
colleagues in the alternative sector. This could serve as the foundation to realising more 
observable and tangible levels of integration or integrated care. However, the conclusion of the 
impact of the pathway on integrated care at the close of the evaluation was that it was limited in 
scope and extent and few of the pre-existing barriers had been noticeably influenced. 
The involvement of clinicians in key roles within the pathway design process can reasonably lead 
to the pathway being described as clinically led. The empowerment of clinicians was not uniform 
with primary care clinicians (GPs and practice nurses) appearing to gain more in this respect than 
hospital-based clinicians both empirically and through the pathway itself. 
Overall, the pathway did address directly and indirectly a significant number of the IBD Standards, 
either wholly or partially. However, in the main this appeared fortuitous, and seldom were the 
IBD Standards explicitly referred to during the discussion of the finer details of the pathway 
design. Crucially, however, no part of the pathway was in direct conflict with any of the IBD 
Standards. As the connection between the pathway and the IBD Standards was more implicit than 
explicit linking project components and milestones to specific standards may be useful to 
reinforce that connection and to maintain focus and engagement for the project. 
The overall impression of the pathway at the point of the evaluation close was one of unfulfilled 
potential and underachievement. That is not to say that it won’t achieve its full potential and 
deliver its implied objectives in the longer term, but the project was beset by a number of small 
and subtle challenges which collectively served to delay and inhibit successful operation at the 
point of the evaluation close. 
The fundamental shortcomings were a lack of leadership, strategic direction, and proper project 
management. Crucially the project lacked a set of explicitly defined, consistent and agreed aims or 
objectives. It is difficult to deliver a project where members of the project board are not 
necessarily working to the same or an agreed agenda. A key aim for the project for some 
members of the project board was a reduction in hospital admissions with an attendant reduction 
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in healthcare expenditure. However the basis for the assumed reductions in admission rates was 
not provided and is best be described as aspirational than founded in any reliable evidence-base. 
However, despite some crucial and fundamental problems with the project set-up, the project 
survived and did deliver a pathway which could reasonably be considered to meet the minimum 
specification, albeit significantly behind schedule and to a lesser specification that had been 
envisaged at earlier stages of the project.  
Some of the challenges which the project experienced were of its own making and some would 
have been difficult to foresee. However a lack of a project plan and active, robust project 
management meant that the project neither identified nor coped as well as it could have. 
Individually, each of these challenges was of a relatively small impact but the cumulative effects 
led to a significant impact.  
The project was not obviously beset by protectionist behaviour from any party, or personal 
disagreements between members of the project board. Although the end-of-evaluation 
interviews did reveal some organisational tensions of limited extent these did not appear to 
impair the project.  
Occasionally brief episodes of tension relating to clinical or care parameters did emerge but these 
were negotiated amenably by all parties. This should be seen as a major strength of the project as 
it was not afflicted by one of the recognised organisational barriers to integrated care. The 
general feeling generated by the project board was one of genuine co-operation and partnership 
between parties. It was not clear if this cordiality would have been maintained had the project 
moved into a more active and broader operational phase where organisational tensions may have 
become more overt. 
At the end of the evaluation the pathway was in a strong position to deliver its implied aims and 
objectives, not least with the appointment of a clinical champion who appeared to possess useful 
attributes to perform such a role. However, the fundamental deficits identified would still need 
resolution and the project board should plan for future challenges, particularly those relating to 
further reorganisations within the local and national NHS. 
Validation of the findings of the IBD pathway project can be inferred from the common findings 
not just with the Department of Health evaluation but with the wider healthcare-change research 
field. 
6.2 Community pharmacy 
The overall impression from the focus groups was that pharmacists and pharmacies were well 
regarded and respected, although some issues existed regarding the pharmacy environment. IBD 
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presented several barriers to patients interacting with community pharmacists in pharmacies. 
Issues relating to medication were common and may often present subtly. 
The evaluation identified that there is some scope for community pharmacists and community 
pharmacy as a whole to become more involved with the management of IBD in adult patients. 
Pharmacy-based services for IBD patients should be introduced cautiously and initially at a basic 
level. There was a substantial potential unmet need in the care of IBD patients with respect to 
medications and drugs as indicated by the survey responses. However the level of involvement 
may need to vary considerably between patients with some not requiring or not feeling 
comfortable with community pharmacist involvement and others very comfortable. Pharmacists 
could offer a range of services for patients to choose from. Service developments will need co-
operation from general medical practitioners and local specialist IBD teams, which are usually 
hospital based. Pharmacists can build on a number of positive aspects relating to the profession 
and existing facilities. Pharmacies may need to improve infrastructure, primarily through 
provision of adequate private consultation facilities, in order to deliver some services for adult IBD 
patients. Pharmacists must be sensitive to the specific needs and requirements of IBD patients. 
The healthcare system should seek to improve community pharmacy integration with other 
primary and secondary healthcare service providers, particularly in the domain of information 
sharing. 
6.3 Integrated care and community pharmacy: Combined findings 
If the IBD integrated care pathway project is to be supported in the longer term then it could 
develop to include a role for community pharmacy as described. However the position of the 
pathway at the time of the evaluation close did not support further complexity and uncertainty 
with expansion to include novel service delivery with community pharmacy. 
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6.4 Closing statement 
As at the evaluation close in March 2012 the IBD integrated care pathway project had overcome 
several barriers, challenges and internal deficiencies. It was in the strongest position it had been 
during its history and crucial to this was the appointment of a clinical leader for the project. 
However, effort, communication and networks will need to be maintained and developed if the 
project is to realise its aims of improved patient outcomes, satisfaction, and reduced healthcare 
utilisation. Additional resources, especially in continued project management and oversight, will 
likely also be required. A dynamic balance between separate but not necessarily independent 
enabling and inhibitory factors is determined by complex interactions. New and unexpected 
challenges may appear and change processes need to be resilient or opportunistic depending on 
the nature of the challenges faced. 
Change within a large and complex healthcare system is achievable but most likely at a slower 
rate and in a different direction to that which was planned or expected. 
William Horsley. April 2015. 
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Appendices 
Appendix 1. Final specification of the IBD annual review summary 
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Appendix 2. ICD-10 codes relevant to IBD 
Non-infective enteritis and colitis (K50-K52) 
K50. Crohn's disease [regional enteritis], incl. granulomatous enteritis, but excl. ulcerative colitis 
K50.0 Crohn's disease of small intestine, incl. Crohn's disease [regional enteritis] of duodenum, 
ileum, jejunum, Ileitis: regional, terminal; but excl. Crohn's disease of large intestine 
K50.1 Crohn's disease of large intestine, incl. colitis; granulomatous, regional Crohn's disease 
[regional enteritis] of colon, large bowel, or rectum; but excl.  Crohn's disease of small 
intestine 
K50.8 Other Crohn's disease, incl. Crohn's disease of both small and large intestine 
K50.9 Crohn's disease, unspecified, incl. regional enteritis not otherwise specified 
K51. Ulcerative colitis 
K51.0 Ulcerative (chronic) pancolitis, incl. backwash ileitis 
K51.2 Ulcerative (chronic) proctitis 
K51.3 Ulcerative (chronic) rectosigmoiditis 
K51.4 Inflammatory polyps 
K51.5 Left sided colitis, incl. left hemicolitis 
K51.8 Other ulcerative colitis 
K51.9 Ulcerative colitis, unspecified 
K52. Other non-infective gastroenteritis and colitis 
K52.3 Indeterminate colitis 
K52.8 Other specified non-infective gastroenteritis and colitis, incl. collagenous colitis, 
eosinophilic gastritis or gastroenteritis, lymphocytic colitis, microscopic colitis (collagenous 
colitis or lymphocytic colitis) 
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Appendix 3. Participant information sheet for Focus Groups – pathway 
evaluation 
An Integrated Care Pathway for patients with Inflammatory Bowel Disease 
We would like to invite you to take part in a research study which is evaluating the [redacted] integrated 
care pathway for patients with inflammatory bowel disease (IBD). Before you decide whether to participate 
you need to understand why the research is being done and what it would involve for you. 
Please take time to read the following information carefully. Talk to others about the study if you wish, 
especially your friends and family, fellow IBD patients, advisers from Crohn’s & Colitis UK and your doctor & 
nurse. 
This information leaflet will provide you with details of the purpose of the study and what will happen to 
you if decide to take part. Please do not hesitate to ask us if there is anything that is not clear or if you 
would like more information.  Take time to decide whether or not you wish to take part. If you do wish to 
take part then there is a consent form for you to complete and return to us. We have provided a stamped 
addressed envelope to return it in if you do decide to participate. 
What is the purpose of the study? 
The [redacted] IBD pathway is the first example in the UK of such a package of care being delivered for IBD 
patients. The pathway is designed to deliver the service standards for IBD healthcare which were published 
in 2009. We will be evaluating the pathway to determine what factors influence its success or otherwise, as 
well as measuring any changes in use of healthcare and health outcomes. 
An important part of the evaluation is to find out what the impact of the pathway is on patients with IBD. 
This is important information to obtain so that if other areas in the UK which wish to introduce a similar 
pathway for their IBD patients they will have extra information available and might do things differently. 
We would like to speak with IBD patients in [redacted] and conduct group interviews with five or six 
patients at a time. These are known as focus groups. 
Why have I been invited? 
You have been invited to take part because you are an IBD patient from one of the participating medical 
practices in [redacted]. This information leaflet, along with the introductory letter and consent forms, have 
been sent to you directly from your medical practice on behalf of the research team so your confidential 
details have not been shared with us. It is possible that more people will volunteer to take part in the focus 
groups than are required. If that happens then we will write to everyone who has volunteered and let them 
know whether we would like them to participate or not. 
What will I have to do? 
You are being invited to take part in a focus group with four to five other IBD patients from [redacted]. In 
the focus groups you will be able to discuss your experiences of care for IBD both before and after the 
introduction of the new care pathway. We anticipate that each session will last up to two hours. Sessions 
will take place at a time that is convenient for all participants, so this could mean possibly an evening or a 
weekend. The sessions will take place at Durham University’s Stockton Campus near the Tees Barrage and 
transport assistance is provided. 
What will happen to me if I take part? 
We are keen to obtain your frank and honest views about the topics discussed. We can assure you anything 
that happens in the sessions will be anonymous and confidential, and nothing that is said will be passed on 
to anyone else in a way that will identify you. However we would also like you to regard any information 
discussed by other participants as confidential. 
We will make a sound recording of the focus groups so we don’t miss any important information when we 
write reports on them. After the focus groups we will copy what is said into a typed document and then 
delete the sound recording. Each focus group will be directed by the lead researcher, Mr William Horsley. 
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He will also have an assistant present to make brief notes during the session and to arrange the sound 
recording. 
Following each focus group there will be a period during which you will be free to ask further questions or 
discuss other issues relevant to the topics discussed with the person running the group or their assistant. 
These discussions will not be recorded at all. We will do our best to provide any further information that 
you request at that time. 
What are the possible benefits of taking part? 
The focus group will provide you with an opportunity to share your experiences and listen to the 
experiences and views of other people with IBD. 
We can’t promise you that your participation in a focus group will help you individually but the information 
we get could help improve the introduction of similar care pathways for IBD patients in other parts of the 
UK, or indeed it might help shape the future of the [redacted] pathway. 
Do I have to take part? 
Participation in these focus groups is entirely voluntary and it is up to you to decide if you take part. After 
you have read this information sheet, if you still want to participate, please complete the consent form and 
sign it to show that you have agreed to take part. There is a copy of the consent form for you to keep with 
this information sheet. 
Of course, if we have more people volunteering to take part than we require for the focus groups then 
unfortunately some people will not be able to take part in a focus group. We will inform you at the earliest 
opportunity whether you will be required for a focus group, but if you are not required at first we would be 
grateful if you could act as a reserve participant in case someone else drops out. 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw at any time, without giving a reason. This will not affect the care you receive or 
your registration with your general practice or membership of Crohn’s & Colitis UK (if applicable). If you 
decide to withdraw after a focus group has started then anything you say up until the point of withdrawal 
will be kept and used as part of the analysis for this study. 
If you do change your mind and decide not to attend the focus group for any reason, please let us know as 
soon as possible because we may be able to find a replacement. 
Will my taking part in the study be kept confidential? 
Yes. The only people who will know that you have taken part will be the research team and the other 
patients who participate in the same focus group as you. The research team will not share your details with 
anyone else and all reports of the sessions will be anonymous. The discussion at the focus group will be 
recorded and typed up, but your name will not be put on the transcript. Participants will be asked to keep 
everything that is discussed in the focus group confidential; however it is possible that members of the 
focus group may discuss what happened at the group with, for example, members of their family; therefore 
absolute confidentiality cannot be guaranteed. The only information that we will keep is a consent form 
which you will be required to fill in. This will be kept in a locked cabinet within Durham University and will 
not be accessible to anyone outside of the research team. 
What will happen to the results of the research study? 
We intend to write up the results of our overall evaluation of the care pathway in 2012. The focus groups 
will be included within that overall evaluation but they may also be reported separately either before or 
after that. We will publish results of the evaluation in an academic journal and we will share our findings at 
academic conferences. In publishing details of the focus groups we may wish to quote statements, 
comments or conversations that occurred, although as with all details they will be anonymous. The 
research team will be happy to provide copies of these reports on request, and discuss and explain them if 
required. 
Will it cost me anything to take part? 
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No, but we are asking you to give up some of your time. The focus group sessions will be held at Durham 
University’s Stockton Campus with facilities that are accessible to all.  
If you require help with transport we can arrange for taxis, and if you make your own transport 
arrangements we will reimburse the cost. Parking at the site is free. We will also provide some light 
refreshments. You will be handed an expense claim form to complete when you arrive and we will aim to 
reimburse you with cash on the same day. If you prefer we can send a cheque to you instead. 
Will my GP or consultant or nurse be involved? 
No. No one other than you, the research team and the other patients in the group will know that you have 
taken part. All reports from the focus groups will be anonymous. Of course, if you wish to tell people that 
you took part in a focus group then you are free to do so. 
Who is organising and funding the research? 
This research is funded by Crohn’s & Colitis UK, also known as the National Association for Colitis & Crohn’s 
Disease (NACC), a leading charity for patients with IBD and their families. The lead researcher is William 
Horsley, a researcher at Durham University. 
Who has reviewed the study? 
This research has been approved by the Research Ethics Committee at Durham University and by the NHS 
National Research Ethics Service Committee East Midlands – Derby 2. 
Harm 
We do not foresee anything harmful happening to you in the focus groups, which you are free to leave at 
any time.  If talking about your condition or anything else that arises makes you upset in any way we will 
make sure someone is able to offer you help at the earliest opportunity. If you wish to speak to someone 
confidentially after the focus group then you can contact Dr Greg Rubin on 0191 33 40031. 
Is there any reason why I shouldn’t take part? 
This invitation is only open to persons aged 18 years or older at the time of providing consent to participate. 
In addition, you should have a diagnosis of ulcerative colitis or Crohn’s disease, both forms of inflammatory 
bowel disease. 
What if there is a problem? 
We will be following all appropriate ethical and legal practice and all information about you will be handled 
in confidence. 
If you have a concern about any aspect of this study you should in the first instance contact the lead 
researcher who will do his best to answer your questions and address your concerns: William Horsley on 
0191 33 40804, or E-mail: william.horsley@durham.ac.uk 
If you remain unhappy and you still have concerns then you can contact: 
Rebecca Perrett 
Research and Development Manager 
Wolfson Research Institute, Durham University, Queen's Campus, Stockton-on-Tees,  
TS17 6BH. Tel: 0191 334 0425.  E-mail:   rebecca.perrett@durham.ac.uk 
Further information and contact details  
If you would like any more information or if you would like to discuss anything verbally or in person please 
contact the lead researcher, Mr William Horsley, on 0191 33 40804,  
or E-mail: william.horsley@durham.ac.uk  
Please keep this information sheet and one copy of the consent form for your records. 
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Appendix 4. IBD patient pharmacy survey 
  
 
209 
  
210 
  
211 
  
212 
Appendix 5. Introductory letter accompanying pharmacy survey 
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Appendix 6. Focus group (pharmacy) notice of interest response card 
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Appendix 7. Focus group (pharmacy) introductory response letter 
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Appendix 8. Focus group (pharmacy) consent form 
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Appendix 9. Focus group (pharmacy) scenarios 
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Appendix 10. Participant information sheet for Focus Groups (pharmacy) 
Community pharmacy and management of IBD 
We would like to invite you to take part in a research study on whether there is a role for community 
pharmacy in the management of patients with inflammatory bowel disease (IBD). Before you decide 
whether to participate you need to understand why the research is being done and what it would involve 
for you. 
Please take time to read the following information carefully. Talk to others about the study if you wish, 
especially fellow members of Crohn’s & Colitis UK (formerly the National Association for Colitis and Crohn’s 
Disease, NACC).  This information leaflet will provide you with details of the purpose of the study and what 
will happen to you if you take part. Please do not hesitate to ask us if there is anything that is not clear or if 
you would like more information.  Take time to decide whether or not you wish to take part. If you do wish 
to take part then there is a consent form for you to complete and return to us. We have provided a 
stamped addressed envelope to return it in if you do decide to participate. 
What is the purpose of the study? 
The study aims to discover if there is any need or desire from patients with IBD for their community 
pharmacy, including community pharmacists and other staff, to be involved in the management of their 
condition. The study will also explore what that role might be. 
If the results do indicate that there is a role for community pharmacy then this could result in pharmacies 
offering specific services in the future. Of course, there might not be any need for community pharmacy to 
be involved, or any desire from patients for community pharmacy to be involved, and we would report this 
message in our research findings. 
You may have already completed a short survey about the extent, nature and your perceptions of contact 
between you and your community pharmacy. The survey results will be combined with the results of these 
group interviews in one study which will show whether IBD patients have any need or desire for specific 
services from their community pharmacies and, if applicable, what those services could be. 
Why have I been invited? 
Working with the [redacted] branch of Crohn’s & Colitis UK and building on the close links between our 
research team and Crohn’s & Colitis UK, we are inviting members to take part in interviews in groups of five 
or six. These are known as focus group interviews.  
As a member of Crohn’s & Colitis UK we have assumed that you have a form of inflammatory bowel disease. 
We would like to seek your views about the extent and nature of contact that you have with your 
community pharmacy and to explore some potential roles and tasks that could be undertaken by 
community pharmacies and pharmacists in the management of IBD. 
Do I have to take part? 
Participation in focus groups is entirely voluntary and it is up to you to decide.  Once you have read this 
information sheet, if you do wish to participate please complete the consent form and sign it to show that 
you have agreed to take part.  You are free to withdraw at anytime without giving a reason.  This would not 
affect the care you receive or your membership of Crohn’s & Colitis UK. There is a copy of the consent form 
for you to keep with this information sheet. It is possible that we might have more people wishing to 
participate in the focus groups than we need. If you are not chosen to participate we will contact you to 
inform you of this. 
What will I have to do? 
You are being asked to take part in a focus group with four to five other people with IBD and also members 
of Crohn’s & Colitis UK. In the focus group you will be able to discuss your experiences of community 
pharmacy, how you perceive community pharmacy services, and what you would think if community 
pharmacies were to provide some additional services for IBD patients. We anticipate the discussion lasting 
up to two hours. The sessions will take place at a time that is convenient for all participants, so this could 
mean possibly an evening or a weekend. The sessions will take place at Durham University’s Stockton 
Campus near the Tees Barrage. 
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What will happen to me if I take part? 
We are keen to obtain your frank and honest views about the topics discussed. We can assure you that 
everything that happens in the sessions will be anonymous and confidential, and nothing that is said will be 
passed on to anyone else in a way that will identify you.  However we would also like you to regard any 
information discussed by other participants as confidential.  
We will make a sound recording of the focus groups in order not to miss any important information when 
we write reports on them. Soon after the interviews we will copy what is said into a typed document and 
then delete the sound recording entirely. The group interviews will be directed by the lead researcher, Mr 
William Horsley. He will also have an assistant present to make brief notes during the session and to 
arrange the sound recording. 
We will be pleased to make these reports available to you once they are finished and we hope to be able to 
present the study to your local group at some point in the future.  
Following the group interview there will be a period during which you will be free to ask further questions 
or discuss other issues relevant to the interviews with the person running the group or their assistant. 
These discussions will not be recorded at all. We will do our best to provide any further information that 
you request at that time. 
What are the possible benefits of taking part? 
We cannot promise the study will help you individually, but the information we get from it could help 
improve the range of services available for IBD patients from community pharmacies. The focus group will 
provide you with an opportunity to share your experiences and listen to the experiences and views of other 
people with IBD. 
Will my taking part in the study be kept confidential? 
Yes. The only people who will know that you have taken part will be the research team and the other 
persons who participate in the same group interview as you. The research team will not share your details 
with anyone else, including Crohn’s & Colitis UK, and all reports of the sessions will be anonymous. The 
discussion at the focus group will be recorded and typed up, but your name will not be put on the 
transcript, only what was said. Participants will be asked to keep everything that is discussed in the focus 
group confidential; however it is possible that members of the focus group may discuss what happened at 
the group with, for example, members of their family; therefore absolute confidentiality cannot be 
guaranteed. The recordings of the interview will be provided to a professional transcription service that will 
type a transcript of the recording and will be bound by a confidentiality agreement. 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw at any time without giving a reason and your future care and membership of 
Crohn’s & Colitis UK will not be affected in any way.  If you do change your mind and decide not to attend 
the focus group for any reason, please let us know as soon as possible because we may be able to find a 
replacement. If you withdraw during or after a focus group we will do our best to remove your data and 
comments from reports but this might not always be possible. 
What will happen to the results of the research study? 
We intend to write up the results of our study in 2011 and to publish them afterwards in an academic 
journal. We will share our findings at academic conferences with colleagues who will be interested the 
study. We are also offering to present the results to your local Crohn’s & Colitis UK branch. 
Will it cost me anything to take part? 
No, but we are asking you to give up some of your time. There is free parking at Durham University’s 
Stockton Campus. The facilities are accessible to all. If you require help with transport we can arrange for 
taxis, and if you make your own transport arrangements we will reimburse the cost. We will also provide 
some light refreshments. You will be handed an expense claim form to complete when you arrive and we 
will aim to reimburse you with cash on the same day. If you prefer we can send a cheque to you instead. 
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Will my local community pharmacy or pharmacist be involved? 
No community pharmacies or pharmacists are aware that this research is being conducted locally and they 
will not be involved. However when the research is eventually published they will have access to the same 
information as everyone else, which will be the published reports. They will not be able to identify any 
participants. 
Who is organising and funding the research? 
We are working with Crohn’s and Colitis UK (formerly NACC) to help us identify people who might have a 
diagnosis of IBD and who are willing to participate in this type of research.  
The research is being organised by William Horsley, a pharmacist and researcher at Durham University. He 
will be supported by colleagues at Durham University and also from Sunderland University. The research is 
funded by the Pharmacy Practice Research Trust (www.pprt.org.uk), which is a charity that specifically 
funds research into community pharmacy and related topics. However none of the research team are 
community pharmacists themselves and none have a vested interest or bias towards community pharmacy. 
Who has reviewed the study? 
This research has been approved by the Research Ethics Committee at Durham University to protect your 
safety, rights, well-being and dignity. The study has the support of Crohn’s & Colitis UK. The lead supervisor, 
Professor Greg Rubin, is an experienced and well-respected researcher in the field of IBD and 
gastroenterology and has worked with Crohn’s & Colitis UK (formerly NACC) for many years. 
Please keep a copy of this information sheet and the consent form for your records. 
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Appendix 11. Practice IBD pathway agreement 
Local Audit Agreement 
 
Integrated Care Pathway 
for 
Inflammatory Bowel Disease  
 
Background 
Through a collaboration between [redacted: PCT, hospital trust, patient organisation], an integrated 
care pathway for patients with inflammatory bowel disease, a UK first, is being established in 
[redacted: locality]. There is evidence that suggests integration can be an effective way of 
delivering health care and that it can provide opportunities to break down barriers between primary 
and secondary health care, as well as health and social care.  The pathway builds on current 
research, funded by the Health Foundation, to develop quality criteria for IBD care in general 
practice. This has resulted a structured review template which was piloted in 5 North East practices 
in 2009. The care pathway to be used in [redacted: locality] utilises this template and also follows 
closely the recommendations of the DH National Standards of Care for IBD (2009). This initiative 
will be evaluated by a research team at Durham University. 
 
Aim 
 
By auditing the care for patients with inflammatory bowel disease, the aim is to build upon current 
good practice and to develop an integrated model of care. This will ensure that individuals with IBD 
have high quality and appropriate management at all stages of their illness. Practices will be 
provided with support to develop their knowledge and skills base for IBD management 
 
Contract Details 
 
Application from practices will receive notification of agreement from the PCT lead within 7 working 
days of sending the completed application. 
 
For information the average number of patients with IBD is 9 per 1000 registered population. The 
practice will be required to submit an estimated number of records to be reviewed based on this 
average against their registered list size as of September 2010. 
 
The practice is required to complete the attached signature sheet in order to participate. The 
anticipated number of records to be reviewed is required to be submitted as part of the application 
and this will be reviewed and agreed by the PCT Lead for IBD. A variance of 10% against this 
anticipated activity will be accepted but any further variance to this must be discussed and agreed 
with the IBD Lead during the contract period. Please note failure to complete the anticipated 
number of records reviews (without a timely agreement) may incur adjustment of the registration 
payment (see below). 
 
Termination of the contract by either party will require a minimum 3 months notice period, however 
the PCT reserves the right to terminate this contact immediately if there is evidence that the terms 
of this specification are not being met. 
 
(continued on next page) 
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Payments 
 
A registration payment of £120 will be paid on submission of the attached signature sheet and 
following agreement of activity by the PCT Lead for IBD.  
 
A total payment of £380 to support e-learning activities for one GP and  the participation of one 
practice nurse in 2 training sessions per year provided by the IBD nurse. This money will provide 
funding for back fill for nurse time if it is a lunch time or half day session. £100 will be paid on 
receipt of an electronic certificate of learning being provide by the GP following successful 
completion of an online module and £280 will be paid following nurse attendance at one of the 
nurse training sessions. Certificates should be forwarded to [redacted] 
 
A payment of £35 per patient reviewed against the completed audit template will be made on 
receipt of satisfactory submission. The payment of £35 will be broken down into two parts £15 for 
validation of the register by the clinician and £20 for the subsequent nursing review. 
 
Requirements for the IBD Audit. 
 
Practices must conduct a review of all their patients with IBD. 
 
In this review practices will be asked to: 
 
• Complete the audit template to comply with the accompanying requirements. 
• Review and discuss at a practice meeting the completed template prior to submission 
• Patients who have died or who have moved away should be excluded. 
 
Reporting Requirements 
 
• Reports must be submitted electronically using the audit template. The template must be 
fully completed for each patient. 
 
• Where requested, practices must be prepared to discuss the results of the review with the 
IBD lead or the project manager 
 
• Participating practices must be prepared to share their returns with the researchers 
undertaking an evaluation of this initiative (the team is based at Durham University School 
of Medicine and Health and is headed by Professor Greg Rubin) 
 
Guidance on Using the Audit template 
 
The template has been designed to be as straight forward as possible. The information required is 
detailed at the top of each column and further details if needed can be found on the ‘comments 
box’ indicated in red at the corner of the ‘cell’. 
 
Some information such as, ‘patients year of birth’ is simply typed into the template. Other 
information is entered from a drop down list; in this case an arrow appears in the corner of the cell. 
 
All fields must be completed for each patient. If a piece of information is not available enter ‘NK’ 
instead. Payment will only be made for each complete record submitted. 
 
Submitting Your Data 
 
You need to submit the data that you have collected to date at the end of each quarter.  
 
Templates should be emailed to [redacted] 
 
(continued on next page) 
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Signature Sheet:  Integrated Care for IBD Audit 
 
Signature on behalf of the Practice: 
 
Signature Name Date 
 
 
 
  
 
Practice Stamp 
 
 
 
 
 
 
Anticipated records to be Reviewed (please use the average 9 per 2000 registered 
population as at September 2010). 
 
 
 
 
 
 
 
 
Signature on behalf of the PCT 
 
Name………………………………………………………………………………………… 
 
Position……………………………………………………………………………………… 
 
Date.………………….………………………………………………………………………. 
 
One copy of this Agreement is to be retained by the practice, and one copy to 
remain with the PCT. 
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Appendix 12. Summed ADQ data set 
Data displayed by month, quarter, and financial year for each of the PCT, the Strategic Health 
Authority (SHA) and the SHA data set excluding the PCT. 
Year Month PCT SHA SHA less PCT 
2009 April 14239 195535 181296 
May 14417 192428 178010 
June 15321 203463 188141 
1
st
 Quarter total 43977 591425 547448 
July 15920 212911 196990 
August 13888 195844 181956 
September 16889 212959 196070 
2
nd
 Quarter total 46697 621713 575016 
October 15249 213615 198366 
November 14442 202728 188285 
December 17141 231946 214806 
3
rd
 Quarter total 46833 648289 601457 
2010 January 15343 199469 184126 
February 13342 195520 182177 
March 17709 220141 202432 
4
th
 Quarter total 46394 615129 568736 
Year total 183901 2476557 2292656 
April 15536 217497 201962 
May 15809 205871 190062 
June 16191 217064 200873 
1
st
 Quarter total 47536 640432 592897 
July 17385 227820 210436 
August 15773 214013 198240 
September 16292 227238 210946 
2
nd
 Quarter total 49450 669072 619622 
October 16384 212528 196144 
November 16639 221594 204955 
December 18505 242170 223665 
3
rd
 Quarter total 51528 676292 624764 
2011 January 15927 209307 193380 
February 15787 205863 190076 
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March 18245 238919 220675 
4
th
 Quarter total 49959 654089 604131 
Year total 198472 2639885 2441414 
April 16652 214232 197579 
May 16637 220598 203961 
June 16752 228900 212148 
1
st
 Quarter total 50041 663730 613689 
July 17175 228713 211538 
August 17099 225902 208804 
September 18170 237855 219685 
2
nd
 Quarter total 52444 692471 640026 
October 16779 220925 204145 
November 17974 234125 216151 
December 18494 249446 230953 
3
rd
 Quarter total 53247 704496 651249 
2012 January 18394 226171 207777 
February 16694 225722 209028 
March 18496 248223 229727 
4
th
 Quarter total 53585 700117 646532 
Year total 209317 2760813 2551496 
Total 591690 7877256 7285566 
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Appendix 13. Summed DDD data set 
Data displayed by month, quarter, and financial year for each of the PCT, the Strategic Health 
Authority (SHA) and the SHA data set excluding the PCT. 
Year Month PCT SHA SHA less PCT 
2009 April 14360 197750 183390 
May 14701 195005 180304 
June 15720 206690 190970 
1
st
 Quarter total 44781 599444 554664 
July 15866 214860 198993 
August 13876 195007 181131 
September 16892 214875 197984 
2
nd
 Quarter total 46634 624742 578108 
October 15620 215299 199678 
November 14628 203475 188847 
December 16978 233912 216934 
3
rd
 Quarter total 47226 652685 605459 
2010 January 15320 202129 186809 
February 13291 196745 183454 
March 17806 222357 204551 
4
th
 Quarter total 46417 621230 574813 
12-month total 185058 2498102 2313044 
April 15824 219932 204108 
May 15540 207882 192342 
June 16340 220163 203823 
1
st
 Quarter total 47704 647977 600273 
July 17310 227935 210625 
August 15849 217049 201200 
September 16379 229200 212821 
2
nd
 Quarter total 49538 674184 624646 
October 16771 214985 198214 
November 16512 223139 206627 
December 18819 245130 226311 
3
rd
 Quarter total 52102 683254 631152 
2011 January 16258 212974 196716 
February 16249 208618 192369 
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March 18318 240636 222317 
4
th
 Quarter total 50825 662228 611403 
12-month total 200170 2667643 2467474 
April 17172 216869 199697 
May 16934 223847 206913 
June 17193 232579 215386 
1
st
 Quarter total 51300 673295 621995 
July 17275 232215 214940 
August 17687 231317 213630 
September 18737 243381 224644 
2
nd
 Quarter total 53699 706913 653214 
October 17189 225872 208683 
November 18648 237795 219147 
December 19121 256400 237279 
3
rd
 Quarter total 54959 720067 665108 
2012 January 18521 230484 211964 
February 17432 230974 213541 
March 18991 253623 234631 
4
th
 Quarter total 54944 715080 660136 
12-month total 214901 2815355 2600454 
36-month total 600130 7981101 7380972 
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Appendix 14. Enablers and barriers to integrating care identified in the 
integrated care pilots evaluation (full list) 
E
n
a
b
le
rs
 
Simple, single-faceted interventions* 
Fewer different partners 
Widespread agreement and shared values among participating staff* 
Clear communication about contributions required from different participants 
Rules to govern how partnerships should work 
Participants confident that that senior management or team leaders were strongly committed to 
implementing lasting change 
On-going, planned communication between senior executives in the partner organisations 
Improved communication and problem solving through co-location and face-to-face contact between 
participants 
Creating shared beliefs about the benefits of change* 
Effective macro- , micro- and clinical leadership 
Project ‘champions’, appointed or emergent* 
Sustained motivation 
Relevant training provision* 
Ability of project to deliver cost efficiencies* 
External policy reforms* 
B
a
rr
ie
rs
 
Multiple components / interventions 
Multiple partners* 
Different information technology systems across partner organisations* 
Poor implementation of shared information (technology) solutions* 
Legal barriers to sharing data 
Absent or poor pre-existing relationships between participants and/or organisations 
Lack of professional engagement, general or specific groups – in particular primary care medical 
practitioners 
Absence of clear and consistent communication from leaders within organisations about what work 
was required and the required participant contributions* 
Uncertainty about what participants were allowed to do 
Mandated, or ‘forced’, changes 
Poorly shared sense of vision or strategic aims 
Poor macro- and micro- leadership 
Perceived erosion of professional identities and loss of previous roles and tasks 
Absence of, or inadequate, training* 
Management responsibilities in professionally-led processes leading to internal tensions from 
professional and patient perspectives 
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B
a
rr
ie
rs
 (
co
n
ti
n
u
e
d
) 
Unaligned professional and patient views in new models of care* 
Increased participant workloads 
Poor recognition of, or response to, project risks 
Change in ‘success’ outcome to cost-based 
Public service bureaucracy, particularly where it caused temporal delays* 
Different employment conditions between organisations 
Budgetary regulations 
External policy reforms 
Concurrent internal reorganisations* 
Staff turn-over 
Organisational culture, including local perceptions of professional boundaries and a ‘blame’ or 
oppositional culture* 
(*) Indicates also identified in the IBD pathway evaluation 
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